

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18382 A1

(51) International Patent Classification⁷: **C07D 471/04**,
A61K 31/437, A61P 25/00 // (C07D 471/04, 231:00,
221:00)

(21) International Application Number: PCT/JP01/07322

(22) International Filing Date: 27 August 2001 (27.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PQ9698 28 August 2000 (28.08.2000) AU

(71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AKAHANE, Atsushi** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **TANAKA, Akira** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **MINAGAWA, Masatoshi** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **ITANI, Hiromichi** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome,

Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). **OHTAKE, Hiroaki** [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(74) Agent: **TABUSHI, Eiji**; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF



(57) Abstract: A pyrazolopyridine compound of formula (I) wherein: R¹ is hydro gen, lower alkyl optionally substituted by substituent(s), or cyclo(lower)alkyl which may be interrupted by an oxygen or nitrogen atom and optionally substituted by substituent(s); R² is hydrogen, halogen or lower alkoxy; R³ is a substituent; and n is an integer from 1 to 4, provided R³ may be different from each other when n is 2, 3 or 4, or a salt thereof. The pyrazolopyridine compound (I) and salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.) Parkinson's disease,

anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.

DESCRIPTION

PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

TECHNICAL FIELD

5 The present invention relates to a novel pyrazolopyridine compound and a salt thereof, which are useful as medicaments.

BACKGROUND ART

Some pyrazolopyridine compounds to be useful as psychostimulant, remedy for renal failure, or the like are known
10 (e.g. EP-0299209, EP-0379979, EP-0467248, EP-0516941, etc.).

DISCLOSURE OF INVENTION

The present invention relates to a novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are useful as medicaments, whose toxicity may be reduced as
15 compared with the known pyrazolopyridine compounds; processes for the preparation of said pyrazolopyridine compound and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; a use of said
20 pyrazolopyridine compound or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said pyrazolopyridine compound or a pharmaceutically acceptable
25 salt thereof to a human being or an animal.

The pyrazolopyridine compound and a salt thereof are adenosine antagonists (especially, A_1 receptor and A_2 (particularly A_{2a}) receptor dual antagonists) and possess various pharmacological actions such as anticatalepsy action,
30 cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective action, cardiotonic action, vasodilating action (e.g. cerebral vasodilating action, etc.), the action of increasing the renal

blood flow, renal protective action, improvement action of renal function, enhancing action of lipolysis, inhibition action of anaphylactic bronchoconstriction, acceleration action of the insulin release, the action of increasing the production of
5 erythropoietin, inhibiting action of platelet aggregation, or the like.

They are useful as cognitive enhancer, antianxiety drug, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of
10 cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, antihypertensive agent, drug for renal failure (renal insufficiency), drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, antiobesity, antiasthmatic,
15 bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere's syndrome, drug for anemia, drug for thrombosis,
20 drug for myocardial infarction, drug for obstruction, drug for arteriosclerosis obliterans, drug for thrombophlebitis, drug for cerebral infarction, drug for transient ischemic attack, drug for angina pectoris, or the like;
and useful for the prevention and/or treatment of a disease
25 resulting from a stimulation of adenosine A_1 and/or A_2 receptor, such as depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure,
30 hypertension (e.g. essential hypertension, nephrogenous hypertension, etc.),
circulatory insufficiency (acute circulatory insufficiency) caused by

for example, ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral ischemia/reperfusion injury, etc.), shock (e.g. endotoxin shock, hemorrhagic shock, etc.),

5 surgical procedure, or the like,

post-resuscitation asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency) (e.g. acute renal failure, etc.),

10 renal toxicity [e.g. renal toxicity induced by a drug such as cisplatin, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc.], nephrosis, nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute

15 angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.), obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc.),


20 pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus (e.g. mechanical ileus, adynamic ileus, etc.), and myocardial infarction, thrombosis (e.g. arterial thrombosis, cerebral thrombosis, etc.), obstruction, arteriosclerosis

25 obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, or the like,

in which the preferred one may be Parkinson's disease and symptoms associating therewith, depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia

30 accompanying Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), Meniere's syndrome or cerebral infarction.

The novel pyrazolopyridine compound of the present invention can be shown by the following formula (I).



10 wherein

R^1 is hydrogen, lower alkyl optionally substituted by suitable substituent(s), or cyclo(lower)alkyl which may be interrupted by an oxygen or nitrogen atom and optionally substituted by suitable substituent(s);


15 R^2 is hydrogen, halogen or lower alkoxy;

R^3 is a substituent; and

n is an integer from 1 to 4, provided R^3 may be different with each other when n is 2, 3 or 4, or a salt thereof.




20 The object compound (I) and a salt thereof of the present invention can be prepared by the following processes.



Process 1



30 or a salt thereof



or a salt thereof

Process 2Process 3Process 4

Process 5



10 or its reactive derivative
at the carboxy group,
or a salt thereof

or its reactive derivative
at the amino group,
or a salt thereof




or a salt thereof

20


Process 6

30 or its reactive derivative
at the carboxy group,
or a salt thereof

or its reactive derivative
at the amino group,
or a salt thereof



10 Process 7




- 20 wherein R¹, R², R³ and n are as defined above,
 R¹⁵ is arylsulfonyl optionally substituted by suitable
 substituent(s),
 di(lower)alkylamino,
 lower alkoxy,
 25 lower alkylthio,
 or acyloxy;
 R^{1a} is lower alkyl or cyclo(lower)alkyl which may be interrupted
 by an oxygen atom;
 R¹⁶ is lower alkyl;
 30 R¹⁷ is a substituent other than hydrogen, selected from among
 -A-R⁴ and -R⁹,
 [in which, A is lower alkylene,
 R⁴ is hydrogen;

cyclo(lower)alkyl;
aryl optionally substituted by lower alkoxy;
a group of the formula:
R⁵-(R⁶-)N-
5 wherein R⁵ and R⁶ are each independently
hydrogen, or
lower alkyl;
heterocyclic group optionally substituted by
oxo, lower alkyl or
10 lower alkoxy(lower)alkyl;
carboxy;
lower alkoxycarbonyl;
aryl(lower)alkoxycarbonyl;
lower alkanoyl;
15 a group of the formula:
R⁷-(R⁸-)N-CO-
wherein R⁷ and R⁸ are each independently
hydrogen;
lower alkyl optionally substituted by
20 lower alkoxy, N,N-di(lower)alkylamino or
heterocyclic group;
cyclo(lower)alkyl optionally substituted by hydroxy;
aryl optionally substituted by lower alkoxy; or
a group of the formula:
25 Het-CO-
wherein Het is N-containing heterocyclic group
optionally substituted by
lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
N,N-di(lower)alkylcarbonyl or aryl(lower)alkyl,
30 R⁹ is hydrogen;
aryl optionally substituted by lower alkanoylamino;
heterocyclic group optionally substituted by
lower alkyl, lower alkanoyl, lower alkoxycarbonyl,


carbamoyl, N,N-di(lower)alkylcarbamoyl,
 aryl(lower)alkyl, lower alkoxy, halo(lower)alkyl or
 nitro; or
 arylsulfonyl optionally substituted by
 5 lower alkyl or lower alkoxy],
 R^{10} and R^{11} are each independently
 hydrogen;
 cyclo(lower)alkyl;
 heterocyclic group optionally substituted by lower alkyl;
 10 lower alkyl optionally substituted by hydroxy, lower alkoxy,
 aryl, aryloxy, N,N-di(lower)alkylamino or heterocyclic
 group,
 R^{10} and R^{11} may be combined together with N atom to which they are
 attached to form N-containing heterocyclic group optionally
 15 substituted by lower alkyl, aryl, lower alkanoyl or heterocyclic
 group;
 R^7 and R^8 are each independently hydrogen;
 lower alkyl optionally substituted by lower alkoxy,
 di(lower)alkylamino or heterocyclic group;
 20 cyclo(lower)alkyl optionally substituted by hydroxy;
 aryl optionally substituted by lower alkoxy; and
 Y is a leaving group.

The starting compound(II) or a salt thereof is novel and
 25 can be prepared, for example, by the following reaction schemes.

Process A




5



or a salt thereof


Process B

10




or a salt thereof

+




or a salt thereof

15



or a salt thereof


20





or a salt thereof

25

30



or a salt thereof

Process C

wherein R², R³, R¹⁵ and n are as defined above,

15 R¹⁸ is lower alkyl,

Z⁻ is an anion.

In addition to the processes as mentioned above, the object compound (I) and a salt thereof can be prepared, for example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.

The starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations in the present specification or in a manner similar thereto.


25 The object compound (I) and a salt thereof can be prepared according to the methods as shown in a Preparation or Examples, or in a manner similar thereto.

It is to be noted that the object compound (I) may include the geometrical isomer(s) due to the double bond(s) and/or the stereo isomer(s) due to the asymmetric carbon atom(s). In this regard, one isomer can be converted to another according to a conventional method in this field of the art.

It is also to be noted that the solvating form of the compound

(I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.

It is further to be noted that the object compound (I) may include the dimer, which is coupling through urea, of the formula (Ij)



wherein

15 R^1 and R^2 are as defined above, or a salt thereof,

Suitable salts of the object compound (I) are conventional pharmaceutically acceptable ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), and the like.

20

25

30

Suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof and which appear in the above and following

description in the present specification are explained in detail as follows.

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

- 5 Suitable "lower alkyl" may include straight or branched ones such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, in which the preferred one may be (C1-C4)alkyl and the more preferred one may be methyl, ethyl, propyl or isopropyl.
- 10 Suitable "lower alkylene" may include straight or branched ones such as methylene, ethylene, propylene, isopropylene, butylene, tert-butylene, pentylene, hexylene or the like, in which the preferred one may be (C1-C5)alkylene and the more preferred one may be methylene, ethylene or propylene.
- 15 Suitable "lower alkynyl" may include straight or branched ones such as ethynyl, 1-propynyl, 1-methylethynyl, 2-butynyl, 2-methyl-3-butynyl, 2-pentynyl, 1-hexynyl or the like, in which the preferred one may be (C.sub.2 -C.sub.4)alkynyl and the more preferred one may be ethynyl.
- 20 Suitable "cyclo(lower)alkyl" may be cyclo(C3-C8)-alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclo(C3-C7)alkyl such as cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl.
- 25 Suitable "lower alkoxy" may include straight or branched ones such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which the preferred one may be (C1-C4)alkoxy and the more preferred one may be methoxy.
- 30 Suitable "aryl" may be phenyl, naphthyl and the like, in which the preferred one may be (C6-C10)aryl and the most preferred one may be phenyl.

Suitable "aryl(lower)alkyl" may include phenyl(lower)alkyl

(e.g. benzyl, phenethyl, etc.), diphenyl(lower)alkyl (e.g. benzhydryl, etc.) or triphenyl(lower)alkyl (e.g. trityl, etc.) and the like, in which the preferred one may be (C6-C10)aryl(lower)alkyl, and the more preferred one may be
5 phenyl(C1-C4)alkyl.

Suitable "arylsulfonyl" may include phenylsulfonyl, tolylsulfonyl, naphthylsulfonyl and the like, and said "arylsulfonyl" may have one or more (preferably 1 to 3) suitable substituent(s) such as aforesaid lower alkoxy, aforesaid
10 halogen, or the like.

Suitable "lower alkylsulfonyl" may be methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, t-butylsulfonyl, pentylsulfonyl, hexylsulfonyl, in which the preferred one may be (C1-C4)alkylsulfonyl and the most preferred one may be
15 methylsulfonyl.

Suitable "halogen" may be fluoro, chloro, bromo and iodo.

Suitable "heterocyclic group" may be saturated or unsaturated monocyclic or polycyclic heterocyclic groups containing at least one hetero atom selected from among oxygen,
20 sulfur and nitrogen.

The particularly preferred example of said heterocyclic group may include unsaturated 3- through 8-membered heteromonocyclic groups containing 1 through 4 nitrogen atom(s), such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl
25 and its N-oxide, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g. 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.), etc.;

30 3- through 8-membered saturated heteromonocyclic groups containing 1 through 4 nitrogen atom(s), such as pyrrolidinyl, imidazolidinyl, piperidyl (e.g. piperidino, etc.), piperazinyl, etc.;

unsaturated condensed heterocyclic groups containing 1 through 5 nitrogen atom(s), such as indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g. 5 tetrazolo[1,5-b]pyridazinyl etc.), dihydrotriazolopyridazinyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atoms and 1 through 3 nitrogen atom(s), such as oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4- 10 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atoms, such as morpholinyl, oxazolidinyl (e.g. 1,3-oxazolidinyl etc.), 15 etc.;

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atom(s), such as benzoxazolyl, benzoxadiazolyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups 20 containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as 1,3-thiazolyl, 1,2-thiazolyl, thiazolinyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl), etc.;

3- through 8-membered saturated heteromonocyclic groups 25 containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolidinyl etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 sulfur atom, such as thienyl etc.;

unsaturated condensed heterocyclic groups containing 1 or 30 2 sulfur atoms and 1 through 3 nitrogen atom(s), such as benzothiazolyl, benzothiadiazolyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as furyl, pyranyl,

dioxolyl, etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as oxolanyl, tetrahydropyranyl (e.g. tetrahydro-2H-pyran-2-yl etc.),
5 dioxolanyl, etc.; and

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s), such as isobenzofuranyl, chromenyl (e.g. 2H-chromen-3-yl etc.), dihydrochromenyl (e.g. 3,4-dihydro-2H-chromen-4-yl etc.), etc.

10 Suitable "N-containing heterocyclic group" may be aforesaid "heterocyclic group", in which said group contains at least one N atom in its ring members.

Suitable "an acyl group" may include lower alkanoyl, carboxy, protected carboxy, and the like.

15 Suitable examples of aforesaid "lower alkanoyl" may be formyl, acetyl, propionyl, butyryl, isobutyryl, pivaloyl, hexanoyl, or the like, in which the preferred one may be (C1-C4) alkanoyl and the more preferred one may be formyl and acetyl.

Suitable examples of aforesaid "protected carboxy" may be

20 i) esterified carboxy, in which suitable esterified carboxy may include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.), aryl(lower)alkoxycarbonyl (e.g. benzyloxycarbonyl, phenethyloxycarbonyl, 2-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 4-phenylpentyloxycarbonyl, 1,3-diphenylhexyloxycarbonyl, etc.), and the like;

ii) amidated carboxy, in which suitable amidated carboxy may include carbamoyl, N-(lower)alkylcarbamoyl (e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N-pentylcarbamoyl, N-hexylcarbamoyl, etc.),
30 N,N-di(lower)alkylcarbamoyl [e.g. N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-

dipropylcarbamoyl, N,N-di(t-butyl)carbamoyl,
N-pentyl-N-hexylcarbamoyl, etc.],
N-lower alkyl-N-ar(lower)alkylcarbamoyl (e.g. N-methyl-
N-benzylcarbamoyl, etc), and the like.

5 Suitable "a leaving group" may include halogen as mentioned
above, hydroxy, acyloxy such as alkanoyloxy (e.g. acetoxy,
propionyloxy, etc.), sulfonyloxy (e.g. mesyloxy, tosyloxy,
etc.), and the like.

 Suitable "anion" may be formate, acetate, trifluoroacetate,
10 maleate, tartrate, methanesulfonate, benzenesulfonate,
toluenesulfonate, chloride, bromide, iodide, sulfate,
phosphate, or the like.

 The preferred embodiment of the compound (I) is explained
as follows.

15

1. The compound (I), wherein

R¹ is hydrogen, lower alkyl optionally substituted by lower
alkoxy, or cyclo(lower)alkyl which may be interrupted by an
oxygen or nitrogen atom and optionally substituted by lower
20 alkyl;

R² is hydrogen, halogen or lower alkoxy;

R³ is a group of the formula:

R⁴-A-O-

in which

25 A is lower alkylene, and

R⁴ is hydrogen;

cyclo(lower)alkyl;

aryl optionally substituted by lower alkoxy;

a group of the formula:

30

R⁵-(R⁶-)N-

wherein R⁵ and R⁶ are each independently
hydrogen, or
lower alkyl;

heterocyclic group optionally substituted by

oxo, lower alkyl or

lower alkoxy(lower)alkyl;

carboxy;

5 lower alkoxycarbonyl;

aryl(lower)alkoxycarbonyl;

lower alkanoyl;

a group of the formula:

$R^7-(R^8-)N-CO-$

10 wherein R^7 and R^8 are each independently
hydrogen;

lower alkyl optionally substituted by

lower alkoxy, N,N-di(lower)alkylamino or
heterocyclic group;

15 cyclo(lower)alkyl optionally substituted by hydroxy;
aryl optionally substituted by lower alkoxy;

a group of the formula:

Het-CO-

wherein Het is N-containing heterocyclic group

20 optionally substituted by

lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
N,N-di(lower)alkylcarbonyl, or

aryl(lower)alkyl; or

halogen.

25

2. The compound (I), wherein

R^1 is hydrogen, lower alkyl optionally substituted by lower
alkoxy, or cyclo(lower)alkyl which may be interrupted by an
oxygen or nitrogen atom and optionally substituted by lower

30 alkyl;

R^2 is hydrogen, halogen or lower alkoxy;

R^3 is a group of the formula:

R^9-O-

in which

R⁹ is hydrogen;

aryl optionally substituted by lower alkanoylamino;

heterocyclic group optionally substituted by

5 lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
 carbamoyl, N,N-di(lower)alkylcarbamoyl,
 aryl(lower)alkyl, lower alkoxy, halo(lower)alkyl or
 nitro;

arylsulfonyl optionally substituted by


10 lower alkyl or lower alkoxy.

3. The compound (I), wherein

R¹ is hydrogen, lower alkyl optionally substituted by lower
alkoxy, or cyclo(lower)alkyl which may be interrupted by an
15 oxygen or nitrogen atom and optionally substituted by lower
alkyl;

R² is hydrogen, halogen or lower alkoxy;

R³ is a group of the formula:



20 in which

R¹⁰ and R¹¹ are each independently
hydrogen;

cyclo(lower)alkyl optionally substituted by hydroxy;

25 heterocyclic group optionally substituted by lower alkyl
 lower alkoxycarbonyl,

 aryl optionally substituted by

 halogen, or aryl(lower)alkyl,

 lower alkoxy, hydroxy, halogen, or halo(lower)alkyl;

30 lower alkyl optionally substituted by

 hydroxy, lower alkoxy, lower alkylthio,

 aryl optionally substituted by lower alkyl, lower alkoxy,
 hydroxy or halogen ,


aryloxy, lower alkoxy, lower alkoxy, lower alkoxy, lower alkoxy,
 N,N-di(lower)alkylamino, or
 heterocyclic group optionally substituted by halogen or
 hydroxy;
 5 lower alkenyl; or
 aryl optionally substituted by
 lower alkyl, hydroxy(lower)alkyl, halo(lower)alkyl,
 lower alkoxy,
 aryloxy optionally substituted by lower alkyl or
 10 halogen,
 hydroxy, halogen, lower alkanoyl, amino, lower
 alkanoylamino, N,N-di(lower)alkylamino,
 aryl(lower)alkanoyle, cyano or nitro;
 R¹⁰ and R¹¹ may be combined together with N atom to which
 15 they are attached to form N-containing heterocyclic group
 optionally substituted by
 lower alkyl optionally substituted by lower alkylamino,
 aryl optionally substituted by lower alkoxy, carbonyl or
 lower alkoxy,
 20 lower alkanoyl, heterocyclic group,
 hydroxy(lower)alkyl, lower alkylsulfonylamino, amino,
 oxo, , nitro, lower alkoxy(lower)alkyl, lower
 alkoxy, carbonyl, N-lower alkylcarbamoyl,
 cyclo(lower)alkyl, aryl(lower)alkoxy or lower alkoxy.

25

4. The compound (I), wherein
 R¹ is hydrogen, lower alkyl optionally substituted by lower
 alkoxy, or cyclo(lower)alkyl which may be interrupted by an
 oxygen or nitrogen atom and optionally substituted by lower
 30 alkyl;

R² is hydrogen, halogen or lower alkoxy;

R³ is a group of the formula:



in which
R¹² and R¹³ are each independently
hydrogen;
lower alkyl optionally substituted by lower alkoxy;
5 lower alkanoyl optionally substituted by aryl or halogen;
lower alkoxy carbonyl;
lower alkylsulfonyl; or
R¹² and R¹³ may be combined together with N atom to which
they are attached to form N-containing heterocyclic group
10 optionally substituted by
hydroxy, oxo, lower alkyl, lower alkoxy,
lower alkanoyl optionally substituted by
N,N-di(lower)alkylamino or aryl,
lower alkoxy carbonyl,
15 N,N-di(lower)alkylcarbamoyl,
lower alkylsulfonyl, arylsulfonyl, aryl,
aryl(lower)alkyl or heterocyclic group.

5. The compound (I), wherein
20 R¹ is hydrogen, lower alkyl optionally substituted by lower
alkoxy, or cyclo(lower)alkyl which may be interrupted by an
oxygen or nitrogen atom and optionally substituted by lower
alkyl;
R² is hydrogen, halogen or lower alkoxy;
25 R³ is a group of the formula:
R¹⁴-A'-
in which
A' is lower alkynyl,
R¹⁴ is hydroxy; cyclo(lower)alkyl; or aryl.

30
6. The compound (I), wherein
R¹ is hydrogen, lower alkyl optionally substituted by lower
alkoxy, or cyclo(lower)alkyl which may be interrupted by an

oxygen or nitrogen atom and optionally substituted by lower alkyl;

R² is hydrogen, halogen or lower alkoxy;

R³ is carboxy, lower alkoxycarbonyl or cyano.

5


The more preferred embodiment of the compound (I) is explained as follows.

1. The compound (I), wherein

10 R¹ is hydrogen, lower alkyl optionally substituted by lower alkoxy, tetrahydrofuryl, tetrahydropyranyl or piperidinyl;

R² is hydrogen, halogen or lower alkoxy;

R³ is a group of the formula:



in which

15 A is lower alkylene, and

R⁴ is hydrogen;

cyclo(lower)alkyl;

phenyl optionally substituted by lower alkoxy;

a group of the formula:

20 R⁵-(R⁶-)N-

wherein R⁵ and R⁶ are each independently

hydrogen or lower alkyl;

aziridinyl, pyrrolidinyl, piperidinyl, morpholinyl,

pyridyl or isoindolyl, each of which is optionally

25 substituted by

oxo, lower alkyl or lower alkoxy(lower)alkyl;


carboxy;

lower alkoxycarbonyl;

phenyl(lower)alkoxycarbonyl;

30 lower alkanoyl;

a group of the formula:



wherein R⁷ and R⁸ are each independently

hydrogen;

lower alkyl optionally substituted by

lower alkoxy, N,N-di(lower)alkylamino or pyridyl;

cyclo(lower)alkyl optionally substituted by hydroxy;

5 phenyl optionally substituted by lower alkoxy; or

a group of the formula:

Het-CO-

wherein Het is pyrrolidinyl, piperidinyl, piperazinyl
or morpholinyl, each of which is optionally substituted

10 by

lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
N,N-di(lower)alkylcarbamoyl, phenyl(lower)alkyl,

2. The compound (I), wherein

15 R¹ is lower alkyl;

R² is hydrogen;

R³ is a group of the formula:

R⁹-O-

in which

20 R⁹ is hydrogen;

phenyl optionally substituted by lower alkanoylamino;

piperidinyl, tetrahydropyranyl or pyridinyl, each of which
is optionally substituted by

lower alkyl, lower alkanoyl, lower alkoxycarbonyl,

25 carbamoyl, N,N-di(lower)alkylcarbamoyl,

phenyl(lower)alkyl, lower alkoxy, halo(lower)alkyl or
nitro;

phenylsulfonyl optionally substituted by

lower alkyl or lower alkoxy.


30

3. The compound (I), wherein

R¹ is lower alkyl;

R² is hydrogen;

R³ is a group of the formula:



in which

R¹⁰ and R¹¹ are each independently

5 hydrogen;

cyclo(lower)alkyl;

thiazolyl optionally substituted by lower alkyl;

lower alkyl optionally substituted by

hydroxy, lower alkoxy, phenyl, phenoxy,

10 N,N-di(lower)alkylamino, pyrrolidinyl or pyridinyl; or

R¹⁰ and R¹¹ may be combined together with N atom to which

they are attached to form pyrrolidinyl, piperidinyl,

hexahydroazepinyl, piperazinyl or morpholinyl, each of

which is optionally substituted by


15 lower alkyl, phenyl, lower alkanoyl or pyridinyl.

4. The compound (I), wherein

R¹ is hydrogen or lower alkyl;

R² is hydrogen;

20 R³ is a group of the formula:



in which

R¹² and R¹³ are each independently

hydrogen;

25 lower alkyl optionally substituted by lower alkoxy;

lower alkanoyl optionally substituted by phenyl or halogen;

lower alkoxycarbonyl;

lower alkylsulfonyl; or

R¹² and R¹³ may be combined together with N atom to which

30 they are attached to form pyrrolidinyl, piperidinyl,

piperazinyl or morpholinyl, each of which is optionally

substituted by

hydroxy, oxo, lower alkyl, lower alkoxy,

lower alkanoyl optionally substituted by
N,N-di(lower)alkylamino or phenyl,
lower alkoxycarbonyl,
N,N-di(lower)alkylcarbamoyl
5 lower alkylsulfonyl, phenylsulfonyl, phenyl,
phenyl(lower)alkyl, pyridinyl or pyrimidinyl.

5. The compound (I), wherein
R¹ is lower alkyl;
10 R² is hydrogen;
R³ is a group of the formula:
R¹⁴-A'-
in which
A' is lower alkynyl,
15 R¹⁴ is hydroxy; cyclo(lower)alkyl; or phenyl.

6. The compound (I), wherein
R¹ is lower alkyl;
R² is hydrogen;
20 R³ is carboxy, lower alkoxycarbonyl or cyano.

The processes for preparing the object pyrazolopyridine compound(I) are explained in detail in the following.

Process 1

25 The compound (Ia) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to hydrolysis.

Suitable salt of the compound (II) can be referred to an acid addition salt as exemplified for the compound (I).

This reaction is carried out in accordance with a
30 conventional method.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base includes an inorganic base and an organic base

such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamide (e.g. trimethylamine, triethylamine, etc.),
5 hydrazine, picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid,
10 trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).

The elimination using Lewis acid such as trihaloacetic acid (e.g. trichloroacetic acid, trifluoroacetic acid, etc.) or the
15 like is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.).

The reaction is usually carried out in a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride,
20 ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.

A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually
25 carried out under cooling to heating.

Process 2

The compound (Ib) or a salt thereof can be prepared by reacting the compound (Ia) or a salt thereof with the compound (III) or a salt thereof.

30 Suitable salt of the compound (Ia) can be referred to an acid addition salt as exemplified for the compound (I).

Suitable salt of the compound (III) can be referred to the ones as exemplified for the compound (I).

The present reaction may be carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, methylene chloride, ethylene chloride, formamide, N,N-dimethylformamide, methanol, ethanol, sec-butanol, amyl
5 alcohol, diethyl ether, dioxane, tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities. Among the solvents, hydrophilic solvents may be used in a mixture with water. When the compound (III) is in liquid, it can also
10 be used as a solvent. The reaction is preferably conducted in the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride (e.g. sodium hydride, etc.), organic base such as trialkylamine, and the like.

15 The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or under heating.

The present reaction is preferably carried out in the presence of alkali metal halide (e.g. sodium iodide, potassium
20 iodide, etc.), alkali metal thiocyanate (e.g. sodium thiocyanate, potassium thiocyanate, etc.), di(lower)alkyl azodicarboxylate (e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc.) or the like.

When Y is -OH, activation of OH with triphenylphosphine and
25 the like may be necessary.

Process 3

The compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to elimination reaction of alkyl group.

30 Suitable salts of the compound (Ic) and (Id) can be referred to the ones as exemplified for the compound (I).

This reaction is carried out in accordance with a conventional method such as hydrolysis.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an
5 alkaline earth metal (e.g. magnesium, calcium, etc.), hydroxide or carbonate or bicarbonate thereof, trialkylamine (e.g. trimethylamine, triethylamine, etc.), hydrazine, picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane,
10 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen
15 chloride, hydrogen bromide, etc.).

The elimination using Lewis acid (e.g. aluminium chloride, titanium trichloride, tin tetrachloride, etc.) or the like is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.).

20 The reaction is usually carried out in a solvent such as water, alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvents which do
25 not adversely affect the reaction, or a mixture thereof. A liquid base or acid can be also used as the solvent.

The reaction of this process can be also carried out according to a conventional reduction method employed in this field of the art (e.g. chemical reduction, catalytic reduction,
30 etc.).

The reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or under heating.

Process 4

The compound (Ie) or a salt thereof can be prepared by reacting the compound (Id) or a salt thereof with the compound (IV) or a salt thereof.

- 5 Suitable salt of the compound (Id), (IV) and (Ie) can be referred to the ones as exemplified for the compound (I).

The reaction of this process can be carried out in the manner similar to that of Process 2.

Process 5

- 10 The compound (Ig) or a salt thereof can be prepared by reacting the compound (If) or its reactive derivative at the carboxy group, or a salt thereof with the compound (V) or its reactive derivative or a salt thereof.

- Suitable reactive derivative of the compound (V) may
15 include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (V) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (V) with a silyl compound such as N,O-bis(trimethylsilyl)acetamide, N-
20 trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (V) with phosphorus trichloride or phosgene, and the like.

- Suitable reactive derivative of the compound (If) may include an acid halide, an acid anhydride, an activated ester,
25 and the like. The suitable example may be an acid chloride; acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.),
30 dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid,

isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride;

an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; an activated ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [(CH₃)₂N⁺=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.); an ester with a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxybenzotriazole (HOBt), N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole, etc.); and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound (If) to be used.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide (DMF), pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

When the compound (If) is used in free acid form or its salt form in the reaction, the reaction is preferable carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide (EDAC);

N,N-carbonyl-bis(2-methylimidazole);
pentamethyleneketene-N-cyclohexylimine;
diphenylketene-N-cyclohexylimine;
ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl
5 phosphite; isopropyl polyphosphate; phosphorous oxychloride
(phosphoryl chloride); phosphorous trichloride; thionyl
chloride; oxalyl chloride; triphenylphosphite;
2-ethyl-7-hydroxybenzisoxazolium salt;
2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intra-
10 molecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-
benzotriazole; so-called Vilsmeier reagent prepared by the
reaction of N,N-dimethylformamide with thionyl chloride,
phosgene, phosphorous oxychloride, etc.; or the like.

The reaction may be also be carried out in the presence
15 of an organic or inorganic base such as an alkali metal
bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)-
alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction
is usually carried out under cooling to heating.

20 Process 6

The compound (Ii) or a salt thereof can be prepared by
reacting the compound (Ih) or its reactive derivative at the
carboxy group, or a salt thereof with the compound (VI) or its
reactive derivative or a salt thereof.

25 This reaction can be carried out in the same manner as in
the aforementioned Process 5, and therefore the reagents to be
used and the reaction conditions (e.g., solvent, reaction
temperature, etc.) can be referred to those of Process 5.

Process 7

30 The object compound (Ia) or a salt thereof can be prepared
by subjecting the compound (VII) or a salt thereof to formation
reaction of pyridazinone ring.

Suitable salts of the compounds (Ia) and (VII) can be

referred to acid addition salts as exemplified for the compound (I).

The formation reaction of this process can be carried out, for example, by reacting the compound (VII) or a salt thereof with glyoxylic acid or its reactive derivative or a salt thereof and hydrazine or a salt thereof.

Suitable salt of glyoxylic acid can be referred to a salt with a base as exemplified for the compound (I).

Suitable salt of hydrazine can be referred to an acid addition salt as exemplified for the compound (I).

Suitable reactive derivative of glyoxylic acid may be the ones conventionally used in this field of the art such as an activated ester thereof.

The reaction can be carried out in the presence or absence of a solvent.

The reaction temperature is not critical and the reaction is usually carried out under warming to heating.

Process A

The compound (II) or a salt thereof can be prepared by reacting the compound (VIII) or a salt thereof with the compound (IX) or a salt thereof.

Suitable salts of the compounds (II), (VIII) and (IX) can be referred to acid addition salts as exemplified for the compound (I).

The reaction is usually carried out in a solvent such as water, methylene chloride, ethylene chloride, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction or a mixture thereof.

The reaction can be carried out in the presence of a base such as alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), ar(lower)alkyltri(lower)alkylammonium halide (e.g.

benzyltrimethylammonium chloride, etc.) or the like.

The reaction temperature is not critical and the reaction is usually carried out under cooling, at room temperature or under warming.

5 Process B

Step 1

 The compound (XI) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (IX) or a salt thereof.

10 This reaction can be carried out in the same manner as in the aforementioned Process A, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process A.

Step 2

15 The deesterification reaction of this step can be carried out by the methods disclosed in Preparation 3 mentioned later or the similar manners thereto.

Step 3

20 The introduction reaction of acetyl group of this step can be carried out by the methods disclosed in Preparation 4 mentioned later or the similar manners thereto.

Process C

25 The compound (VII) or a salt thereof can be prepared by reacting the compound (XIII) or a salt thereof with the compound (IX) or a salt thereof.

 This reaction can be carried out in the same manner as in the aforementioned Process A, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process A.

30 The object compound (I) of the present invention is an adenosine antagonist and possesses the various pharmacological actions as stated before.

 In order to show the usefulness of the compound (I) of the

present invention, the pharmacological test result of the representative compound of the present invention is shown in the following.

5 Test 1 : Adenosine antagonistic activity

[I] Test method

The adenosine antagonistic activity [K_i (nM)] of the test compound was examined by radioligand binding techniques using 8-cyclopentyl-1,3-dipropylxanthine, [dipropyl-2,3- ^3H (N)]
10 ([^3H]DPCPX, 4.5nM) for human A_1 receptor and [^3H]CGS 21680 (20nM) for human A_{2a} receptor.

[II] Test compound

5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-
15 yl)-2-phenylpyrazolo[1,5-a]pyridine (Example 2)

5-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-
yl)-2-phenylpyrazolo[1,5-a]pyridine (Example 3)

5-(2-Dimethylamino)ethoxy-3-(3-oxo-2-isopropyl-2,3-
dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
20 (Example 4)

5-(2-pyridinyloxy)-3-(3-oxo-2-isopropyl-2,3-
dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
(Example 31)

N,N-dimethyl-3-(3-oxo-2-isopropyl-2,3-
25 -dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-
carboxamide (Example 72)

5-(4-methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-
dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
(Example 96)

30 tert-butyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-
yl)-2-phenylpyrazolo[1,5-a]pyridin-5-ylcarbamate
(Example 145)

[III] Test result

Table 1

		Adenosine receptor binding	
Test compound (Example No.)		(K _i :nM)	
5		A ₁	A _{2a}
	2	0.15	1.38
	3	0.14	1.05
	4	0.98	2.35
	31	0.42	1.44
10	72	0.25	1.68
	96	0.24	1.28
	145	0.48	1.03

Test 2 : Anticatalepsy activity in Mouse

15 [I] Test method

The test compound (3.2mg/kg) was administered orally with ddY mice(n=7). Then, haloperidol (0.32mg/kg) was injected intraperitoneally 30 min. after the administration of the compound. Thirty min. after the injection, the cataleptic responses of mice were measured. The forelimbs of each mouse were placed on a 3 cm high, 3 mm wide horizontal bar, and the duration of cataleptic posture was measured for up to 30 sec.

[II] Test compound

5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (Example 2)

5-(2-Dimethylamino)ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (Example 4)

5-(2-pyridinyloxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (Example 31)

N,N-dimethyl- 3-(3-oxo-2-isopropyl-2,3

-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide (Example 72)

5-(4-methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

5 (Example 96)

tert-butyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-ylcarbamate

(Example 145)

10 [III] Test result

Table 2

Test compound (Example No.)	Manifestation rate of catalepsy (number of mouse)
2	0/7
15 4	0/7
31	0/7
72	0/7
96	0/7
145	0/7

20

The pyrazolopyridine compound (I) and a salt thereof of this invention are useful as adenosine antagonists (especially, A₁ receptor and A₂ (particularly A_{2a}) receptor dual antagonists) and for the prevention and/or the treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant

death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction,
5 arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, and the like.

The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in a
10 solid, semisolid or liquid form, which contains the pyrazolopyridine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical),
15 oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments,
20 aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. In addition, auxiliary, stabilizing agents, thickening agents, coloring agents and perfumes may be used where necessary. The pyrazolopyridine compound (I) or a pharmaceutically acceptable
25 salt thereof is included in a pharmaceutical composition in an amount sufficient to produce the desired aforesaid pharmaceutical effect upon the process or condition of diseases.

For applying the composition to a human being or an animal, it is preferable to apply it by intravenous, intramuscular,
30 pulmonary or oral administration, or insufflation. While the dosage of therapeutically effective amount of the pyrazolopyridine compound (I) varies depending on the age and condition of each individual patient to be treated, in the case of

intravenous administration, a daily dose of 0.01 - 100 mg of the pyrazolo-pyridine compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.1 - 100 mg of the pyrazolopyridine compound (I) per kg weight of a human being or an animal, and in case of oral administration, a daily dose of 0.5 - 100 mg of the pyrazolopyridine compound (I) per kg weight of a human being or an animal is generally given for the prevention and/or treatment of the aforesaid diseases.

10

The following Preparation and Examples are given for the purpose of illustrating the present invention in more detail.

Preparation 1

To a stirred mixture of 1-amino-4-methoxypyridinium iodide (400 mg) and 3-benzenesulfonyl-6-phenylethynylpyridazine (250 mg) in N,N-dimethylformamide (10 ml) was added powder potassium carbonate (650 mg) at ambient temperature. After being stirred at ambient temperature for 18 hours, the mixture was poured into water. The resultant precipitate was collected by filtration to give 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine (100 mg).

mp: 203.5-205.5°C (AcOEt)
IR (nujol): 1644, 1540, 1523, 1332 cm⁻¹
NMR (DMSO-d₆, δ): 3.91 (3H, s), 6.81 (1H, dd, J=2.8, 7.5 Hz), 7.36-7.62 (7H, m), 7.62-7.89 (4H, m), 8.08 (1H, d, J=6.7 Hz), 8.19 (1H, d, J=9.1 Hz), 8.76 (1H, d, J=7.5 Hz)

APCI/MS: 443 [M+H]⁺
Anal. Calcd for C₂₄H₁₈N₄O₃S: C, 65.14; H, 4.10; N, 12.66
Found: C, 64.77; H, 4.18; N, 12.37

30

Preparation 2

To a stirred mixture of 1-amino-4-methoxypyridinium iodide (91.1 g) and ethyl phenylpropiolate (18.0 g) in N,N-

- dimethylformamide(180 ml) was added potassium carbonate(57.1 g) at ambient temperature. After being stirred at ambient temperature for 18 hours, the mixture was poured into water. The mixture was extracted with ethyl acetate. The organic layer
- 5 was washed with water and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel column chromatography (ethylacetate : n-hexane = 1 : 4) to give ethyl 5-methoxy-2-phenylpyrazolo[1,5-a]pyridine-3-carboxylate (24.7 g).
- 10 IR (nujol): 1714, 1643, 1546, 1513, 1417, 1299, 1226, 1201, 1174, 1133 cm^{-1}
- NMR (DMSO- d_6 , δ): 1.23(3H, t, J=1.2Hz), 3.93(3H, s), 4.20(2H, q, J=7.1Hz), 6.86(1H, dd, J=2.8, 7.5Hz), 7.39-7.53(4H, m), 7.63-7.80(2H, m), 8.74(1H, d, J=7.5Hz)
- 15 APCI/MS: 297[M+H]⁺

Preparation 3

- To a stirred mixture of ethyl 5-methoxy-2-phenylpyrazolo[1,5-a]pyridine-3-carboxylate (32.0 g) in methanol (160 ml) was added 10% aqueous sodium hydroxide (86.4
- 20 ml) at ambient temperature. After being stirred at 75°C for 3 hours, the reaction mixture was cooled to room temperature, and the solvent methanol was evaporated. To the residue was added N,N-dimethylformamide (160 ml) and the mixture was acidified with 6N-hydrochloric acid (45 ml). After being stirred at 90°C
- 25 for 1 hour, the reaction mixture was poured into ice-water (300 ml). After being stirred at 0°C for 1 hour, the resultant precipitate was collected by filtration to give 5-methoxy-2-phenylpyrazolo[1,5-a]pyridine(23.63 g).
- IR (nujol): 1644, 1565, 1536, 1265, 1228 cm^{-1}
- 30 NMR (DMSO- d_6 , δ): 3.84(3H, s), 6.56(1H, dd, J=2.7, 7.6Hz), 6.83(1H, s), 7.01(1H, d, J=2.6Hz), 7.30-7.55(3H, m), 7.90-8.03(2H, m), 8.54(1H, d, J=7.6Hz)
- APCI/MS: 225[M+H]⁺

Preparation 4

A mixture of 5-methoxy-2-phenylpyrazolo[1,5-a]pyridine (1.50 g), acetic anhydride (0.76 ml), methanesulfonic acid (22 μ l), and nitrobenzene (6.00 ml) was stirred at 125°C for 6 hours. Then to the reaction mixture was added methanol (1.50 ml) and 10% aqueous sodium hydroxide (19.5 ml) at 0°C. The mixture was extracted with dichloromethane. The organic layer was washed with water and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel column chromatography (dichloromethane : ethylacetate = 1:0 - 50:1 - 30:1) to give 1-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)ethanone (1.23 g).
IR (nujol): 1646, 1617, 1508, 1267, 1236 cm^{-1}
NMR (DMSO- d_6 , δ): 2.02 (3H, s), 3.93 (3H, s), 6.89 (1H, dd, J=2.7, 7.5 Hz), 7.42-7.68 (7H, m), 8.73 (1H, d, J=7.5 Hz)
APCI/MS: 267 [M+H]⁺

Preparation 5

To a stirred solution of 4-phenyl-3-buten-2-one (4.2 g) and 1-amino-4-methoxypyridinium iodide (16.2 g) in N,N-dimethylformamide (110 ml) was added powder potassium carbonate (16.1 g) at ambient temperature. After stirring for 14 hours, water was added to the mixture. The resultant precipitate was collected by filtration to give 1-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)ethanone (6.78 g).
NMR (DMSO- d_6 , δ): 2.20 (3H, s), 3.93 (3H, s), 6.89 (1H, dd, J=2.8 Hz, 7.5 Hz), 7.49-7.64 (6H, m), 8.73 (1H, d, J=7.5 Hz)
APCI/MS: 267 [M+H]⁺

Preparation 6

The solution of (2R,6S)-2,6-dimethylmorpholine (1.61 ml), 2-bromoethanol (1.36 ml), KHCO_3 (2.87 g) in CH_3CN (7 ml) was stirred at 70°C for 3 hours. After being cooled, the mixture

was filtered, and washed with CH_2Cl_2 , then evaporated. The residue was purified by silica-gel (55 g) column chromatography (CHCl_3 : MeOH = 9:1) to give 2-((2R,6S)-2,6-dimethylmorpholinyl)ethanol (1.94 g).

- 5 NMR (CDCl_3 , δ): 1.18 (6H, d, $J=6.3\text{Hz}$), 1.93 (2H, t, $J=10.9\text{Hz}$), 2.61 (2H, t, $J=5.3\text{Hz}$), 2.86 (2H, td, $J=1.6, 10.5\text{Hz}$), 3.12 (1H, br, s), 3.69 (2H, t, $J=5.3\text{Hz}$), 3.70-3.90 (2H, m)

APCI/MS: 160 $[\text{M}+\text{H}]^+$

Preparation 7

- 10 To the solution of 2-((2R,6S)-2,6-dimethylmorpholinyl)ethanol (1.0 g) in Toluene (5 ml) was added the solution of SOCl_2 (0.596 ml) in Toluene (1 ml) at 0°C , and the mixture was stirred for 1 hour at 70°C . After being cool, to the mixture was added IPE, and stirred for 20 minutes at 0°C . The resultant
15 precipitate was collected by filtration, and dried in vacuo for 6 hours at ambient temperature to give (2R,6S)-4-(2-chloroethyl)-2,6-dimethylmorpholine hydrochloride (0.86 g).
NMR ($\text{DMSO}-d_6$, δ): 1.12 (6H, d, $J=6.3\text{Hz}$), 2.60-2.80 (2H, m), 3.44-3.50 (4H, m), 3.95-4.10 (4H, m), 11.47 (1H, br, s)
20 APCI/MS: 178 $[\text{M}-\text{HCl}+\text{H}]^+$

Preparation 8

- To the solution of 1-(2-hydroxyethyl)-2-pyrrolidinone (3.0 g) in Toluene (15 ml) was added the solution of SOCl_2 (2.2 ml) in Toluene (3 ml) at 0°C , and the mixture was stirred for 1 hour
25 at 60°C . To the mixture was added saturated sodium hydrogen carbonate solution and the mixture was stirred for 30 minutes, and separated. The water layer was extracted with AcOEt , then the organic layer was washed with saturated sodium hydrogen carbonate solution, water and brine, and dried over magnesium
30 sulfate, then evaporated in vacuo. The residue was purified by silica-gel (90 g) column chromatography (AcOEt : n-hexane = 1:1 - 1:0) to give 1-(2-chloroethyl)-2-pyrrolidinone (2.75g).

NMR(CDCl₃, δ) : 1.95-2.20 (2H, m), 2.41 (2H, t, J=8.0Hz),
3.53 (2H, t, J=7.0Hz), 3.55-3.80 (4H, m)
APCI/MS: 148 [M+H]⁺

Preparation 9

5 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Preparation 1.

NMR(DMSO-d₆, δ): 3.93 (3H, s), 6.89 (1H, dd, J=7.5, 2.8Hz), 7.30-7.51 (3H, m), 7.56-7.84 (6H, m), 8.06 (2H, d, J=8.0Hz), 8.24 (1H, d,
10 J=9.1Hz), 8.79 (1H, d, J=7.5Hz)

APCI/MS: 461 [M+H]⁺

Preparation 10

5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar
15 procedure as that of Preparation 1.

NMR(DMSO-d₆, δ): 3.91 (3H, s), 6.86 (1H, dd, J=7.5, 2.7Hz), 7.33 (2H, t, J=8.8Hz), 7.49 (1H, d, J=9.1Hz), 7.57-7.81 (6H, m), 8.08 (2H, d, J=7.7Hz), 8.21 (1H, d, J=9.1Hz), 8.76 (1H, d, J=7.5Hz)

APCI/MS: 461 [M+H]⁺

20 Preparation 11

To a solution of 3-(6-methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine (0.5 g) in tetrahydrofuran (25 ml) was added dropwise 1.56M n-butyllithium in n-hexane (1.27 ml) below -70°C under nitrogen atmosphere. After stirring at
25 -70°C for 5 minutes, a piece of dry ice was added to the mixture, which was stirred for 0.5 hours under the same conditions. Evaporation the solvent gave a residue, which was dissolved in water and acidified with 1N-HCl. The resultant precipitate was collected by filtration, which was dissolved in chloroform. The
30 organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was recrystallized from a mixture of AcOEt and n-hexane to give 3-(6-methoxy-3-

pyridazinyl)-2- phenylpyrazolo[1,5-a]pyridine-7-carboxylic acid(0.46 g) as a solid.

mp: 181-182°C

NMR(DMSO-d₆, δ): 4.09(3H,s), 7.18(1H,d,J=4.8Hz), 7.25(1H,d,
5 J=4.8Hz), 7.47-7.65(7H,m), 8.22-8.25(1H,m), 14.27(1H,s)

ESI/MS: 345 [M-H]⁺

Preparation 12

A mixture of 3-(3-methoxy-6-pyridazinyl)-2-
10 phenylpyrazolo[1,5-a]pyridine-7-carboxylic acid(247 mg),
triethylamine (0.189 ml), and diphenylphosphoryl azide (0.292
ml) in t-BuOH (4.3 ml) was stirred at 80°C for 16 hours. After
cooling to room temperature, the mixture was partitioned between
AcOEt and water. The organic layer washed with water and brine,
15 dried over magnesium sulfate and evaporated in vacuo. The residue
was purified by silica gel column chromatography (CHCl₃-AcOEt,
97:3 elution) to give tert-butyl 3-(3-methoxy-6-
pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-
ylcarbamate(293 mg)

20 mp: 178-179°C

NMR(DMSO-d₆, δ): 1.54(9H,s), 4.08(3H,s), 7.15(1H,d,J=9.2Hz),
7.28(1H,d,J=9.2Hz), 7.39-7.48(5H,m), 7.60-7.73(2H,m), 7.73-
7.75(1H,m), 9.33(1H,s)

ESI/MS: 418 [M+H]⁺

25 Preparation 13

To a solution of tert-butyl 3-(3-methoxy-6-
pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-ylcarbamate in
dioxane(2 ml) was added 4N-HCl in dioxane(2 ml) at ambient
temperature. After stirring for 1 hour, the mixture was
30 partitioned between an aqueous sodium bicarbonate and
chloroform. The organic layer was dried over magnesium sulfate
and evaporated in vacuo. The residue was recrystallized from
a mixture of AcOEt and n-hexane to give 7-amino-3-(3

-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine (111 mg) as a solid.

mp: 235-238°C

NMR(DMSO-d₆, δ): 4.05(3H, s), 6.18-6.21(1H, m), 6.88(2H, s),
5 7.09(1H, d, J=4.6Hz), 7.21(1H, d, J=4.6Hz), 7.27-7.31(2H, m),
7.44-7.47(3H, m), 7.56-7.59(2H, m)

ESI/MS: 318 [M+H]⁺

Preparation 14

A mixture of 2-iodo-5-methoxypyridine (81.5 g),
10 ethynylbenzene(45.7 ml), (Ph₃P)₂PdCl₂(12.2 g), CuI(3.3 g) and
triethylamine(145 ml) in THF (800 ml) was stirred at reflux for
8 hours. After being cool, the reaction mixture was filtered
and evaporated. The residue was purified by silica-gel (600 g)
column chromatography (n-Hexane : AcOEt = 4 : 1 → 1 : 1). The
15 residue was purified again by silica-gel (550 g) column
chromatography (CH₂Cl₂ only → CHCl₃ only → CHCl₃: AcOEt = 9:1)
to give 5-methoxy-2-(phenylethynyl)pyridine (38.72 g).

NMR(DMSO-d₆, δ): 3.91(3H, s), 7.30-7.50(4H, m), 7.50-7.65(3H,
m), 8.19(1H, d, J=8.2Hz)

20 ESI/MS: 210 [M+H]⁺

Preparation 15

A mixture of 5-methoxy-2-(phenylethynyl)pyridine(40 g) and
O-(2,4-dinitrophenyl)hydroxylamine(76.1 g) in dioxane (800 ml)
was stirred at 90°C for 5.5 hours. After being cooled, K₂CO₃(52.8
25 g) and DMF (400 ml) was added, and the mixture was stirred at
ambient temperature for 5 hours. The reaction mixture was poured
into water (2 l), and extracted with AcOEt (2 l x 2). The organic
layer was washed with water (1 l x 4), 1N-HCl (500 ml), water
(500 ml), saturated sodium hydrogen carbonate solution (1 l),
30 water(1 l), and brine(1 l), dried over magnesium sulfate,
filtered, and evaporated in vacuo. The residue was purified by
silica-gel (750 g) column chromatography (n-Hexane : AcOEt =
4:1) to give 6-methoxy-2-phenylpyrazolo[1,5-a]pyridine (16.58

g).

ESI/MS: 225 [M+H]⁺

Preparation 16

A mixture of 6-methoxy-2-phenylpyrazolo[1,5-a]pyridine (15 g), MsOH (0.217 ml) and Ac₂O (88.4 ml) was stirred at 125°C for 7 hours. To the reaction mixture were added MeOH (54 ml) and aq. NH₃ at 0°C, and the mixture was extracted three times with AcOEt (250 ml). The organic layer was combined and washed with water (300 ml) and brine (100 ml), and was dried over magnesium sulfate, and evaporated. The residue was purified by silica-gel (400 g) column chromatography (n-Hexane : AcOEt = 4:1 → 1:1) to give 3-acetyl-6-methoxy-2-phenylpyrazolo[1,5-a]pyridine (8.70 g).

ESI/MS: 289 [M+Na]⁺

15 Preparation 17

7-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Preparation 1.

NMR (DMSO-d₆, δ): 4.16 (3H, s), 6.68 (1H, d, J=7.3 Hz), 7.35-7.62 (5H, m), 7.62-7.90 (5H, m), 7.92 (1H, d, J=8.5 Hz), 8.00-8.15 (2H, m), 8.22 (1H, d, J=9.1 Hz)

APCI/MS: 443 [M+H]⁺

Preparation 18

4-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Preparation 1.

NMR (DMSO-d₆, δ): 3.74 (3H, s), 6.84 (1H, d, J=7.7 Hz), 7.01 (1H, t, J=7.3 Hz), 7.16-7.45 (5H, m), 7.62-7.90 (3H, m), 7.95-8.14 (2H, m), 8.17 (1H, d, J=8.8 Hz), 8.46 (1H, d, J=8.8 Hz), 8.49 (1H, d, J=6.5 Hz)

30 APCI/MS: 443 [M+H]⁺

Example 1

A mixture of 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine (50.0 mg), sodium hydroxide (500 mg), water (2.0 ml), and dioxane (5.0 ml) was refluxed for 5 hours. The reaction mixture was acidified with 1N-hydrochloric acid. The mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium hydrogen carbonate and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel column chromatography (chloroform : methanol=9:1) to give 5-methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]-pyridine (40.0 mg).

mp: 245.5-247°C (AcOEt)

IR (nujol): 1679, 1652, 1575, 1560, 1540, 1513 cm⁻¹

NMR (DMSO-d₆, δ): 3.86 (3H, s), 6.74 (1H, dd, J=2.8, 7.5 Hz), 6.81 (1H, d, J=9.8 Hz), 7.08 (1H, d, J=9.8 Hz), 7.16 (1H, d, J=2.8 Hz), 7.36-7.64 (5H, m), 8.67 (1H, d, J=7.5 Hz), 13.07 (1H, s)

APCI/MS: 319 [M+H]⁺

Anal. Calcd for C₁₈H₁₄N₄O₂: C, 67.91; H, 4.43; N, 17.60

Found: C, 68.05; H, 4.37; N, 17.58

Example 2

To a stirred solution of 5-methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (400 mg) in N,N-dimethylformamide (10 ml) was added 60%-sodium hydride (80.0 mg) at ambient temperature. After being stirred for 15 minutes, isopropyl iodide (290 μl) was added to the mixture, and the mixture was stirred at ambient temperature for 18 hours. The mixture was partitioned between water and ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel column chromatography (n-hexane : ethyl acetate=2:1 to 1:1) to give 5-methoxy-3-(3-oxo-2-isopropyl-

2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
(340 mg).

mp: 180.5–181.5°C (AcOEt)

IR (nujol): 1648, 1570, 1538, 1523 cm⁻¹

5 NMR (DMSO-d₆, δ): 1.34 (6H, d, J=6.6 Hz), 3.88 (3H, s), 5.10–
5.35 (1H, m), 6.76 (1H, dd, J=2.8, 7.5 Hz), 6.83 (1H, d, J=9.6 Hz),
7.06 (1H, d, J=9.6 Hz), 7.28 (1H, d, J=2.8 Hz), 7.40–7.65 (5H, m),
8.69 (1H, d, J=7.5 Hz)

APCI/MS: 361 [M+H]⁺

10 Anal. Calcd for C₂₁H₂₀N₄O₂: C, 69.98; H, 5.59; N, 15.55

Found: C, 70.48; H, 5.59; N, 15.64

Example 3

Boron tribromide (14.4 ml) was dissolved in dichloromethane
(50 ml). To the solution was added dropwise a solution of
15 5-methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-
-phenylpyrazolo[1,5-a]pyridine (11.0 g) in dichloromethane
(150 ml) over the period of 30 minutes. After being stirred at
ambient temperature for 17 hours, the reaction mixture was poured
into water (300 ml). The mixture was extracted with
20 dichloromethane. The organic layer was washed with water and
brine, and dried over magnesium sulfate, then evaporated in vacuo.
The residue was triturated by ethyl acetate. The resultant
crystals were collected by filtration to give 5-hydroxy-3-
(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-
25 phenylpyrazolo[1,5-a]pyridine (6.59 g).

mp: >250°C (AcOEt)

IR (nujol): 1646, 1560, 1540, 1521 cm⁻¹

NMR (DMSO-d₆, δ): 1.34 (6H, d, J=6.6 Hz), 5.10–5.34 (1H, m),
6.66 (1H, dd, J=2.6, 7.5 Hz), 6.79 (1H, d, J=9.6 Hz),
30 6.99 (1H, d, J=9.6 Hz), 7.17 (1H, d, J=2.6 Hz), 7.34–7.65 (5H, m),
8.62 (1H, d, J=7.5 Hz), 10.66 (1H, s)

APCI/MS: 347 [M+H]⁺

Anal. Calcd for C₂₀H₁₈N₄O₂: C, 69.35; H, 5.24; N, 16.17

Found: C, 69.29; H, 5.24; N, 15.91

Example 4

To a solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (47.0 g) in N,N-dimethylformamide (470 ml) was added 60%-sodium hydride (16.3 g) at ambient temperature. After being stirred for 1 hour, a suspension of 2-(dimethylamino)ethylchloride hydrochloride (19.5 g) in N,N-dimethylformamide (200 ml) was added to the mixture, and the mixture was heated at 85°C for 1.5 hours. The mixture was poured into water and extracted by ethyl acetate. The organic layer was washed with water and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel column chromatography (ethyl acetate only, chloroform : methanol=9:1) to give 5-(2-dimethylamino)ethoxy-3-(3-oxo -2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (37.6 g).

mp: 138-139°C (AcOEt-IPE)

IR (nujol): 1648, 1585, 1538, 1280 cm⁻¹

NMR (DMSO-d₆, δ): 1.33 (6H, d, J=6.6Hz), 2.23 (6H, s), 2.69 (2H, t, J=5.8Hz), 4.15 (2H, t, J=5.8Hz), 5.10-5.36 (1H, m), 6.75 (1H, dd, J=2.7, 7.5Hz), 6.84 (1H, d, J=9.6Hz), 7.08 (1H, d, J=9.6Hz), 7.28 (1H, d, J=2.7Hz), 7.36-7.64 (5H, m), 8.67 (1H, d, J=7.5Hz)

APCI/MS: 418 [M+H]⁺

Anal. Calcd for C₂₄H₂₇N₅O₂: C, 69.04; H, 6.52; N, 16.77

Found: C, 69.35; H, 6.52; N, 16.82

Example 5

A mixture of 1-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)ethanone (1.20 g), glyoxylic acid monohydrate (1.66 g), and 1,4-dioxane (12 ml) was stirred at 85°C for 24 hours. After being cool, to the reaction mixture was added hydrazine monohydrate (3.28 ml). Then the reaction mixture was stirred

at 85°C for 4 hours. To the mixture was added ice-water (48 ml), and was stirred for 2 hours at ambient temperature. The resultant precipitate was collected by filtration to give 5-methoxy - 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (493 mg).

IR (nujol): 1673, 1644, 1577, 1565, 1540, 1515 cm⁻¹

NMR (DMSO-d₆, δ): 3.86 (3H, s), 6.74 (1H, dd, J=2.8, 7.6Hz), 6.81 (1H, d, J=9.9Hz), 7.08 (1H, d, J=9.8Hz), 7.16 (1H, d, J=2.6Hz), 7.28-7.75 (5H, m), 8.67 (1H, d, J=7.6Hz), 13.07 (1H, s)

10 APCI/MS: 319 [M+H]⁺

Example 6

The solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (80 mg), 4-(2-chloroethyl)morpholine hydrochloride (64.5 mg) and 15 K₂CO₃ (192 mg) in N,N-dimethylformamide (5 ml) was stirred at 50°C for 24 hours. The mixture was poured into water (30 ml) and the mixture was extracted with CHCl₃ (20 ml x 3). The organic layer was washed with water and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel 20 (5 g) column chromatography (CHCl₃ : MeOH = 9:1) to give 5-[2-(4-morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (48.0 mg).

mp: 160-162°C (CHCl₃ - n-Hexane)

25 NMR (DMSO-d₆, δ): 1.32 (6H, d, J=6.6Hz), 2.40-2.50 (4H, m), 2.76 (2H, t, J=5.6Hz), 3.58 (4H, t, J=4.6Hz), 4.19 (2H, t, J=5.7Hz), 5.10-5.35 (1H, m), 6.76 (1H, dd, J=2.7, 7.5Hz), 6.84 (1H, d, J=9.6Hz), 7.10 (1H, d, J=9.6Hz), 7.28 (1H, d, J=2.6Hz), 7.40-7.70 (5H, m), 8.67 (1H, d, J=7.5Hz)

30 APCI/MS: 460 [M+H]⁺

Example 7

To the solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (80

mg), and triethylamine (0.0644 ml) in tetrahydrofuran (3 ml) was added the solution of 4-methoxybenzenesulfonyl chloride (47.7 mg) in tetrahydrofuran (2 ml) at 0°C, and the mixture was stirred at < 5°C for 20 hours. To the mixture was added 1N-HCl (30 ml) and the mixture was extracted with AcOEt (20 ml x 3). The organic layer was washed with sat. aq. NaHCO₃ and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel (2.5 g) column chromatography (CHCl₃ : MeOH = 19:1 - 9:1) to give 5-(4-methoxyphenylsulfonyl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine.

mp: 155-157°C (CHCl₃ - n-Hexane)

NMR (DMSO-d₆, δ): 1.26 (6H, d, J=6.6 Hz), 3.86 (3H, s), 5.10-5.35 (1H, m), 6.81 (1H, dd, J=2.7, 7.5 Hz), 6.83 (1H, d, J=9.7 Hz), 6.99 (1H, d, J=9.6 Hz), 7.18 (2H, td, J=2.6, 9.5 Hz), 7.40-7.65 (6H, m), 7.86 (2H, td, J=3.6, 9.5 Hz), 8.88 (1H, d, J=7.5 Hz)

APCI/MS: 517 [M+H]⁺

Example 8

To the solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (150 mg) in N,N-dimethylformamide (1 ml) was added NaH (20.8 mg) at 0°C, and the mixture was stirred for 15 min at ambient temperature. To the mixture was added benzylbromide (0.0515 ml) at 0°C, and the mixture was stirred at 85°C for 7 hours. To the mixture was added water (2 ml) and the mixture was extracted with CHCl₃ (5 ml). The organic layer was washed with water and passed through the Presep (diatomaceous earth, granular) column with CHCl₃, and evaporated. The residue was purified by silica-gel preparative TLC (AcOEt : n-Hexane = 1:1) to give 5-benzyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine.

mp: 167.5-168.5°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.28 (6H, d, J=6.6 Hz), 5.05-5.40 (3H, m), 6.75-

6.90 (2H, m), 7.07 (1H, d, J=9.6 Hz), 7.25-7.70 (11H, m), 8.71 (1H, d, J=7.5 Hz)

APCI/MS: 487 [M+H]⁺

Example 9

5 5-Phenethyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 154.5-155.5 °C (AcOEt)

NMR (DMSO-d₆, δ): 1.27 (6H, d, J=6.6 Hz), 3.12 (2H, t, J=6.8 Hz),
10 4.31 (2H, t, J=6.9 Hz), 5.05-5.30 (1H, m), 6.74 (1H, d, J=2.6, 7.5 Hz),
6.83 (1H, d, J=9.6 Hz), 7.08 (1H, d, J=9.6 Hz), 7.10-7.40 (6H, m),
7.40-7.65 (5H, m), 8.67 (1H, d, J=7.5 Hz)

APCI/MS: 451 [M+H]⁺

Example 10

15 5-Isopropoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 162-163 °C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.20-1.50 (12H, m), 4.60-4.85 (1H, m), 5.10-
20 5.35 (1H, m), 6.70 (1H, dd, J=2.7, 7.5 Hz), 6.81 (1H, d, J=9.6 Hz),
7.01 (1H, d, J=9.7 Hz), 7.21 (1H, d, J=2.6 Hz), 7.40-7.65 (5H, m),
8.67 (1H, d, J=7.5 Hz)

APCI/MS: 389 [M+H]⁺

Example 11

25 5-[3-{(2R)-2-Methoxymethyl-4-morpholinyl}propoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (amorphous) was prepared by similar procedure as that of Example 8.

NMR (DMSO-d₆, δ): 1.35 (6H, d, J=6.6 Hz), 1.78 (1H, t, J=10.6 Hz),
30 1.85-2.15 (3H, m), 2.35-2.55 (2H, m), 2.60-2.90 (3H, m), 3.23 (3H, s),
3.90-3.90 (1H, m), 4.05-4.20 (2H, m), 5.10-5.35 (1H, m), 6.75 (1H, dd, J=2.7, 7.5 Hz),
6.83 (1H, d, J=9.6 Hz), 7.04 (1H, d, J=9.6 Hz),

7.29 (1H, d, J=2.5Hz), 7.40-7.65 (5H, m), 8.68 (1H, d, J=7.5Hz)

APCI/MS: 518 [M+H]⁺

Example 12

5 5-(2-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
prepared by similar procedure as that of Example 8.

mp: 150-151°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.25 (6H, d, J=6.6Hz), 5.05-5.30 (1H, m),
5.31 (2H, s), 6.82 (1H, d, J=9.6Hz), 6.89 (1H, dd, J=2.8, 7.5Hz),
10 7.03 (1H, d, J=9.6Hz), 7.25-7.65 (8H, m), 7.80-7.95 (1H, m),
8.60 (1H, d, J=4.0Hz), 8.73 (1H, d, J=7.5Hz)

APCI/MS: 438 [M+H]⁺

Example 13

To the solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3
15 -dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (250
mg) in N,N-dimethylformamide (1 ml) was added NaH (52 mg) at 0°C,
and the mixture was stirred for 15 min at ambient temperature.
To the mixture was added 2-(2-bromoethyl)-1H-isoindole-
1,3(2H)-dione (238 mg) at 0°C, and the mixture was stirred at
20 70°C for 24 hours. To the mixture was added water (5 ml) and the
mixture was extracted with AcOEt (5 ml) twice. The organic layer
was washed with water and brine, and dried over magnesium sulfate,
then evaporated in vacuo. The residue was purified by silica-gel
(30 g) column chromatography (AcOEt : n-Hexane = 1:1) to give
25 2-(2-{[3-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-2-
phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}ethyl)-1H-isoindole-
1,3(2H)-dione (150 mg).

NMR (DMSO-d₆, δ): 1.30 (6H, d, J=6.6Hz), 4.06 (2H, d, J=5.1Hz),
4.36 (2H, d, J=5.2Hz), 5.10-5.35 (1H, m), 6.66 (1H, dd, J=2.6, 7.5Hz),
30 6.84 (1H, d, J=9.7Hz), 7.10 (1H, d, J=9.6Hz), 7.23 (1H, d, J=2.6Hz),
7.30-8.00 (9H, m), 8.64 (1H, d, J=7.5Hz)

APCI/MS: 520 [M+H]⁺

Example 14

To the solution of 2-(2-{[3-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}ethyl)-1H-isoindole-1,3(2H)-dione (130 mg) in EtOH (3 ml) was added hydrazine monohydrate (0.0188 ml) at ambient temperature, and the mixture was stirred at ambient temperature for 3 hours. The mixture was filtered, and the mother solution was evaporated in vacuo. The residue was dissolved in CH₂Cl₂ (5 ml) and the solution was washed with water and brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel (30 g) column chromatography (CHCl₃ : MeOH = 9:1) to give 5-(2-aminoethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (45 mg).

NMR (DMSO-d₆, δ): 1.34 (6H, d, J=6.6Hz), 2.94 (2H, t, J=5.5Hz), 4.01 (2H, t, J=5.6Hz), 5.10-5.40 (1H, m), 6.76 (1H, dd, J=2.8, 7.5Hz), 6.83 (1H, d, J=9.6Hz), 7.06 (1H, d, J=9.6Hz), 7.26 (1H, d, J=2.6Hz), 7.30-7.65 (5H, m), 8.68 (1H, d, J=7.5Hz)

APCI/MS: 390 [M+H]⁺

Example 15

5-(3-Dimethylaminopropoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 125-126°C (AcOEt - IPE)

NMR (DMSO-d₆, δ): 1.34 (6H, d, J=6.6Hz), 1.80-2.05 (2H, m), 2.16 (6H, s), 2.38 (2H, t, J=7.0Hz), 4.11 (2H, t, J=6.5Hz), 5.05-5.40 (1H, m), 6.75 (1H, dd, J=2.7, 7.5Hz), 6.83 (1H, d, J=9.6Hz), 7.06 (1H, d, J=9.6Hz), 7.29 (1H, d, J=2.6Hz), 7.40-7.65 (5H, m), 8.67 (1H, d, J=7.5Hz)

APCI/MS: 432 [M+H]⁺

Example 16

5-[2-(1-Piperidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was

prepared by similar procedure as that of Example 8.

mp: 144-144.5°C (AcOEt - IPE)

NMR (DMSO-d₆, δ): 1.32 (6H, d, J=6.6Hz), 1.40-1.60 (6H, m),
2.72 (2H, t, J=6.1Hz), 4.17 (2H, t, J=5.7Hz), 5.10-5.35 (1H, m),
5 6.75 (1H, dd, J=2.7, 7.5Hz), 6.84 (1H, d, J=9.6Hz),
7.09 (1H, d, J=9.6Hz), 7.28 (1H, d, J=2.2Hz), 7.40-7.65 (5H, m),
8.67 (1H, d, J=7.5Hz)

APCI/MS: 458 [M+H]⁺

Example 17

10 5-[2-(1-Pyrrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
prepared by similar procedure as that of Example 8.

mp: 149-150°C (AcOEt - IPE)

NMR (DMSO-d₆, δ): 1.33 (6H, d, J=6.6Hz), 1.69 (4H, qn, J=3.4Hz),
15 2.85 (2H, t, J=5.8Hz), 4.17 (2H, t, J=5.9Hz), 5.05-5.35 (1H, m),
6.76 (1H, dd, J=2.7, 7.6Hz), 6.83 (1H, d, J=9.6Hz), 7.08 (1H, d,
J=9.6Hz), 7.28 (1H, d, J=2.6Hz), 7.40-7.65 (5H, m), 8.67 (1H, d,
J=7.6Hz)

APCI/MS: 444 [M+H]⁺

20 Example 18

5-[2-((3R,5S)-3,5-Dimethyl-4-morpholinyl)ethoxy]-3-(3-
-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-
-phenylpyrazolo[1,5-a]pyridine was prepared by similar
procedure as that of Example 8.

25 mp: 145-146°C (AcOEt - IPE)

NMR (DMSO-d₆, δ): 0.99 (6H, d, J=6.2), 1.34 (6H, d, J=6.6Hz), 2.50-
2.75 (2H, m), 2.90-2.75 (4H, m), 3.62 (2H, dd, J=2.9, 11.1Hz),
4.10 (2H, t, J=6.0Hz), 5.10-5.35 (1H, m), 6.73 (1H, dd, J=2.7,
7.5Hz), 6.84 (1H, d, J=9.6Hz), 7.05 (1H, d, J=9.6Hz),
30 7.31 (1H, d, J=2.6Hz), 7.35-7.65 (5H, m), 8.68 (1H, d, J=7.5Hz)

APCI/MS: 488 [M+H]⁺

Example 19

5-(4-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

5 mp: 218-219.5°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.22 (6H, d, J=6.6Hz), 5.05-5.30 (1H, m), 5.34 (2H, s), 6.83 (1H, d, J=9.6Hz), 6.90 (1H, dd, J=2.8, 7.5Hz), 7.05 (1H, d, J=9.6Hz), 7.27 (1H, d, J=2.5Hz), 7.40-7.65 (7H, m), 8.61 (2H, dd, J=1.6, 4.4Hz), 8.75 (1H, d, J=7.5Hz)

10 APCI/MS: 438 [M+H]⁺

Example 20

5-(3-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

15 mp: 145-146°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.28 (6H, d, J=6.6Hz), 5.10-5.30 (1H, m), 5.28 (2H, s), 6.80-6.95 (2H, m), 7.10 (1H, d, J=9.6Hz), 7.36 (1H, d, J=2.6Hz), 7.40-7.70 (6H, m), 7.85-8.00 (1H, dd, J=1.6, 4.8Hz), 8.59 (2H, m), 8.70-8.80 (2H, m)

20 APCI/MS: 438 [M+H]⁺

Example 21

5-Propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

25 mp: 161.5-162.5°C (AcOEt)

NMR (DMSO-d₆, δ): 1.00 (3H, t, J=7.4Hz), 1.34 (6H, d, J=6.6Hz), 1.80 (2H, q, J=7.2Hz), 4.03 (2H, t, J=6.6Hz), 5.10-5.35 (1H, m), 6.70-6.80 (1H, m), 6.83 (1H, d, J=9.6Hz), 7.06 (1H, d, J=9.7Hz), 7.25-7.35 (1H, m), 7.45-7.70 (5H, m), 8.68 (1H, d, J=7.5Hz)

30 APCI/MS: 389 [M+H]⁺

Example 22

5-Isopentyloxy-3-(3-oxo-2-isopropyl-2,3

-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 163-163.5°C (AcOEt)

NMR (DMSO-d₆, δ): 0.95 (6H, d, J=6.3Hz), 1.34 (6H, d, J=6.6Hz),
5 1.60-1.90 (3H, m), 4.09 (2H, t, J=6.6Hz), 5.10-5.35 (1H, m), 6.74 (1H, dd, J=2.7, 7.5Hz), 6.83 (1H, d, J=9.6Hz), 7.05 (1H, d, J=9.6Hz), 7.40-7.65 (5H, m), 8.67 (1H, d, J=7.5Hz)

APCI/MS: 417 [M+H]⁺

Example 23

10 5-(2-Cyclohexylethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 146-147°C (AcOEt)

NMR (DMSO-d₆, δ): 0.80-1.10 (2H, m), 1.10-1.30 (3H, m), 1.33 (6H, d, J=6.6Hz),
15 1.40-1.60 (1H, m), 1.60-1.85 (6H, m), 4.10 (2H, t, J=6.7Hz), 5.10-5.40 (1H, m), 6.74 (1H, dd, J=2.7, 7.6Hz), 6.83 (1H, d, J=9.7Hz), 7.06 (1H, d, J=9.7Hz), 7.29 (1H, d, J=2.4Hz), 7.40-7.65 (5H, m), 8.67 (1H, d, J=7.6Hz)

APCI/MS: 457 [M+H]⁺

20 Example 24

5-[2-{(2R, 6S)-2,6-Dimethyl-4-morpholinyl}ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

25 mp: 157.5-158°C (AcOEt)

NMR (DMSO-d₆, δ): 1.04 (6H, d, J=6.3Hz), 1.32 (6H, d, J=6.6Hz),
1.74 (2H, t, J=10.6Hz), 2.60-2.95 (4H, m), 3.40-3.75 (2H, m),
4.19 (2H, t, J=5.6Hz), 5.05-5.35 (1H, m), 6.76 (1H, dd, J=2.7, 7.5Hz),
6.84 (1H, d, J=9.7Hz), 7.10 (1H, d, J=9.7Hz), 7.27 (1H, d, J=2.6Hz),
30 7.40-7.65 (5H, m), 8.67 (1H, d, J=7.5Hz)

APCI/MS: 488 [M+H]⁺

Example 25

5-[2-(Diethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

5 mp: 92.5-94.5°C (Et₂O - n-Hexane)

NMR(DMSO-d₆, δ): 0.98(6H,t,J=7.1Hz), 1.33(6H,d,J=6.6Hz),
2.52(4H,q,J=6.9Hz), 2.84(2H,t,J=6.1Hz), 4.11(2H,t,J=6.1Hz),
5.10-5.40(1H,m), 6.74(1H,dd,J=2.7, 7.5Hz), 6.83(1H,d,J=9.6Hz),
7.07(1H,d,J=9.6Hz), 7.29(1H,d,J=2.6Hz), 7.40-7.65(5H,m),
10 8.67(1H,d,J=7.5Hz)

APCI/MS: 446[M+H]⁺

Example 26

5-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
15 prepared by similar procedure as that of Example 8.

mp: 181-182°C (AcOEt)

NMR(DMSO-d₆, δ): 1.33(6H,d,J=6.6Hz), 1.40(3H,t,J=6.9Hz),
4.14(2H,t,J=7.0Hz), 5.10-5.35(1H,m), 6.74(1H,dd,J=2.8, 7.5Hz),
6.82(1H,d,J=9.6Hz), 7.05(1H,d,J=9.7Hz), 7.26(1H,d,J=2.6Hz),
20 7.40-7.65(5H,m), 8.67(1H,d,J=7.5Hz)

APCI/MS: 375[M+H]⁺

Example 27

5-(2-Oxopropoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
25 prepared by similar procedure as that of Example 8.

mp: 172.5-173.5°C (AcOEt - n-Hexane)

NMR(DMSO-d₆, δ): 1.31(6H,d,J=6.6Hz), 2.17(3H,s), 4.98(2H,s),
5.10-5.35(1H,m), 6.75-6.90(2H,m), 7.00-7.20(2H,m),
7.40-7.65(5H,m), 8.71(1H,d,J=7.6Hz)

30 APCI/MS: 403[M+H]⁺

Example 28

5-[2-(2-Oxo-1-pyrrolidinyl)ethoxy]-3-(3-oxo-2-

isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 162-163°C (AcOEt - n-Hexane)

- 5 NMR(DMSO-d₆, δ): 1.48(6H,d,J=6.6Hz), 2.07(2H,qn,J=7.6Hz),
2.42(2H,t,J=8.0Hz), 3.59(2H,t,J=7.0Hz), 3.76(2H,t,J=5.1Hz),
4.18(2H,t,J=5.1Hz), 5.30-5.60(1H,m), 6.59(1H,dd,J=2.7, 7.5Hz),
6.73(1H,d,J=9.6Hz), 6.96(1H,d,J=9.6Hz), 7.33(1H,d,J=2.7Hz),
7.40-7.55(3H,m), 7.55-7.70(2H,m), 8.36(1H,d,J=7.5Hz)
- 10 APCI/MS: 458[M+H]⁺

Example 29

tert-Butyl 4-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}-1

- 15 -piperidinecarboxylate was prepared by similar procedure as that of Example 8.

mp: 176-179°C (AcOEt)

- NMR(DMSO-d₆, δ): 1.34(6H,d,J=6.6Hz), 1.41(9H,s), 1.50-1.80
(2H,m), 1.90-2.15(2H,m), 3.05-3.25(2H,m), 3.60-3.85(2H,m),
20 4.55-4.80(1H,m), 5.10-5.35(1H,m), 6.75(1H,dd,J=2.7, 7.5Hz),
6.82(1H,d,J=9.6Hz), 7.03(1H,d,J=9.6Hz), 7.29(1H,d,J=2.6Hz),
7.40-7.55(5H,m), 8.69(1H,d,J=7.5Hz)

ESI/MS: 552[M+Na]⁺

Example 30

- 25 To the solution of tert-Butyl 4-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}-1-piperidinecarboxylate(1.32 g) in AcOEt (26 ml) was added 4N-HCl/AcOEt (6.23 ml), and the mixture was stirred at 65°C for 2.5 hours. After being cool, the resultant precipitate
30 was collected by filtration, and washed with AcOEt, then dried in vacuo at ambient temperature for 15 hours to give 5-(4-Piperidinyloxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

hydrochloride(1.06 g).

NMR(DMSO-d₆, δ): 1.32(6H,d,J=6.6Hz), 1.80-2.05(2H,m), 2.05-2.30(2H,m), 2.90-3.20(2H,m), 3.20-3.40(2H,m), 4.65-4.90(1H,m), 5.10-5.35(1H,m), 6.70-6.90(2H,m), 7.08(1H,d,J=9.6Hz), 7.25(1H,
5 d,J=2.6Hz), 7.40-7.65(5H,m), 8.73(1H,d,J=7.5Hz),
8.91(2H,br,s)

APCI/MS: 430[M-HCl+H]⁺

Example 31

The solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3
10 -dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (300
mg), 2-bromopyridine(0.124 ml), K₂CO₃(359 mg) in DMF (4 ml) was
stirred at 120°C for 18 hours. After being cooled, to the mixture
was added water(20 ml) and the mixture was extracted with AcOEt
(15 ml X 3). The organic layer was washed with water and brine,
15 and dried over magnesium sulfate, then evaporated in vacuo. The
residue was purified by silica-gel(15 g) column chromatography
(AcOEt : n-Hexane = 1:1) to give 5-(2-pyridinyloxy)-3-(3-
oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-
phenylpyrazolo[1,5-a]pyridine (113.1 mg).

20 mp: 140.5-141.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.13(6H,d,J=6.6Hz), 5.00-5.25(1H,m), 6.79(1H,
d,J=9.7Hz), 6.90-7.10(2H,m), 7.20-7.35(2H,m), 7.45-7.70(6H,m),
7.90-8.10(1H,m), 8.30-8.40(1H,m), 8.87(1H,d, J=7.5Hz)

APCI/MS: 424[M+H]⁺

25 Example 32

Benzyl {[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin -6-
yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetate was
prepared by similar procedure as that of Example 8.

mp: 174-174.5°C (AcOEt)

30 NMR(DMSO-d₆, δ): 1.26(6H,d,J=6.6Hz), 5.03(2H,s), 5.15-5.30(3H,
m), 6.75-6.90(2H,m), 7.05(1H,d,J=9.6Hz), 7.17(1H,d,J=2.6Hz),
7.25-7.40(5H,m), 7.40-7.65(5H,m), 8.72(1H,d,J=7.6Hz)

APCI/MS: 495 [M+H]⁺

Example 33

To the solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (200 mg), 2-cyclopentylethanol (0.086 ml), PPh₃ (303 mg) in THF (4 ml) was added dropwise DEAD (0.182 ml) at 0°C. The mixture was stirred at ambient temperature for 36 hours. To the mixture was added saturated sodium hydrogen carbonate solution and the mixture was extracted with AcOEt. The organic layer was washed with brine, and dried over magnesium sulfate, then evaporated in vacuo. The residue was purified by silica-gel (40 g) column chromatography (CHCl₃ : MeOH = 50:1) to give 5-(2-cyclopentylethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (14.1 mg).

mp: 159.5-160.5°C (Et₂O - n-Hexane)

NMR (DMSO-d₆, δ): 1.05-1.30 (2H, m), 1.34 (6H, d, J=6.6 Hz), 1.45-1.70 (4H, m), 1.70-2.05 (5H, m), 4.08 (2H, t, J=6.6 Hz), 5.10-5.35 (1H, m), 6.74 (1H, dd, J=2.7, 7.5 Hz), 6.82 (1H, d, J=9.6 Hz), 7.04 (1H, d, J=9.6 Hz), 7.30 (1H, d, J=2.6 Hz), 7.45-7.65 (5H, m), 8.67 (1H, d, J=7.5 Hz)

APCI/MS: 443 [M+H]⁺

Example 34

5-[2-(1-Aziridinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 33.

mp: 159-160°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.25-1.45 (6H, m), 1.85-2.30 (4H, m), 3.85-4.10 (2H, m), 5.10-5.30 (1H, m), 5.90-6.05 (1H, m), 6.73 (1H, dd, J=2.7, 7.5 Hz), 6.82 (1H, d, J=9.6 Hz), 7.02 (1H, d, J=9.6 Hz), 7.35-7.70 (5H, m), 8.69 (1H, d, J=7.5 Hz)

APCI/MS: 416 [M+H]⁺

Example 35

5-(4-Pyridinyloxy)-3-(3-oxo-2-isopropyl-2,3

-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 31.

mp: 218.5-219.5°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 1.07 (6H, d, J=6.6Hz), 5.00-5.23 (1H, m), 6.79 (1H, d, J=9.7Hz), 7.01 (1H, d, J=9.7Hz), 7.05 (1H, dd, J=2.5, 7.5Hz), 7.29 (2H, dd, J=1.6, 4.6Hz), 7.42 (1H, d, J=2.2Hz), 7.45-7.65 (5H, m), 8.61 (2H, dd, J=1.6, 4.6Hz), 8.91 (1H, d, J=7.5Hz)

APCI/MS: 424 [M+H]⁺

Example 36

10 The solution of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (346
mg), 3-(acetylamino)phenylboronic acid (180 mg), Cu(OAc)₂ (181
mg), Et₃N (0.696 ml), 4AMS (125 mg) in CH₂Cl₂ (5 ml) was refluxed
for 20 hours. After being cooled, the mixture was filtrated by
15 Celite, and washed with AcOEt. The solvent was evaporated in
vacuo. The residue was purified by silica-gel (35 g) column
chromatography (AcOEt : n-Hexane = 1:1 → 3:2 → 2:1 → 3:1 → 1:0)
to give N-(3-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-
yl)
20 -2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}phenyl)acetamide
(41.7 mg).

mp: 177.5-178.5°C (AcOEt)

NMR (DMSO-d₆, δ): 0.99 (6H, d, J=6.6Hz), 2.04 (3H, s), 4.97-5.15 (1H, m), 6.72 (1H, d, J=9.7Hz), 6.88 (1H, d, J=9.7Hz), 6.90-7.00 (1H, m), 7.02 (1H, dd, J=2.6, 7.5Hz), 7.16 (1H, d, J=7.5Hz), 7.41 (2H, d, J=5.1Hz), 7.45-7.65 (5H, m), 7.65 (1H, s), 8.84 (1H, d, J=7.5Hz), 10.13 (1H, s)

APCI/MS: 480 [M+H]⁺

Example 37

30 5-Phenoxy-3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
prepared by similar procedure as that of Example 36.

mp: 181-182°C (AcOEt - n-Hexane)

NMR (DMSO-d₆, δ): 0.97 (6H, d, J=6.6Hz), 4.90-5.20 (1H, m), 6.72 (1H, d, J=9.7Hz), 6.88 (1H, d, J=9.7Hz), 6.95-7.05 (1H, m), 7.12 (1H, d, J=2.2Hz), 7.25-7.40 (3H, m), 7.45-7.65 (7H, m), 8.83 (1H, d, J=7.0Hz)

5 APCI/MS: 423 [M+H]⁺

Example 38

Ethyl {[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetate was prepared by similar procedure as that of Example 8.

10 mp: 193-194°C (AcOEt)

NMR (DMSO-d₆, δ): 1.25 (3H, t, J=7.1Hz), 1.31 (6H, d, J=6.6Hz), 4.18 (2H, q, J=7.1Hz), 4.95 (2H, s), 5.10-5.35 (1H, m), 6.75-6.90 (2H, m), 7.03 (1H, d, J=9.6Hz), 7.18 (1H, d, J=2.7Hz), 7.40-7.65 (5H, m), 8.73 (1H, d, J=7.6Hz)

15 APCI/MS: 433 [M+H]⁺

Example 39

To the solution of ethyl {[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetate (2.30 g) in EtOH (20 ml) was added 1N-aq.NaOH (6 ml), and the mixture was stirred at 70°C for 30 minutes. The reaction mixture was acidified with 1N-aq.HCl to pH 1-2, and extracted with AcOEt twice, and the organic layer was washed with water twice and brine, and dried over magnesium sulfate, then evaporated in vacuo to give [3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxyacetic acid (2.13 g).

mp: 219.5-218.3°C (75% aq.EtOH)

NMR (DMSO-d₆, δ): 1.33 (6H, d, J=6.6Hz), 4.83 (2H, s), 5.10-5.35 (1H, m), 6.70-6.90 (2H, m), 7.01 (1H, d, J=9.6Hz), 7.19 (1H, d, J=2.6Hz), 7.40-7.70 (5H, m), 8.71 (1H, d, J=7.5Hz), 13.25 (1H, br, s)

30 APCI/MS: 405 [M+H]⁺

Example 40

To the solution of [{3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin
-5-yl}oxy]acetic acid (500 mg), 2-(1H-benzotriazol-1-yl)-
5 1,1,3,3-tetramethyluronium tetrafluoroborate; TBTU(794 mg) in
DMF(2.5 ml) was added ethyldiisopropylamine(0.646 ml), and the
mixture was stirred at ambient temperature for 15 minutes. To
the mixture was added N,N-dimethylamine hydrochloride(151 mg),
and the mixture was stirred at ambient temperature for 1.5 hours.
10 To the reaction mixture was added saturated sodium hydrogen
carbonate solution, and was acidified with 1N-HCl, then was
extracted with AcOEt. The organic layer was washed with water
twice and saturated sodium hydrogen carbonate solution, water
and brine, then dried over magnesium sulfate, and evaporated
15 in vacuo. The residue was purified by silica-gel(11 g) column
chromatography (CHCl₃ : MeOH = 40:1 - 20:1) to give 2-{{[3-
(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin
-5-yl]oxy}-N,N-dimethylacetamide(390 mg).
20 mp: 189-190°C (AcOEt - n-Hexane)
NMR(DMSO-d₆, δ): 1.33(6H,d,J=6.6Hz), 2.96(3H,s), 2.98(3H,s),
5.01(2H,s), 5.10-5.30(1H,m), 6.75-6.85(2H,m), 6.97(1H,d,
J=9.6Hz), 7.15(1H,d,J=2.5Hz), 7.40-7.70(5H,m), 8.69(1H,d,
J=7.5Hz)
25 APCI/MS: 432[M+H]⁺

Example 41

N,N-Diethyl-2-{{[3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin
-5-yl]oxy}acetamide was prepared by similar procedure as that
30 of Example 40.
mp: 125-126.5°C (AcOEt - n-Hexane)
NMR(DMSO-d₆, δ): 1.03(3H,t,J=7.1Hz), 1.17(3H,dt,J=2.7, 7.1 Hz),
1.33(6H,d,J=6.6Hz), 3.20-3.45(4H,m), 4.97(2H,s), 5.05-5.35(1H,

m), 6.70-6.90 (2H, m), 7.02 (1H, d, J=9.6Hz), 7.17 (1H, d, J=2.5Hz), 7.40-7.65 (5H, m), 8.70 (1H, d, J=7.5Hz)

APCI/MS: 460 [M+H]⁺

Example 42

- 5 tert-Butyl 4-({[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetyl)-1-piperazinecarboxylate was prepared by similar procedure as that of Example 40.

mp: 139.5-143.5°C (AcOEt - n-Hexane)

- 10 NMR(DMSO-d₆, δ): 1.32 (6H, d, J=6.6Hz), 1.42 (9H, s), 2.69 (4H, s), 3.25-3.55 (4H, m), 5.02 (2H, s), 5.10-5.35 (1H, m), 6.70-6.90 (2H, m), 7.03 (1H, d, J=9.6Hz), 7.17 (1H, d, J=2.5Hz), 7.35-7.65 (5H, m), 8.70 (1H, d, J=7.5Hz)

ESI/MS: 495 [M+Na]⁺

- 15 Example 43

5-[2-Oxo-2-(1-piperazinyl)]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride was prepared by similar procedure as that of Example 30.

- 20 mp: 191-193.5°C (IPA)

NMR(DMSO-d₆, δ): 1.32 (6H, d, J=6.6Hz), 3.00-3.25 (4H, m), 3.55-3.85 (4H, m), 5.08 (2H, s), 5.10-5.35 (1H, m), 6.75-6.90 (2H, m), 7.04 (1H, d, J=9.6Hz), 7.16 (1H, d, J=2.5Hz), 7.40-7.65 (5H, m), 8.71 (1H, d, J=7.5Hz), 9.21 (2H, br, s)

- 25 APCI/MS: 473 [M-HCl+H]⁺

Example 44

2-({[3-(3-Oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}-N-phenylacetamide was prepared by similar procedure as that of Example 40.

- 30 mp: 208-209°C (AcOEt)

NMR(DMSO-d₆, δ): 1.23 (6H, d, J=6.6Hz), 4.86 (2H, s), 5.05-5.30 (1H, m), 6.79 (1H, d, J=9.6Hz), 6.85-6.95 (1H, m), 6.95-7.15 (2H, m),

7.23 (1H, d, J=2.6Hz), 7.33 (2H, t, J=7.8Hz), 7.40-7.75 (7H, m),
8.75 (1H, d, J=7.6Hz), 10.18 (1H, s)

APCI/MS: 480 [M+H]⁺

Example 45

- 5 N-Isobutyl-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of Example 40.

mp: 167.5-168.5°C (AcOEt)

- 10 NMR(DMSO-d₆, δ): 0.79 (6H, d, J=6.7Hz), 1.30 (6H, d, J=6.6Hz),
1.55-1.85 (1H, m), 2.95 (2H, t, J=6.4Hz), 4.62 (2H, s), 5.05-5.35 (1H,
m), 6.75-6.95 (2H, m), 7.08 (1H, d, J=9.6Hz), 7.16 (1H, d, J=2.6Hz),
7.35-7.65 (5H, m), 8.16 (1H, t, J=5.7Hz), 8.73 (1H, d, J=7.5Hz)

APCI/MS: 460 [M+H]⁺

- 15 Example 46

5-(Tetrahydropyran-4-yl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 210.5-211°C (AcOEt)

- 20 NMR(DMSO-d₆, δ): 1.35 (6H, d, J=6.6Hz), 1.55-1.80 (2H, m), 1.95-
2.20 (2H, m), 3.80-4.00 (2H, m), 4.55-4.80 (1H, m), 5.10-5.35 (1H, m),
6.75 (1H, dd, J=2.7, 7.6Hz), 6.81 (1H, d, J=9.7Hz), 7.31 (1H, d,
J=2.6Hz), 7.40-7.65 (5H, m), 8.69 (1H, d, J=7.5Hz)

ESI/MS: 453 [M+Na]⁺

- 25 Example 47

5-[(5-Methoxy-2-pyridinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

mp: 148-150°C (AcOEt)

- 30 NMR(DMSO-d₆, δ): 1.09 (6H, d, J=6.6Hz), 3.86 (3H, s), 4.95-5.25 (1H,
m), 6.76 (1H, d, J=9.6Hz), 6.90-7.10 (2H, m), 7.25-7.40 (2H, m),
7.40-7.75 (6H, m), 7.75-7.90 (1H, m), 8.84 (1H, d, J=7.5Hz)

ESI/MS: 476[M+Na]⁺

Example 48

5-[(5-Nitro-2-pyridinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
5 prepared by similar procedure as that of Example 8.

mp: 182-183.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.20(6H, d, J=6.6Hz), 5.00-5.30(1H, m), 6.84(1H, d, J=9.6Hz), 7.00-7.20(2H, m), 7.35-7.65(6H, m), 7.72(1H, d, J=2.4Hz), 8.71(1H, dd, J=2.9, 9.1Hz), 8.94(1H, d, J=7.5Hz),
10 9.10(1H, d, J=2.8Hz)

ESI/MS: 491[M+Na]⁺

Example 49

Methyl {[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetate was prepared by similar procedure as that of
15 Example 19.

NMR(DMSO-d₆, δ): 1.32(6H, d, J=6.6Hz), 3.73(3H, s), 4.97(2H, s), 5.10-5.35(1H, m), 6.750-6.90(2H, m), 7.02(1H, d, J=9.6Hz), 7.19(1H, d, J=2.7Hz), 7.40-7.65(5H, m), 8.72(1H, d, J=7.5Hz)

20 ESI/MS: 441[M+Na]⁺

Example 50

To the mixture of [{3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl}oxy]acetic acid (200 mg), WSC-HCl(114 mg), HOBt(80.2 mg)
25 in DMF(1.0 ml) was added 1-methylpiperadine(0.0603 ml) at 0°C, and the mixture was stirred at ambient temperature for 3.5 hours. To the reaction mixture was added water, and the mixture was extracted with AcOEt three times, then the organic layer was washed with water twice and brine, and dried over magnesium
30 sulfate, and evaporated in vacuo. The residue was purified by silica-gel(8 g) column chromatography (CHCl₃ : MeOH = 9:1) to give 5-[2-(4-methyl-1-piperazinyl)-2-oxo]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-

a]pyridine (151.0 mg).

mp: 147-148°C (AcOEt - n-Hexane)

NMR(DMSO-d₆, δ): 1.32(6H,d,J=6.6Hz), 2.19(3H,s), 2.10-2.45(4H,m), 3.25-3.60(4H,m), 5.00(2H,s), 5.05-5.35(1H,m), 6.70-6.90(2H,m), 7.03(1H,d,J=9.6Hz), 7.16(1H,d,J=2.6Hz), 7.35-7.65(5H,m), 8.69(1H,d,J=7.5Hz)

ESI/MS: 487[M+H]⁺

Example 51

5-[2-(4-Morpholinyl)-2-oxo]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 50.

mp: 192.5-193.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.33(6H,d,J=6.6Hz), 3.35-3.75(8H,m), 5.02(2H,s), 5.10-5.35(1H,m), 6.70-6.90(2H,m), 7.03(1H,d,J=9.6Hz), 7.17(1H,d,J=2.6Hz), 7.35-7.65(5H,m), 8.70(1H,d,J=7.5Hz)

ESI/MS: 474[M+Na]⁺

Example 52

N,N-Bis(2-ethoxyethyl)-2-[(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetamide (amorphous) was prepared by similar procedure as that of Example 50.

NMR(DMSO-d₆, δ): 0.90-1.15(6H,m), 1.32(6H,d,J=6.6Hz), 3.20-3.60(12H,m), 5.06(2H,s), 5.10-5.30(1H,m), 6.70-6.90(2H,m), 7.03(1H,d,J=9.6Hz), 7.08(1H,d,J=2.6Hz), 7.35-7.65(5H,m), 8.69(1H,d,J=7.5Hz)

ESI/MS: 570[M+Na]⁺

Example 53

5-[2-(4-Benzyl-1-piperazinyl)-2-oxo]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 50.

mp: 128-129.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.31(6H, d, J=6.6Hz), 2.20-2.50(4H, m), 3.30-3.60(4H, m), 5.00(2H, s), 5.05-5.30(1H, m), 6.70-6.90(2H, m), 7.03(1H, d, J=9.6Hz), 7.14(1H, d, J=2.6Hz), 7.20-7.40(5H, m), 8.69(1H, d, J=7.5Hz)

5 ESI/MS: 563[M+H]⁺

Example 54

5-[2-(4-Acetyl-1-piperazinyl)-2-oxo]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar
10 procedure as that of Example 50.

mp: 170-171.5°C (AcOEt - IPE)

NMR(DMSO-d₆, δ): 1.32(6H, d, J=6.6Hz), 2.04(3H, s), 3.30-3.65(8H, m), 5.05(2H, s), 5.10-5.35(1H, m), 6.75-6.90(2H, m), 7.03(1H, d, J=9.7Hz), 7.18(1H, d, J=2.6Hz), 7.35-7.65(5H, m), 8.70(1H, d,
15 J=7.6Hz)

ESI/MS: 537[M+Na]⁺

Example 55

To a solution of 5-[2-(1-piperazinyl)-2-oxo]ethoxy-3-(3-oxo-2-isopropyl-2,3
20 -dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride(100 mg) in CH₂Cl₂(1.0 ml) was added triethylamine(0.0548 ml) at 0°C. To the mixture was added dropwise N,N-dimethylcarbonylchloride(0.0181 ml) in CH₂Cl₂(1.0 ml) at 0°C during 5 minutes, and the mixture was stirred at
25 ambient temperature for 3 hours. To the reaction mixture was added water, and the mixture was stirred for 15 minutes, then the organic layer passed through the Presep(diatomaceous earth, granular) column with CH₂Cl₂, and evaporated. The residue was purified by silica-gel(4 g < 30 V >) column chromatography
30 (chloroform : MeOH = 19:1) to give N,N-dimethyl-4-[(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetyl-1-piperazinecarboxamide (53.4 mg).

mp: 151-152°C (AcOEt - IPE)

NMR(DMSO-d₆, δ): 1.32(6H, d, J=6.6Hz), 2.77(6H, s), 3.00-3.60(8H, m), 5.03(2H, s), 5.05-5.35(1H, m), 6.75-6.90(2H, m), 7.03(1H, d, J=9.6Hz), 7.17(1H, d, J=2.6Hz), 7.35-7.65(5H, m), 8.70(1H, d, J=7.6Hz)

ESI/MS: 566[M+Na]⁺

Example 56

N,N-Dimethyl-4-[(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-1-piperidinecarboxamide was prepared by similar procedure as that of Example 55.

mp: 164-166°C (AcOEt)

NMR(DMSO-d₆, δ): 1.35(6H, d, J=6.7Hz), 1.55-1.85(2H, m), 1.90-2.20(2H, m), 2.75(6H, s), 2.85-3.15(2H, m), 3.25-3.60(2H, m), 4.55-4.75(1H, m), 5.10-5.35(1H, m), 6.65-6.90(2H, m), 7.01(1H, d, J=9.6Hz), 7.30(1H, d, J=2.6Hz), 7.40-7.65(5H, m), 8.69(1H, d, J=7.5Hz)

ESI/MS: 523[M+Na]⁺

Example 57

5-[(1-Acety-4-piperidinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 55.

mp: 198-199°C (AcOEt - IPE)

NMR(DMSO-d₆, δ): 1.35(6H, d, J=6.7Hz), 1.45-1.85(2H, m), 1.85-2.20(2H, m), 2.03(3H, s), 3.05-3.45(2H, m), 3.60-4.05(2H, m), 4.60-4.80(1H, m), 5.10-5.35(1H, m), 6.76(1H, dd, J=2.7, 7.6Hz), 6.82(1H, d, J=9.7Hz), 7.03(1H, d, J=9.6Hz), 7.30(1H, d, J=2.6Hz), 7.40-7.65(5H, m), 8.69(1H, d, J=7.5Hz)

ESI/MS: 494[M+Na]⁺

Example 58

To the mixture of { [3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin

-5-yl]oxy}acetic acid(150 mg), WSC-HCl(85.3 mg), HOBt(60.1 mg) in DMF (1.0 ml) was added N,N-dimethylethylenediamine(0.0448 ml) at 0°C, and the mixture was stirred at ambient temperature for 1.5 hours. To the reaction mixture was added water, and the mixture was extracted with AcOEt, then the organic layer was washed with water twice and brine. Then the organic layer was passed through the Presep (diatomaceous earth, granular) column with AcOEt, and evaporated. The residue was purified by silica-gel(5 g) column chromatography (chloroform : MeOH = 9:1) to give N-[2-(dimethylamino)ethyl]-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide(83.0 mg).
mp: 117-119°C (AcOEt - IPE)

NMR(DMSO-d₆, δ): 1.325(6H,d,J=6.6Hz), 2.11(6H,s), 2.29(2H,t,J=6.7Hz), 3.22(2H,q,J=6.3Hz), 4.61(2H,s), 5.10-5.35(1H,m), 6.75-6.90(2H,m), 7.08(1H,d,J=9.7Hz), 7.18(1H,d,J=2.6Hz), 7.40-7.65(5H,m), 8.07(1H,t,J=5.6Hz), 8.72(1H,d,J=7.5Hz)
ESI/MS: 475[M+H]⁺

20 Example 59

2-{[3-(3-Oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}-N-(3-methoxybenzyl)acetamide was prepared by similar procedure as that of Example 58.

25 mp: 166-167.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.29(6H,d,J=6.6Hz), 2.90(2H,t,J=7.2Hz), 3.51(2H,q,J=6.5Hz), 4.60(2H,s), 5.05-5.30(1H,m), 6.75-6.90(2H,m), 7.07(1H,d,J=9.7Hz), 7.10-7.25(3H,m), 7.40-7.70(6H,m), 8.28(1H,t,J=5.8Hz), 8.40-8.50(1H,m), 8.72(1H,d,J=7.5Hz)

30 ESI/MS: 546[M+Na]⁺

Example 60

2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}-N-[2-(2-

pyridinyl)

-ethyl]acetamide was prepared by similar procedure as that of Example 58.

mp: 188-190°C (AcOEt)

- 5 NMR (DMSO-d₆, δ): 1.30 (6H, d, J=6.6Hz), 2.90 (3H, s), 4.32 (2H, d, J=6.0Hz), 4.70 (2H, s), 5.05-5.30 (1H, m), 6.70-6.90 (5H, m), 7.00-7.25 (3H, m), 7.40-7.65 (5H, m), 8.65-8.80 (2H, m)

ESI/MS: 531 [M+Na]⁺

Example 61

- 10 N-Cyclopropyl-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of Example 58.

mp: 199-200°C (AcOEt)

- 15 NMR (DMSO-d₆, δ): 0.35-0.55 (2H, m), 0.55-0.75 (2H, m), 1.31 (6H, d, J=6.6Hz), 2.60-2.80 (1H, m), 4.57 (2H, s), 5.05-5.35 (1H, m), 6.75-6.90 (2H, m), 7.07 (1H, d, J=9.6Hz), 7.16 (1H, d, J=2.6Hz), 7.35-7.65 (5H, m), 8.22 (1H, d, J=4.0Hz), 8.72 (1H, d, J=7.5Hz)

ESI/MS: 466 [M+Na]⁺

- 20 Example 62

N-Cyclopentyl-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of Example 58.

- 25 mp: 187-188°C (AcOEt)

NMR (DMSO-d₆, δ): 1.30 (6H, d, J=6.6Hz), 1.30-1.95 (8H, m), 3.95-4.20 (1H, m), 4.58 (2H, s), 5.05-5.35 (1H, m), 6.75-6.95 (2H, m), 7.09 (1H, d, J=9.6Hz), 7.15 (1H, d, J=2.6Hz), 7.35-7.65 (5H, m), 8.06 (1H, d, J=7.4Hz), 8.72 (1H, d, J=7.5Hz)

- 30 ESI/MS: 494 [M+Na]⁺

Example 63

N-Cyclohexyl-2-{[3-(3-oxo-2-isopropyl-2,3

-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of Example 58.

mp: 170-171.5°C (AcOEt)

5 NMR(DMSO-d₆, δ): 0.95-1.45(5H,m), 1.30(6H,d,J=6.6Hz), 1.45-1.85(5H,m), 3.45-3.75(1H,m), 4.58(2H,s), 5.05-5.30(1H,m), 6.75-6.95(2H,m), 7.10(1H,d,J=9.6Hz), 7.15(1H,d,J=2.6Hz), 7.35-7.65(5H,m), 7.98(1H,d,J=8.0Hz), 8.72(1H,d,J=7.5Hz)

ESI/MS: 508[M+Na]⁺

10 Example 64

N-(4-Hydroxycyclohexyl)-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of Example 58.

15 mp: 146-148°C (AcOEt)

NMR(DMSO-d₆, δ): 1.05-1.45(4H,m), 1.29(6H,d,J=6.6Hz), 1.60-1.90(4H,m), 3.40-3.70(1H,m), 4.53(1H,d,J=4.4Hz), 4.57(2H,s), 5.05-5.35(1H,m), 6.75-6.90(2H,m), 7.10(1H,d,J=9.6Hz), 7.14(1H,d,J=2.6Hz), 7.35-7.65(5H,m), 7.95(1H,d,J=7.9Hz), 8.72(1H,d,
20 J=7.5Hz)

Negative ESI/MS: 500[M-H]⁻

Example 65

N-Butyl-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that
25 of Example 58.

mp: 151-152°C (AcOEt)

NMR(DMSO-d₆, δ): 0.82(3H,t,J=7.2Hz), 1.10-1.50(4H,m), 1.31(6H,d,J=6.6Hz), 3.16(2H,q,J=6.4Hz), 4.60(2H,s), 5.05-5.35(1H,m),
30 6.75-6.90(2H,m), 7.07(1H,d,J=9.6Hz), 7.17(1H,d,J=2.6Hz), 7.35-7.65(5H,m), 8.15(1H,d,J=5.6Hz), 8.72(1H,d,J=7.5Hz)

ESI/MS: 482[M+Na]⁺

Example 66

N-(2-Methoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide was prepared by similar procedure as that
5 of Example 58.

mp: 144.5-145.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.31(6H,d,J=6.6Hz), 3.21(3H,s), 3.25-3.45(4H,m), 4.62(2H,s), 5.10-5.30(1H,m), 6.75-6.90(2H,m), 7.08(1H,d,J=9.6Hz), 7.18(1H,d,J=2.6Hz), 7.40-7.65(5H,m), 8.22(1H,t,
10 J=5.2Hz), 8.72(1H,d,J=7.5Hz)

ESI/MS: 484 [M+Na]⁺

Example 67

N-(2-Ethoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide was prepared by similar procedure as that
15 of Example 58.

mp: 126.5-127.5°C (AcOEt)

NMR(DMSO-d₆, δ): 1.05(3H,t,J=6.9Hz), 1.31(6H,d,J=6.6Hz), 3.15-3.50(6H,m), 4.62(2H,s), 5.05-5.30(1H,m), 6.75-6.95(2H,m),
20 7.07(1H,d,J=9.6Hz), 7.18(1H,d,J=2.5Hz), 7.40-7.65(5H,m), 8.20(1H,t,J=5.4Hz), 8.72(1H,d,J=7.5Hz)

ESI/MS: 498 [M+Na]⁺

Example 68

To a mixture of 5-hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
25 (1.00 g) and 2,6-lutidine (0.67 ml) in CH₂Cl₂ (20 ml) was added trifluoromethanesulfonic anhydride (0.73 ml) at 5°C. After stirring for 1.5 hours, the reaction mixture was concentrated and dissolved in AcOEt, washed with water, 1N HCl, water,
30 saturated sodium hydrogen carbonate solution, water, and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (n-hexane-AcOEt 3:2 elution) to give [3-(3-oxo-2-isopropyl-2,3

-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl] -trifluoromethanesulfonate (1.31 g) as a solid.

¹H NMR (CDCl₃, δ): 1.49 (6H, d, J=6.6Hz), 5.44 (1H, h, J=6.6Hz), 6.76 (1H, d, J=9.7Hz), 6.86 (1H, dd, J=7.6, 2.8Hz), 6.97 (1H, d, J=9.7Hz),
5 7.40-7.66 (5H, m), 8.04 (1H, dd, J=2.8, 0.5Hz), 8.57 (1H, dd, J=7.6, 0.5Hz)

APCI/MS: 479 [M+H]⁺

Example 69

A mixture of [3-(3-oxo-2-isopropyl-2,3
10 -dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl] -trifluoromethanesulfonate (800 mg), palladium(II) acetate (75 mg), 1,3-bis(diphenylphosphino)propane (138 mg), triethylamine (0.70 ml), and MeOH (4 ml) in DMF (8 ml) was stirred under carbon monoxide atmosphere at ambient temperature for 2
15 hours. The reaction mixture was diluted with AcOEt, washed with water, saturated sodium hydrogen carbonate solution, water (x 3), and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl₃-AcOEt 5:1 elution) to give methyl 3-(3-oxo-2-
20 isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
-5-carboxylate (553.2 mg) as a solid.

mp: 186-187°C (AcOEt)

IR (KBr): 1714, 1664, 1595, 1533, 1469, 1294 cm⁻¹

25 ¹H NMR (CDCl₃, δ): 1.52 (6H, d, J=6.6Hz), 3.98 (3H, s), 5.46 (1H, h, J=6.6Hz), 6.78 (1H, d, J=9.7Hz), 7.03 (1H, d, J=9.7Hz), 7.43-7.55 (4H, m), 7.55-7.68 (2H, m), 8.54 (1H, dd, J=7.3, 0.9Hz), 8.83 (1H, dd, J=1.9, 0.9Hz)

ESI/MS: 411 [M+Na]⁺

30 Example 70

To a solution of methyl 3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5
-carboxylate (524 mg) in MeOH-THF (1:1, 15 ml) was added 1N NaOH

solution (6.75 ml) and the mixture was stirred at ambient temperature for 1 hour. The organic solvent was evaporated, and THF was added. Then the mixture was acidified with 1N HCl under ice-cooling, and extracted with AcOEt. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid (438.2 mg) as a solid.

IR (KBr): 2927, 1703, 1643, 1574, 1535 cm^{-1}

¹H NMR (CDCl_3 , δ): 1.35 (6H, d, J=6.6Hz), 5.25 (1H, h, J=6.6Hz), 6.89 (1H, d, J=9.6Hz), 7.13 (1H, d, J=9.6Hz), 7.43 (1H, dd, J=7.2, 1.8Hz), 7.45-7.70 (5H, m), 8.61 (1H, dd, J=1.8, 0.8Hz), 8.89 (1H, dd, J=7.2, 0.8Hz), 13.50 (1H, br)

Negative ESI/MS: 373 [M-H]⁻

15 Example 71

A mixture of [3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-trifluoromethanesulfonate (90 mg), tetrakis(triphenylphosphine)palladium(0) (33 mg), $\text{Zn}(\text{CN})_2$ (45 mg), triethylamine (0.078 ml) in DMF was stirred at 80°C for 31 hours. After cooling to ambient temperature, the reaction mixture was diluted with AcOEt, washed with saturated sodium hydrogen carbonate solution, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-AcOEt 3:4 elution) to give 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carbonitrile (59.2 mg) as a solid.

mp: 202-203°C (AcOEt)

IR (KBr): 2981, 2227, 1658, 1587 cm^{-1}

¹H NMR (CDCl_3 , δ): 1.50 (6H, d, J=6.6Hz), 5.44 (1H, h, J=6.6Hz), 6.78 (1H, d, J=9.6Hz), 6.99 (1H, d, J=9.6Hz), 7.02 (1H, dd, J=7.2, 1.9Hz), 7.40-7.66 (5H, m), 8.39 (1H, dd, J=1.9, 1.0Hz), 8.59 (1H, dd, J=7.2,

1.0Hz)

APCI/MS: 356[M+H]⁺

Example 72

To a solution of 3-(3-oxo-2-isopropyl-2,3
5 -dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-
carboxylic acid (50 mg) and 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) (86 mg) in
DMF (2 ml) was added N,N-diisopropylethylamine (0.082 ml), and
the mixture was stirred at ambient temperature for 10 minutes.
10 To the mixture was added dimethylamine hydrochloride (22 mg),
and stirred at the same temperature for 4 hours. The reaction
mixture was diluted with AcOEt, washed with 0.1N HCl, water,
saturated sodium hydrogen carbonate solution, water and brine,
dried over magnesium sulfate, and evaporated in vacuo. The
15 residue was purified by silica gel column chromatography
(CH₂Cl₂-MeOH, 20:1 elution) to give N,N-dimethyl- 3-(3-oxo-
2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5
-carboxamide (61.8 mg) as a solid.
20 IR (KBr): 2925, 1662, 1641, 1591, 1537, 1496, 1468, 1448, 1389
cm⁻¹
¹H NMR (CDCl₃, δ): 1.46 (6H, d, J=6.6Hz), 3.15 (6H, s), 5.43 (1H, h,
J=6.6Hz), 6.76 (1H, d, J=9.6Hz), 6.99 (1H, dd, J=7.1, 1.8Hz), 7.01
(1H, d, J=9.6Hz), 7.40-7.68 (5H, m), 8.06 (1H, dd, J=1.8, 0.9Hz),
25 8.55 (1H, dd, J=7.1, 0.9Hz)

APCI/MS: 402[M+H]⁺

Example 73

To a mixture of 3-(3-oxo-2-isopropyl-2,3
-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5
30 -carboxylic acid (50 mg) and pyrrolidine (0.015 ml) in DMF (2 ml)
was added 1-hydroxybenzotriazole (27 mg) and 1-ethyl-3-(3'-
dimethylaminopropyl)carbodiimide hydrochloride (51 mg). After
stirring at ambient temperature for 24 hours, the reaction

mixture was diluted with AcOEt, washed with 0.1N HCl, water, saturated sodium hydrogen carbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography

5 (CH₂Cl₂-MeOH, 20:1 elution) to give 5-(1-pyrrolidinylcarbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (56.2 mg) as a solid.

mp: 189-190°C (AcOEt)

10 IR (KBr): 1668, 1616, 1595, 1531, 1469, 1404 cm⁻¹

¹H NMR (CDCl₃, δ): 1.46 (6H, d, J=6.6Hz), 1.85-2.10 (4H, m), 3.48-3.77 (4H, m), 5.43 (1H, h, J=6.6Hz), 6.77 (1H, d, J=9.6Hz), 7.02 (1H, d, J=9.6Hz), 7.09 (1H, dd, J=7.1, 1.8Hz), 7.40-7.68 (5H, m), 8.16 (1H, s), 8.54 (1H, d, J=7.1Hz)

15 APCI/MS: 428 [M+H]⁺

Example 74

5-[(4-Methyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example

20 73.

IR (KBr): 1664, 1639, 1591, 1533, 1475 cm⁻¹

¹H NMR (CDCl₃, δ): 1.47 (6H, d, J=6.6Hz), 2.34 (3H, s), 2.30-2.58 (4H, m), 3.45-3.90 (4H, m), 5.43 (1H, h, J=6.6Hz), 6.76 (1H, d, J=9.6Hz), 6.96 (1H, dd, J=7.1, 1.8Hz), 7.00 (1H, d, J=9.6Hz), 7.40-7.68 (5H, m),

25 8.03 (1H, dd, J=1.8, 0.9Hz), 8.56 (1H, dd, J=7.1, 0.9Hz)

APCI/MS: 457 [M+H]⁺

Example 75

N-(2-Hydroxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example

30 73.

IR (KBr): 3271, 1653, 1587, 1533 cm⁻¹

^1H NMR (CDCl_3 , δ): 1.47 (6H, d, $J=6.6\text{Hz}$), 3.00–3.18 (1H, m), 3.57–3.77 (2H, m), 3.77–3.97 (2H, m), 5.36 (1H, h, $J=6.6\text{Hz}$), 6.61 (1H, d, $J=9.6\text{Hz}$), 6.94 (1H, d, $J=9.6\text{Hz}$), 7.25–7.65 (6H, m), 8.40–8.58 (2H, m)

5 APCI/MS: 418 $[\text{M}+\text{H}]^+$

Example 76

N-[2-(Dimethylamino)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of
10 Example 73.

mp: 157–158°C (AcOEt – n-Hexane)

IR (KBr): 3309, 1666, 1641, 1593, 1531 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.52 (6H, d, $J=6.6\text{Hz}$), 2.27 (6H, s), 2.54 (2H, t, $J=5.8\text{Hz}$), 3.48–3.62 (2H, m), 5.45 (1H, h, $J=6.6\text{Hz}$), 6.77 (1H, d, $J=9.6\text{Hz}$), 6.89–7.02 (1H, m), 7.02 (1H, d, $J=9.6\text{Hz}$), 7.34 (1H, dd, $J=7.3, 2.0\text{Hz}$), 7.37–7.54 (3H, m), 7.54–7.67 (2H, m), 8.41–8.47 (1H, m), 8.47–8.58 (1H, m)

ESI/MS: 445 $[\text{M}+\text{H}]^+$

Example 77

20 3-(3-Oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenyl-N-[(1S)-1-phenylethyl]-pyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

IR (KBr): 3273, 2974, 1666, 1653, 1630, 1589, 1533 cm^{-1}

25 ^1H NMR (CDCl_3 , δ): 1.42 (6H, d, $J=6.5\text{Hz}$), 1.64 (3H, d, $J=6.9\text{Hz}$), 5.25–5.48 (2H, m), 6.66 (1H, d, $J=9.6\text{Hz}$), 6.67–6.83 (1H, m), 6.95 (1H, d, $J=9.6\text{Hz}$), 7.24–7.65 (11H, m), 8.42 (1H, d, $J=1.0\text{Hz}$), 8.51 (1H, d, $J=7.5\text{Hz}$)

Negative ESI/MS: 476 $[\text{M}-\text{H}]^-$

30 Example 78

N-(2-Ethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5

-carboxamide was prepared by similar procedure as that of Example 73.

mp: 149-150 °C (AcOEt)

IR (KBr): 3296, 2978, 1668, 1641, 1593, 1531 cm⁻¹

5 ¹H NMR (CDCl₃, δ): 1.23 (3H, t, J=7.0Hz), 1.51 (6H, d, J=6.6Hz), 3.46-3.77 (6H, m), 5.45 (1H, h, J=6.6Hz), 6.50-6.70 (1H, m), 6.77 (1H, d, J=9.6Hz), 7.02 (1H, d, J=9.6Hz), 7.29 (1H, dd, J=7.3, 2.0Hz), 7.35-7.70 (5H, m), 8.45-8.62 (2H, m)

ESI/MS: 468 [M+Na]⁺

10 Example 79

N-Methyl-N-[2-(2-pyridinyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5

-carboxamide was prepared by similar procedure as that of Example 73.

IR (neat): 2979, 1655, 1631, 1591, 1533 cm⁻¹

¹H NMR (CDCl₃, δ): 1.43 (6H, d, J=6.6Hz), 2.85-3.32 (5H, m), 3.75-4.05 (2H, m), 5.41 (1H, h, J=6.6Hz), 6.55-6.65 (14H, m)

ESI/MS: 515 [M+Na]⁺

20 Example 80

5-[(4-Acetyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 73.

25 IR (KBr): 2978, 1649, 1587, 1533, 1475 cm⁻¹

¹H NMR (CDCl₃, δ): 1.45 (6H, d, J=6.6Hz), 2.15 (3H, s), 3.40-3.90 (8H, m), 5.43 (1H, h, J=6.6Hz), 6.77 (1H, d, J=9.7Hz), 6.95 (1H, dd, J=7.1, 1.9Hz), 7.01 (1H, d, J=9.7Hz), 7.35-7.68 (5H, m), 7.98-8.10 (1H, m), 8.58 (1H, dd, J=7.1, 0.7Hz)

30 ESI/MS: 507 [M+Na]⁺

Example 81

5-[(cis-2,6-Dimethyl-4-morpholinyl)carbonyl]-3-(3-oxo-

2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 73.

IR (KBr): 2976, 1664, 1591, 1533, 1475 cm^{-1}

- 5 ^1H NMR (CDCl_3 , δ): 1.02-1.37 (6H, m), 1.46 (6H, d, $J=6.6\text{Hz}$), 2.50-4.70 (6H, m), 5.44 (1H, m, $J=6.6\text{Hz}$), 6.77 (1H, d, $J=9.6\text{Hz}$), 6.97 (1H, dd, $J=7.1, 1.8\text{Hz}$), 7.01 (1H, d, $J=9.6\text{Hz}$), 7.38-7.65 (5H, m), 8.04 (1H, dd, $J=1.7, 0.8\text{Hz}$), 8.57 (1H, dd, $J=7.1, 0.8\text{Hz}$)

ESI/MS: 494 $[\text{M}+\text{Na}]^+$

10 Example 82

N-Benzyl-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

- 15 IR (KBr): 2978, 1664, 1633, 1591, 1533, 1491 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.28-1.50 (6H, m), 2.91-3.17 (3H, m), 4.50-4.87 (2H, m), 5.40 (1H, h, $J=6.6\text{Hz}$), 6.75 (1H, d, $J=9.6\text{Hz}$), 6.85-7.68 (12H, m), 7.96-8.13 (1H, m), 8.45-8.60 (1H, m)

ESI/MS: 500 $[\text{M}+\text{Na}]^+$

20 Example 83

N-(tert-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

- 25 mp: 200-201°C (AcOEt-Et₂O)

IR (KBr): 2970, 1678, 1657, 1589, 1531, 1506, 1460 cm^{-1}

- ^1H NMR (CDCl_3 , δ): 1.50 (9H, s), 1.52 (6H, d, $J=6.6\text{Hz}$), 5.47 (1H, h, $J=6.6\text{Hz}$), 6.01 (1H, s), 6.76 (1H, d, $J=9.6\text{Hz}$), 7.02 (1H, d, $J=9.6\text{Hz}$), 7.33 (1H, dd, $J=7.2, 1.9\text{Hz}$), 7.38-7.67 (5H, m), 8.36 (1H, d, $J=1.0\text{Hz}$),
30 8.53 (1H, d, $J=7.2\text{Hz}$)

Negative ESI/MS: 428 $[\text{M}-\text{H}]^-$

Example 84

5-[(4-Phenyl-1-piperidinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 73.

mp: 184-185°C (AcOEt - n-Hexane)

IR (KBr): 3054, 2856, 1666, 1630, 1595, 1477, 1412 cm⁻¹

¹H NMR (CDCl₃, δ): 1.46(6H,d,J=6.6Hz), 1.46-2.08(6H,m), 2.71-3.27(3H,m), 5.43(1H,h,J=6.6Hz), 6.76(1H,d,J=9.6Hz), 6.99(1H,dd, J=7.0, 1.8Hz), 7.01(1H,d,J=9.6Hz), 7.12-7.65(10H,m), 8.00-8.08(1H,m), 8.56(1H,d,J=7.0Hz)

ESI/MS: 540 [M+Na]⁺

Example 85

N,N-Diethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

mp: 157-158°C (AcOEt)

IR (KBr): 2976, 1660, 1639, 1537, 1479 cm⁻¹

¹H NMR (CDCl₃, δ): 1.05-1.32(6H,m), 1.44(6H,d,J=6.6Hz), 3.27-3.67(4H,m), 5.42(1H,h,J=6.6Hz), 6.76(1H,d,J=9.6Hz), 6.92(1H,dd, J=7.1, 1.9Hz), 7.01(1H,d,J=9.6Hz), 7.38-7.68(5H,m), 8.00(1H,dd, J=1.9, 0.8Hz), 8.55(1H,dd,J=7.1, 0.8Hz)

ESI/MS: 452 [M+Na]⁺

Example 86

N-(2-Isopropoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

mp: 124-125°C (AcOEt)

IR (KBr): 3306, 2972, 1668, 1641, 1593, 1531 cm⁻¹

¹H NMR (CDCl₃, δ): 1.18(6H,d,J=6.1Hz), 1.51(6H,d,J=6.6Hz), 3.52-3.73(5H,m), 5.44(1H,h,J=6.6Hz), 6.54-6.67(1H,m), 6.77(1H,

d, J=9.6Hz), 7.03 (1H, d, J=9.6Hz), 7.25 (1H, dd, J=7.2, 2.0Hz), 7.40-7.68 (5H, m), 8.45-8.60 (2H, m)

Negative ESI/MS: 458 [M-H]⁻

Example 87

5 N-(3-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

mp: 192-193°C (AcOEt)

10 IR (KBr): 3313, 1666, 1637, 1593, 1527, 1309 cm⁻¹

¹H NMR (CDCl₃, δ): 1.39 (6H, d, J=6.6Hz), 4.70 (2H, d, J=5.7Hz), 5.33 (1H, h, J=6.6Hz), 6.65 (1H, d, J=9.6Hz), 6.96 (1H, d, J=9.6Hz), 6.90-7.08 (1H, m), 7.19-7.37 (2H, m), 7.37-7.67 (5H, m), 7.67-7.78 (1H, m), 8.40-8.66 (4H, m)

15 Negative ESI/MS: 463 [M-H]⁻

Example 88

N-Methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

20 mp: 225-226°C (CHCl₃-Et₂O)

IR (KBr): 3359, 2972, 1651, 1587, 1558, 1539, 1468 cm⁻¹

¹H NMR (CDCl₃, δ): 1.50 (6H, d, J=6.6Hz), 3.07 (3H, d, J=4.9Hz), 5.44 (1H, h, J=6.6Hz), 6.18-6.38 (1H, m), 6.76 (1H, d, J=9.6Hz), 7.02 (1H, d, J=9.6Hz), 7.24 (1H, dd, J=7.3, 2.0Hz), 7.35-7.70 (5H, m), 8.40-8.57 (2H, m)

25 Negative ESI/MS: 386 [M-H]⁻

Example 89

5-(1-Piperidinylcarbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 73.

30 mp: 185-186°C (AcOEt)

IR (KBr): 2933, 2854, 1668, 1624, 1595, 1529, 1469 cm⁻¹

^1H NMR (CDCl_3 , δ): 1.46 (6H, d, $J=6.6\text{Hz}$), 1.46–1.83 (6H, m), 3.35–3.85 (4H, m), 5.42 (1H, h, $J=6.6\text{Hz}$), 6.76 (1H, d, $J=9.6\text{Hz}$), 6.94 (1H, dd, $J=7.1$, 1.7Hz), 7.01 (1H, d, $J=9.6\text{Hz}$), 7.37–7.67 (5H, m), 8.01 (1H, dd, $J=1.7$, 0.9Hz), 8.54 (1H, dd, $J=7.1$, 0.9Hz)

5 ESI/MS: 464 $[\text{M}+\text{Na}]^+$

Example 90

N-[2-(1-Pyrrolidinyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example
10 73.

IR (KBr): 2968, 1668, 1653, 1589, 1533 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.50 (6H, d, $J=6.6\text{Hz}$), 1.70–1.90 (4H, m), 2.55–2.75 (4H, m), 2.81 (2H, t, $J=5.7\text{Hz}$), 3.55–3.70 (2H, m), 5.44 (1H, h, $J=6.6\text{Hz}$), 6.78 (1H, d, $J=9.6\text{Hz}$), 7.05 (1H, d, $J=9.6\text{Hz}$), 7.16–
15 7.35 (1H, m), 7.37 (1H, dd, $J=7.2$, 2.0Hz), 7.37–7.69 (5H, m), 8.46–8.59 (2H, m)

ESI/MS: 471 $[\text{M}+\text{H}]^+$

Example 91

N-(5-Methyl-1,3-thiazol-2-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example
20 73.

IR (KBr): 3238, 2970, 1641, 1581, 1562, 1537, 1462, 1304 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.41 (6H, d, $J=6.7\text{Hz}$), 2.32 (3H, d, $J=0.9\text{Hz}$), 5.33 (1H, h, $J=6.7\text{Hz}$), 6.72–6.88 (2H, m), 7.03 (1H, d, $J=9.6\text{Hz}$), 7.39 (1H, dd, $J=7.3$, 1.9Hz), 7.40–7.70 (5H, m), 8.49–8.75 (2H, m), 12.12 (1H, br)

Negative ESI/MS: 469 $[\text{M}-\text{H}]^-$

30 Example 92

N-(2-Phenoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-

carboxamide was prepared by similar procedure as that of Example 73.

mp: 156-157°C (AcOEt)

IR (KBr): 3336, 2979, 1666, 1631, 1591, 1533, 1496, 1466 cm⁻¹

5 ¹

¹H NMR (CDCl₃, δ): 1.43 (6H, d, J=6.6Hz), 3.85-4.00 (2H, m), 4.19 (2H, t, J=4.9Hz), 5.39 (1H, h, J=6.6Hz), 6.62-6.75 (1H, m), 6.75 (1H, d, J=9.6Hz), 6.85-7.00 (3H, m), 7.01 (1H, d, J=9.6Hz), 7.23-

10 7.38 (3H, m), 7.38-7.70 (5H, m), 8.50 (1H, d, J=1.4Hz),

8.55 (1H, d, J=6.8Hz)

Negative ESI/MS: 492 [M-H]⁻

Example 93

N,N-Bis(2-methoxyethyl)-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5 -
15 carboxamide was prepared by similar procedure as that of Example 73.

IR (KBr): 2978, 2929, 1658, 1637, 1591, 1535, 1477 cm⁻¹

¹H NMR (CDCl₃, δ): 1.45 (6H, d, J=6.6Hz), 3.10-3.88 (14H, m), 5.42 (1H, h, J=6.6Hz), 6.77 (1H, d, J=9.6Hz), 7.00 (1H, dd, J=7.1, 1.8Hz),
20 7.03 (1H, d, J=9.6Hz), 7.38-7.68 (5H, m), 7.98-8.08 (1H, m), 8.47-8.58 (1H, m)

ESI/MS: 512 [M+Na]⁺

Example 94

N-(1-Methyl-1-phenylethyl)-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5 -
25 carboxamide was prepared by similar procedure as that of Example 73.

IR (KBr): 3305, 2974, 1651, 1587, 1535, 1495 cm⁻¹

¹H NMR (CDCl₃, δ): 1.46 (6H, d, J=6.6Hz), 1.86 (6H, s), 5.43 (1H, h, J=6.6Hz), 6.50 (1H, br s), 6.75 (1H, d, J=9.6Hz), 7.01 (1H, d, J=9.6 Hz), 7.20-7.68 (11H, m), 8.35-8.42 (1H, m), 8.46-8.57 (1H, m)

Negative ESI/MS: 490 [M-H]⁻

Example 95

N-Isopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 73.

5 mp: 230-232°C (AcOEt)

IR (KBr): 3298, 2972, 1668, 1635, 1630, 1593, 1531 cm⁻¹

¹H NMR (CDCl₃, δ): 1.30 (6H, d, J=6.5Hz), 1.52 (6H, d, J=6.6Hz),
4.16-4.43 (1H, m), 5.47 (1H, h, J=6.6Hz), 6.03 (1H, d, J=7.7Hz),
6.75 (1H, d, J=9.6Hz), 7.01 (1H, d, J=9.6Hz), 7.31 (1H, dd, J=7.1,
10 2.0Hz), 7.37-7.68 (5H, m), 8.39-8.46 (1H, m), 8.46-8.57 (1H, m)
Negative ESI/MS: 414 [M-H]⁻

Example 96

A mixture of [3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl] -
15 trifluoromethanesulfonate (60 mg), 1-methylpiperazine (0.034 ml), Cs₂CO₃ (58 mg), Pd₂(dba)₃ (4.6 mg), BINAP (9.4 mg), and 18-crown-6 (3.3 mg) in toluene (1 ml) was stirred at 100°C for 16 hours. After cooling to ambient temperature, the reaction mixture was diluted with AcOEt, washed with water and brine,
20 dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (CH₂Cl₂-MeOH 10:1 elution) to give 5-(4-methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (37.6 mg) as a solid.

25 mp: 170-171°C (AcOEt)

IR (KBr): 1658, 1643, 1587, 1535, 1448 cm⁻¹

¹H NMR (CDCl₃, δ): 1.49 (6H, d, J=6.6 Hz), 2.38 (3H, s), 2.53-2.68
(4H, m), 3.25-3.40 (4H, m), 5.45 (1H, h, J=6.6Hz), 6.67 (1H, dd, J=7.7,
2.8Hz), 6.70 (1H, d, J=9.6Hz), 6.95 (1H, d, J=9.6Hz), 7.30 (1H, d,
30 J=2.8Hz), 7.36-7.65 (5H, m), 8.31 (1H, d, J=7.7Hz)
APCI/MS: 429 [M+H]⁺

Example 97

5-(1-Pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3 -

dihydropyridazin-6-yl)-2-pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

mp: 165-167°C (AcOEt-Et₂O)

IR (KBr): 1671, 1643, 1589, 1516 cm⁻¹

5 ¹H NMR (CDCl₃, δ): 1.50 (6H, d, J=6.6Hz), 1.98-2.20 (4H, m), 3.30-3.48 (4H, m), 5.45 (1H, h, J=6.6Hz), 6.43 (1H, dd, J=7.6, 2.7Hz), 6.67 (1H, d, J=9.7Hz), 6.95 (1H, d, J=9.7Hz), 6.95 (1H, d, J=2.7Hz), 7.37-7.66 (5H, m), 8.27 (1H, d, J=7.6Hz)

ESI/MS: 400 [M+H]⁺

10 Example 98

5-(4-Morpholinyl)-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

mp: 182-187°C (AcOEt)

15 IR (KBr): 1657, 1643, 1587, 1535, 1444 cm⁻¹

¹H NMR (CDCl₃, δ): 1.49 (6H, d, J=6.6Hz), 3.15-3.35 (4H, m), 3.80-4.00 (4H, m), 5.45 (1H, h, J=6.6Hz), 6.57-6.70 (1H, m), 6.71 (1H, d, J=9.6 Hz), 6.96 (1H, d, J=9.6Hz), 7.29 (1H, d, J=2.7Hz), 7.35-7.70 (5H, m), 8.34 (1H, d, J=7.7Hz)

20 APCI/MS: 416 [M+H]⁺

Example 99

5-(4-Phenyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

25 mp: >240°C (AcOEt)

IR (KBr): 2814, 1662, 1645, 1591, 1535, 1487, 1446 cm⁻¹

¹H NMR (CDCl₃, δ): 1.51 (6H, d, J=6.6Hz), 3.25-3.53 (8H, m), 5.46 (1H, h, J=6.6Hz), 6.62-6.77 (2H, m), 6.85-7.65 (12H, m), 8.27-8.38 (1H, m)

30 ESI/MS: 491 [M+H]⁺

Example 100

5-(cis-2,6-Dimethyl-4-morpholinyl)-3-(3-oxo-2 -

isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

mp: 176-177°C (AcOEt - n-Hexane)

5 IR (KBr): 2974, 1647, 1585, 1537, 1448 cm⁻¹

¹H NMR (CDCl₃, δ): 1.28 (6H, d, J=6.2Hz), 1.51 (6H, d, J=6.7Hz),
2.43-2.63 (2H, m), 3.43-3.62 (2H, m), 3.68-3.93 (2H, m), 5.46 (1H, h,
J=6.7Hz), 6.67 (1H, dd, J=7.6, 2.6Hz), 6.70 (1H, d, J=9.6Hz),
6.95 (1H, d, J=9.6Hz), 7.32 (1H, d, J=2.6Hz), 7.33-7.66 (5H, m),
10 8.32 (1H, d, J=7.6Hz)

ESI/MS: 444 [M+H]⁺

Example 101

5-(4-Hydroxy-1-piperidiny1)-3-(3-oxo-2-isopropyl-2,3 -
dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
15 prepared by similar procedure as that of Example 96.

mp: 213-215°C (AcOEt)

IR (KBr): 3400, 2935, 1647, 1576, 1533, 1512, 1487 cm⁻¹

¹H NMR (CDCl₃, δ): 1.49 (6H, d, J=6.6Hz), 1.55-1.83 (2H, m), 1.92-
2.10 (2H, m), 3.00-3.18 (2H, m), 3.57-3.75 (2H, m), 3.86-4.05 (1H, m),
20 5.45 (1H, h, J=6.6Hz), 6.67 (1H, dd, J=7.6, 2.7Hz), 6.69 (1H, d, J=9.6
Hz), 6.95 (1H, d, J=9.6Hz), 7.31 (1H, d, J=2.7Hz), 7.35-7.65 (5H, m),
8.30 (1H, d, J=7.6Hz)

ESI/MS: 430 [M+H]⁺

Example 102

25 5-[4-(2-Pyridinyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-
2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
was prepared by similar procedure as that of Example 96.

mp: 221-222°C (AcOEt)

IR (KBr): 2972, 2927, 2821, 1653, 1583, 1535, 1487 cm⁻¹

30 ¹H NMR (CDCl₃, δ): 1.51 (6H, d, J=6.7Hz), 3.34-3.50 (4H, m), 3.65-
3.80 (4H, m), 5.46 (1H, h, J=6.7Hz), 6.63-6.77 (4H, m), 6.96 (1H, d,
J=9.6Hz), 7.34 (1H, d, J=2.5Hz), 7.35-7.65 (6H, m), 8.18-

8.27 (1H, m), 8.35 (1H, d, J=7.6 Hz)

ESI/MS: 492 [M+H]⁺

Example 103

5 5-[4-(2-Pyrimidinyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

mp: >240°C (AcOEt)

IR (KBr): 2972, 2925, 2817, 1653, 1585, 1543, 1504 cm⁻¹

10 ¹H NMR (CDCl₃, δ): 1.51 (6H, d, J=6.7 Hz), 3.30-3.46 (4H, m), 3.95-4.08 (4H, m), 5.46 (1H, h, J=6.7 Hz), 6.57 (1H, t, J=4.6 Hz), 6.70 (1H, d, J=9.6 Hz), 6.73 (1H, dd, J=7.7, 2.6 Hz), 6.95 (1H, d, J=9.6 Hz), 7.33 (1H, d, J=2.6 Hz), 7.36-7.65 (5H, m), 8.35 (1H, d, J=7.7 Hz), 8.37 (2H, d, J=4.6 Hz)

15 ESI/MS: 493 [M+H]⁺

Example 104

tert-Butyl 4-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-1-piperazinecarboxylate was prepared by similar procedure as that
20 of Example 96.

mp: 163-164°C (AcOEt)

IR (KBr): 2976, 1701, 1645, 1585, 1535, 1458, 1421 cm⁻¹

¹H NMR (CDCl₃, δ): 1.50 (6H, d, J=6.6 Hz), 1.50 (9H, s), 3.20-3.33 (4H, m), 3.55-3.67 (4H, m), 5.45 (1H, h, J=6.6 Hz), 6.66 (1H, dd, J=7.7, 2.6
25 Hz), 6.70 (1H, d, J=9.6 Hz), 6.95 (1H, d, J=9.6 Hz), 7.28 (1H, d, J=2.6 Hz), 7.37-7.63 (5H, m), 8.33 (1H, d, J=7.7 Hz)

ESI/MS: 515 [M+H]⁺

Example 105

5-(4-Benzyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

mp: 136-138°C (AcOEt)

IR (KBr): 1647, 1581, 1537, 1516, 1491, 1454 cm⁻¹

^1H NMR (CDCl_3 , δ): 1.47 (6H, d, $J=6.6\text{Hz}$), 2.54–2.70 (4H, m), 3.22–3.38 (4H, m), 3.59 (2H, s), 5.43 (1H, h, $J=6.6\text{Hz}$), 6.60–6.74 (2H, m), 6.94 (1H, d, $J=9.6\text{Hz}$), 7.20–7.64 (11H, m), 8.30 (1H, d, $J=7.7\text{Hz}$)

ESI/MS: 505 $[\text{M}+\text{H}]^+$

5 Example 106

To a solution of 5-(4-hydroxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (52.6 mg) in DMF (3 ml) was added NaH (60% oil suspension, 5.9 mg) at ambient temperature. After stirring for 10 minutes, iodomethane (0.038 ml) was added thereto. And the mixture was stirred for 5 hours at the same temperature. To the reaction mixture was added NaH (60% oil suspension, 5.9 mg) and iodomethane (0.038 ml), and stirred for 1.5 hours at 60°C. The reaction mixture was poured into ice-water, extracted with AcOEt, washed with water and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (n-hexane-EtOAc 2:5 elution) to give 5-(4-methoxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (13.9 mg) as a solid.

mp: 177–178°C (AcOEt-Et₂O)

IR (KBr): 1658, 1643, 1587, 1533, 1514, 1462, 1425 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.49 (6H, d, $J=6.7\text{Hz}$), 1.55–2.10 (4H, m), 3.04–3.24 (2H, m), 3.40 (3H, s), 3.35–3.70 (3H, m), 5.45 (1H, h, $J=6.7\text{Hz}$), 6.67 (1H, dd, $J=7.7, 2.6\text{Hz}$), 6.69 (1H, d, $J=9.6\text{Hz}$), 6.95 (1H, d, $J=9.6\text{Hz}$), 7.30 (1H, d, $J=2.6\text{Hz}$), 7.35–7.65 (5H, m), 8.29 (1H, d, $J=7.7\text{Hz}$)

ESI/MS: 444 $[\text{M}+\text{H}]^+$

Example 107

To a solution of tert-butyl 4-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-1-piperazinecarboxylate (557 mg) in CH_2Cl_2 (12 ml) was added 4N hydrogen chloride 1,4-dioxane solution (5.4 ml) at 5°C. After stirring at ambient temperature for 16 hours, saturated sodium

hydrogen carbonate solution was added thereto, and the mixture was extracted with CHCl_3 , washed with brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl_3 -MeOH 10:1 elution) to give
5 5-(1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (417 mg) as a solid.

mp: 203-204°C (AcOEt)

IR (KBr): 1643, 1583, 1535, 1514, 1489, 1448 cm^{-1}

10 ^1H NMR (CDCl_3 , δ): 1.49 (6H, d, $J=6.6\text{Hz}$), 3.00-3.13 (4H, m), 3.20-3.33 (4H, m), 5.45 (1H, h, $J=6.6\text{Hz}$), 6.68 (1H, dd, $J=7.7$, 2.6Hz), 6.70 (1H, d, $J=9.6\text{Hz}$), 6.95 (1H, d, $J=9.6\text{Hz}$), 7.29 (1H, d, $J=2.6\text{Hz}$), 7.36-7.65 (5H, m), 8.31 (1H, d, $J=7.7\text{Hz}$)

ESI/MS: 415 $[\text{M}+\text{H}]^+$

15 Example 108

To a solution of 5-(1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (50 mg) and triethylamine (0.022 ml) in CH_2Cl_2 (1.5 ml) was added methyl chlorocarbonate (0.010 ml) at 5°C. After stirring at
20 ambient temperature for 1 hour, the reaction mixture was diluted with AcOEt, washed with saturated sodium hydrogen carbonate solution, water, and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (n-hexane-AcOEt 1:10 elution) to give
25 methyl 4-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-1-piperazinecarboxylate (55.2 mg) as a solid.

mp: 206-207°C (AcOEt)

IR (KBr): 1707, 1651, 1583, 1537, 1475 cm^{-1}

30 ^1H NMR (CDCl_3 , δ): 1.49 (6H, d, $J=6.6\text{Hz}$), 3.20-3.35 (4H, m), 3.60-3.75 (4H, m), 3.76 (3H, s), 5.45 (1H, h, $J=6.6\text{Hz}$), 6.61-6.75 (2H, m), 6.95 (1H, d, $J=9.7\text{Hz}$), 7.29 (1H, d, $J=2.6\text{Hz}$), 7.38-7.65 (5H, m), 8.34 (1H, d, $J=7.7\text{Hz}$)

ESI/MS: 473[M+H]⁺

Example 109

4-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl-1-piperazinecarboxamide was prepared by similar procedure as that of Example 108.

mp: 160-161°C (AcOEt)

IR (KBr): 1647, 1583, 1535, 1491, 1456, 1392 cm⁻¹

¹H NMR (CDCl₃, δ): 1.49 (6H, d, J=6.6Hz), 2.89 (6H, s), 3.22-3.47 (8H, m), 5.45 (1H, h, J=6.6Hz), 6.67 (1H, dd, J=7.7, 2.7Hz), 6.71 (1H, d, J=9.6Hz), 6.95 (1H, d, J=9.6Hz), 7.28 (1H, d, J=2.7Hz), 7.37-7.65 (5H, m), 8.33 (1H, d, J=7.7Hz)

ESI/MS: 508[M+Na]⁺

Example 110

5-[4-(Methylsulfonyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 108.

mp: 219-220°C (AcOEt)

IR (KBr): 2979, 2837, 1655, 1583, 1539, 1452 cm⁻¹

¹H NMR (CDCl₃, δ): 1.49 (6H, d, J=6.6Hz), 2.86 (3H, s), 3.35-3.50 (8H, m), 5.49 (1H, h, J=6.6Hz), 6.65 (1H, dd, J=7.7, 2.8Hz), 6.71 (1H, d, J=9.6Hz), 6.95 (1H, d, J=9.6Hz), 7.33 (1H, d, J=2.8Hz), 7.37-7.64 (5H, m), 8.36 (1H, d, J=7.7Hz)

ESI/MS: 515[M+Na]⁺

Example 111

5-[4-(Phenylsulfonyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 108.

mp: 219-220°C (AcOEt)

IR (KBr): 2970, 2862, 1649, 1587, 1539, 1450 cm⁻¹

^1H NMR (CDCl_3 , δ): 1.49 (6H, d, $J=6.6\text{Hz}$), 3.12–3.44 (8H, m), 5.46 (1H, h, $J=6.6\text{Hz}$), 6.56 (1H, dd, $J=7.7$, 2.8Hz), 6.70 (1H, d, $J=9.6\text{Hz}$), 6.93 (1H, d, $J=9.6\text{Hz}$), 7.27 (1H, d, $J=2.8\text{Hz}$), 7.36–7.70 (8H, m), 7.70–7.88 (2H, m), 8.30 (1H, d, $J=7.7\text{Hz}$)

5 ESI/MS: 555 $[\text{M}+\text{H}]^+$

Example 112

5-(4-Benzoyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 108.

10 mp: 124–126°C (AcOEt - n-Hexane)

IR (KBr): 2978, 2833, 1658, 1639, 1583, 1533, 1514, 1460, 1421 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.48 (6H, d, $J=6.6\text{Hz}$), 3.18–4.05 (8H, m), 5.45 (1H, h, $J=6.6\text{Hz}$), 6.66 (1H, dd, $J=7.7$, 2.6Hz), 6.71 (1H, d, $J=9.7\text{Hz}$),
15 6.95 (1H, d, $J=9.7\text{Hz}$), 7.30 (1H, d, $J=2.6\text{Hz}$), 7.34–7.65 (10H, m), 8.35 (1H, d, $J=7.7\text{Hz}$)

ESI/MS: 541 $[\text{M}+\text{Na}]^+$

Example 113

5-(4-Acetyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3 - dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 108.

mp: 148–149°C (AcOEt - n-Hexane)

IR (KBr): 1643, 1583, 1535, 1444, 1423 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.49 (6H, d, $J=6.7\text{Hz}$), 2.17 (3H, s), 3.19–3.38 (4H, m), 3.57–3.88 (4H, m), 5.46 (1H, h, $J=6.7\text{Hz}$), 6.66 (1H, dd, $J=7.7$, 2.6Hz), 6.71 (1H, d, $J=9.6\text{Hz}$), 6.95 (1H, d, $J=9.6\text{Hz}$), 7.29 (1H, d, $J=2.6\text{Hz}$), 7.36–7.64 (5H, m), 8.35 (1H, d, $J=7.7\text{Hz}$)

ESI/MS: 479 $[\text{M}+\text{Na}]^+$

Example 114

30 To a mixture of 5-(1-piperazinyl)-3-(3-oxo-2-isopropyl -2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (45 mg), N,N-dimethylglycine hydrochloride (18.2 mg), and

N,N-diisopropylethylamine (0.023 ml) in DMF(1 ml) was added
1-hydroxybenzotriazole(22 mg) and 1-ethyl-3-(3'-
dimethylaminopropyl)carbodiimide hydrochloride (31.3 mg).
After stirring at ambient temperature for 4 hours, the reaction
5 mixture was diluted with AcOEt, washed with saturated sodium
hydrogen carbonate solution, water and brine, dried over
magnesium sulfate, and evaporated in vacuo. The residue was
purified by silica gel column chromatography (CHCl₃-MeOH, 10:1
elution) to give 5-{4-[(dimethylamino)acetyl]-1-piperazinyl}
10 -3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2 -
phenylpyrazolo[1,5-a]pyridine (52.2 mg) as a solid.

mp: 129-130°C (AcOEt)

IR (KBr): 1647, 1585, 1537, 1458, 1423 cm⁻¹

¹H NMR (CDCl₃, δ): 1.49(6H,d,J=6.6Hz), 2.30(6H,s), 3.17(2H,s),
15 3.18-3.38(4H,m), 3.73-3.90(4H,m), 5.46(1H,h,J=6.6Hz), 6.67(1H,
dd,J=7.7, 2.7Hz), 6.70(1H,d,J=9.6Hz), 6.95(1H,d,J=9.6Hz),
7.29(1H,d,J=2.7Hz), 7.37-7.65(5H,m), 8.34(1H,d,J=7.7Hz)

ESI/MS: 500 [M+H]⁺

Example 115

20 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-
2-phenylpyrazolo[1,5-a]pyridine was prepared by similar
procedure as that of Example 2.

mp: 183-184°C (AcOEt)

NMR (CDCl₃, δ): 3.91(3H,s), 3.92(3H,s), 6.60(1H,dd,J=7.5,
25 2.8Hz), 6.75(1H,d,J=9.7Hz), 6.98(1H,d,J=9.7Hz),
7.30(1H,d,J=2.8Hz), 7.41-7.47(3H,m), 7.54-7.61(2H,m),
8.34(1H,dd,J=7.5, 0.4Hz)

APCI/MS: 333 [M+H]⁺

Anal.Calcd for C₁₉H₁₆N₄O₂: C,68.66; H,4.85; N,16.86

30 Found: C,68.29; H,4.76; N,16.62

Example 116

5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-
2-phenylpyrazolo[1,5-a]pyridine was prepared by similar

procedure as that of Example 2.

mp: 148-149°C (AcOEt)

NMR (CDCl₃, δ): 1.51 (3H, t, J=7.2Hz), 3.91 (3H, s), 4.34 (2H, q, J=7.2Hz), 6.60 (1H, dd, J=7.5, 2.8Hz), 6.74 (1H, d, J=9.7Hz), 6.98 (1H, d, J=9.7Hz), 7.32 (1H, d, J=2.8Hz), 7.41-7.47 (3H, m), 7.56-7.62 (2H, m), 8.34 (1H, d, J=7.5Hz)

APCI/MS: 347 [M+H]⁺

Anal. Calcd for C₂₀H₁₈N₄O₂: C, 69.35; H, 5.24; N, 16.17

Found: C, 69.67; H, 5.23; N, 16.27

10 Example 117

5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 174°C (AcOEt)

15 NMR (CDCl₃, δ): 1.06 (3H, t, J=7.4Hz), 1.89-2.08 (2H, m), 3.90 (3H, s), 4.25 (2H, t, J=7.2Hz), 6.60 (1H, dd, J=7.5, 2.8Hz), 6.74 (1H, d, J=9.7Hz), 6.97 (1H, d, J=9.7Hz), 7.30 (1H, d, J=2.7Hz), 7.41-7.47 (3H, m), 7.55-7.62 (2H, m), 8.33 (1H, d, J=7.5Hz)

APCI/MS: 361 [M+H]⁺

20 Anal. Calcd for C₂₁H₂₀N₄O₂: C, 69.98; H, 5.59; N, 15.55

Found: C, 70.00; H, 5.52; N, 15.46

Example 118

5-Methoxy-3-[3-oxo-2-(tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 207-208°C (AcOEt)

NMR (CDCl₃, δ): 2.28-2.58 (2H, m), 3.87-3.98 (1H, m), 3.94 (3H, s), 4.06-4.30 (3H, m), 5.80-5.91 (1H, m), 6.60 (1H, dd, J=7.5, 2.7Hz), 6.70 (1H, d, J=9.7Hz), 6.98 (1H, d, J=9.7Hz), 7.42-7.51 (4H, m), 7.55-7.61 (2H, m), 8.33 (1H, d, J=7.5Hz)

APCI/MS: 389 [M+H]⁺

Anal. Calcd for C₂₂H₂₀N₄O₃: C, 68.03; H, 5.19; N, 14.42

Found: C, 68.26; H, 5.15; N, 14.44

Example 119

5-Methoxy-3-[3-oxo-2-((3R)-tetrahydrofuran-3-yl)-2,3 - dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was
5 prepared by similar procedure as that of Example 2.

mp: 194-195°C (AcOEt)

NMR (CDCl₃, δ): 2.28-2.58(2H,m), 3.87-3.98(1H,m), 3.95(3H,s),
4.06-4.27(3H,m), 5.80-5.91(1H,m), 6.60(1H,dd,J=7.5, 2.7Hz),
6.70(1H,d,J=9.7Hz), 6.98(1H,d,J=9.7Hz), 7.44-7.51(4H,m),
10 7.55-7.61(2H,m), 8.33(1H,d,J=7.5Hz)

APCI/MS: 389 [M+H]⁺

Anal.Calcd for C₂₂H₂₀N₄O₃: C, 68.03; H, 5.19; N, 14.42

Found: C, 68.06; H, 5.14; N, 14.38

Example 120

15 5-Methoxy-3-[3-oxo-2-((3S)-tetrahydrofuran-3-yl)-2,3 - dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 194-195°C (AcOEt)

NMR (CDCl₃, δ): 2.28-2.58(2H,m), 3.87-3.98(1H,m), 3.95(3H,s),
20 4.06-4.27(3H,m), 5.80-5.91(1H,m), 6.60(1H,dd,J=7.5, 2.7Hz),
6.70(1H,d,J=9.7Hz), 6.98(1H,d,J=9.7Hz), 7.44-7.51(4H,m),
7.55-7.61(2H,m), 8.33(1H,d,J=7.5Hz)

APCI/MS: 389 [M+H]⁺

Anal.Calcd for C₂₂H₂₀N₄O₃: C, 68.03; H, 5.19; N, 14.42

25 Found: C, 67.85; H, 5.14; N, 14.33

Example 121

5-Methoxy-3-[3-oxo-2-(1-methoxy-2-propyl)-2,3 - dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

30 mp: 138-139°C (AcOEt)

NMR (CDCl₃, δ): 1.47(3H,d,J=6.8Hz), 3.37(3H,s), 3.59(1H,dd,
J=10.1, 5.2Hz), 3.90(3H,s), 3.95(1H,dd,J=10.1, 8.0Hz),

5.52-5.59 (1H,m), 6.60 (1H,dd,J=7.5, 2.7Hz), 6.74 (1H,d,J=9.7Hz),
6.97 (1H,d,J=9.7Hz), 7.37 (1H,d,J=2.7Hz), 7.43-7.48 (3H,m),
7.58-7.62 (2H,m), 8.33 (1H,d,J=7.5Hz)

APCI/MS: 391 [M+H]⁺

5 Example 122

A mixture of 5-methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (274 mg), 4-hydroxy-1-methylpiperidine (159 mg), diethyl azodicarboxylate (299 mg) and triphenylphosphine (451 mg) in tetrahydrofuran (5.5 ml) was
10 stirred at ambient temperature for 18 hours. After the solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate and the solution was extracted with 6 N hydrochloric acid. Potassium carbonate was added to the aqueous solution to adjust pH to 9 and extracted twice with ethyl acetate.
15 The combined extracts were washed with water and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give crude material, which was then purified by silica gel column chromatography using a mixture of chloroform and methanol (50:1) to give 5-methoxy-3-[3-oxo-2-(1-
20 methylpiperidin-4-yl)-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine.

mp: 154-155°C (AcOEt-Diisopropyl ether)

NMR (DMSO-d₆, δ): 1.84-2.10 (6H,m), 2.20 (3H,s), 2.86-2.89 (2H,m),
3.89 (3H,s), 4.79-4.82 (1H,m), 6.77 (1H,dd,J=7.5, 2.7Hz), 6.85 (1H,
25 d,J=9.6Hz), 7.07 (1H,d,J=9.6Hz), 7.32 (1H,d,J=2.7Hz), 7.45-7.60 (5H,m), 8.69 (1H,d,J=7.5Hz)

APCI/MS: 416 [M+H]⁺

Example 123

5-Methoxy-3-[3-oxo-2-(1-methylpiperidin-3-yl)-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was
30 prepared by similar procedure as that of Example 122.

mp: 179-180°C (AcOEt-Diisopropyl ether)

NMR (DMSO-d₆, δ): 1.63-1.89 (6H,m), 2.19 (3H,s), 2.75-2.80 (1H,m),

2.92-2.97 (1H,m), 3.91 (3H,s), 4.93 (1H,m), 6.76 (1H,dd, J=7.5, 2.7Hz), 6.85 (1H,d, J=9.7Hz), 7.07 (1H,d, J=9.7Hz), 7.46-7.56 (5H,m), 8.69 (1H,d, J=7.5Hz)

APCI/MS: 416 [M+H]⁺

5 Example 124

5-Methoxy-3-[3-oxo-2-(tetrahydropyran-4-yl)-2,3 - dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 122.

mp: 224-225°C (AcOEt)

10 NMR (CDCl₃, δ): 1.95 (2H,dd, J=12.3, 2.4Hz), 2.16-2.37 (2H,m), 3.64 (2H,t, J=11.3Hz), 3.93 (3H,s), 4.12 (2H,dd, J=11.3, 4.4Hz), 5.23-5.38 (1H,m), 6.62 (1H,dd, J=7.5, 2.7Hz), 6.73 (1H,d, J=9.7Hz), 6.99 (1H,d, J=9.7Hz), 7.42-7.47 (4H,m), 7.57-7.52 (2H,m), 8.35 (1H,d, J=7.5Hz)

15 APCI/MS: 403 [M+H]⁺

Example 125

5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(2 - fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 1.

20 NMR (DMSO-d₆, δ): 3.88 (3H,s), 6.76-6.84 (2H,m), 7.12 (1H,d, J=9.8Hz), 7.24-7.38 (3H,m), 7.49-7.68 (2H,m), 8.70 (1H,d, J=7.5Hz), 13.0 (1H,brd s)

APCI/MS: 337 [M+H]⁺

Example 126

25 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 220.5-221.5°C (95% EtOH)

30 NMR (DMSO-d₆, δ): 3.71 (3H,s), 3.92 (3H,s), 6.80 (1H,dd, J=7.6, 2.8Hz), 6.85 (1H,d, J=9.7Hz), 7.05 (1H,d, J=9.7Hz), 7.29-7.40 (3H,m), 7.51-7.68 (2H,m), 8.70 (1H,d, J=7.6Hz)

APCI/MS: 351 [M+H]⁺

Anal.Calcd for $C_{19}H_{15}FN_4O_2$: C, 65.14; H, 4.32; N, 15.99

Found: C, 65.20; H, 4.22; N, 15.93

Example 127

5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 174-175°C (AcOEt-Diisopropyl Ether)

NMR (DMSO- d_6 , δ): 1.23 (6H, d, J=6.6Hz), 3.90 (3H, s), 5.10-5.23 (1H, m), 6.79 (1H, dd, J=7.5, 2.7Hz), 6.86 (1H, d, J=9.7Hz), 7.18 (1H, d, J=9.7Hz), 7.27-7.39 (3H, m), 7.49-7.68 (2H, m), 8.71 (1H, d, J=7.5Hz)

APCI/MS: 379 [M+H]⁺

Anal.Calcd for $C_{21}H_{19}FN_4O_2$: C, 66.66; H, 5.06; N, 14.81

Found: C, 66.52; H, 5.02; N, 14.70

15 Example 128

5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 1.

NMR (DMSO- d_6 , δ): 4.05 (3H, s), 6.74 (1H, dd, J=7.5, 2.7Hz), 6.83 (1H, dd, J=9.8, 2.0Hz), 7.10-7.15 (2H, m), 7.30 (2H, t, J=8.8Hz), 7.57-7.64 (2H, m), 8.67 (1H, d, J=7.5Hz), 13.0 (1H, brd s)

APCI/MS: 337 [M+H]⁺

Example 129

5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 176-177°C (AcOEt-Diisopropyl Ether)

NMR (DMSO- d_6 , δ): 1.33 (6H, d, J=6.6Hz), 3.87 (3H, s), 5.22 (1H, m), 6.76 (1H, dd, J=7.6, 2.8Hz), 6.86 (1H, d, J=9.6 Hz), 7.11 (1H, d, J=9.6Hz), 7.25-7.36 (3H, m), 7.57-7.64 (2H, m), 8.68 (1H, d, J=7.6Hz)

APCI/MS: 379 [M+H]⁺

Example 130

5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

5 mp: 221-222°C (AcOEt)

NMR (DMSO-d₆, δ): 3.75(3H,s), 3.89(3H,s), 6.75(1H,dd,J=7.6, 2.8Hz), 6.87(1H,d,J=9.6Hz), 7.08(1H,d,J=9.6Hz), 7.27-7.35(3H,m), 7.59-7.66(2H,m), 8.67(1H,d,J=7.6Hz)

APCI/MS: 351 [M+H]⁺

10 Example 131

5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 179-180°C (AcOEt-Diisopropyl Ether)

15 NMR (DMSO-d₆, δ): 1.33(3H,t,J=7.2Hz), 3.88(3H,s), 4.16(2H,q,J=7.2Hz), 6.76(1H,dd,J=7.5, 2.8Hz), 6.87(1H,d,J=9.6Hz), 7.11(1H,d,J=9.6Hz), 7.24-7.35(3H,m), 7.59-7.66(2H,m), 8.68(1H,d,J=7.5Hz)

APCI/MS: 365 [M+H]⁺

20 Example 132

5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 190-191°C (AcOEt-Diisopropyl Ether)

25 NMR (DMSO-d₆, δ): 0.93(3H,t,J=7.4Hz), 1.71-1.89(2H,m), 3.87(3H,s), 4.10(2H,t,J=7.0Hz), 6.76(1H,dd,J=7.5, 2.7Hz), 6.87(1H,d,J=9.7Hz), 7.10(1H,d,J=9.7Hz), 7.22(1H,d,J=2.7Hz), 7.30(2H,t,J=7.9Hz), 7.58-7.65(2H,m), 8.67(1H,d,J=7.5Hz)

APCI/MS: 379 [M+H]⁺

30 Example 133

The mixture of 7-amino-3-(6-methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine (87 mg) and conc.HCl(1 ml) in

EtOH(2 ml) was heated with stirring at 80°C for 17 hours. The mixture was made basic with sodium hydrogen carbonate solution. The resultant precipitate was collected by filtration to give 7-amino-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2 -

5 phenylpyrazolo[1,5-a]pyridine (85 mg).

mp: 157-159°C

NMR (DMSO-d₆, δ): 6.17-6.25(1H,m), 6.78(1H,d,J=9.8Hz), 6.88-7.28(5H,m), 7.46-7.48(3H,m), 7.60-7.63(2H,m), 13.04(1H,s)

ESI/MS: 304 [M+H]⁺

10 Example 134

7-Amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)--2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

mp: 218-219°C

15 NMR (DMSO-d₆, δ): 1.29(6H,d,J=6.6Hz), 5.15-5.24(1H,m), 6.19-6.21(1H,m), 6.81(1H,d,J=9.6Hz), 6.91(2H,s), 7.09(1H,d,J=9.6Hz), 7.16-7.19(1H,m), 7.29-7.33(1H,m), 7.46-7.49(3H,m), 7.60-7.63(2H,m)

ESI/MS: 346 [M+H]⁺

20 Example 135

To a solution of 5-methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (2.0 g) in AcOH (30 ml) was added pyridinium hydrobromide perbromide (2.67 g) and the mixture was stirred at ambient temperature for 25 1.5 hours. The reaction mixture was concentrated, diluted with AcOEt, washed with water, 5% sodium thiosulfate solution, 1N NaOH solution, and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl₃-AcOEt, 3:1) to give 4-bromo-5-methoxy-30 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (2.43 g) as a white solid.

mp: 205-206°C (AcOEt)

IR (KBr): 2972, 1658, 1633, 1587, 1468, 1421 cm⁻¹

^1H NMR (CDCl_3 , δ): 1.30 (6H, d, $J=6.6\text{Hz}$), 4.01 (3H, s), 5.37 (1H, h, $J=6.6\text{Hz}$), 6.71 (1H, d, $J=7.6\text{Hz}$), 6.85 (1H, d, $J=9.5\text{Hz}$), 7.18 (1H, d, $J=9.5\text{Hz}$), 7.27–7.57 (5H, m), 8.49 (1H, d, $J=7.6\text{Hz}$)

ESI/MS: 461, 463 $[\text{M}+\text{Na}]^+$

5 Example 136

To a mixture of 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl trifluoromethanesulfonate (60.0 mg), 2-methyl-3-butyn-2-ol (0.018 ml), dichlorobis(triphenylphosphine)palladium (II) (0.9 mg) and CuI (0.2 mg) in DMF (1 ml) was added triethylamine (0.053 ml) and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with AcOEt, washed with water and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (n-hexane-AcOEt, 2:3) to give 5-(3-hydroxy-3-methyl-1-butynyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (50.7 mg) as a solid.

mp: 171–172°C (AcOEt)

IR (KBr): 3273, 2979, 2222, 1647, 1574, 1527 cm^{-1}

20 ^1H NMR (CDCl_3 , δ): 1.47 (6H, d, $J=6.6\text{Hz}$), 1.65 (6H, s), 5.43 (1H, h, $J=6.6\text{Hz}$), 6.77 (1H, d, $J=9.6\text{Hz}$), 6.85 (1H, dd, $J=7.1$, 1.9Hz), 7.01 (1H, d, $J=9.6\text{Hz}$), 7.37–7.67 (5H, m), 7.98–8.03 (1H, m), 8.42 (1H, dd, $J=7.1$, 0.8Hz)

ESI/MS: 435 $[\text{M}+\text{Na}]^+$

25 Example 137

5-[(1-Hydroxycyclohexyl)ethynyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 136.

IR (KBr): 3371, 2931, 2854, 2220, 1651, 1585, 1533 cm^{-1}

30 ^1H NMR (CDCl_3 , δ): 1.24–1.39 (1H, m), 1.47 (6H, d, $J=6.6\text{Hz}$), 1.53–1.85 (7H, m), 1.96–2.10 (2H, m), 2.25 (1H, s), 5.44 (1H, h, $J=6.6\text{Hz}$), 6.77 (1H, d, $J=9.6\text{Hz}$), 6.87 (1H, dd, $J=7.2$,

1.8Hz), 7.00 (1H, d, J=9.6Hz), 7.39-7.68 (5H, m), 8.09 (1H, dd, J=1.8, 0.8Hz), 8.43 (1H, dd, J=7.2, 0.8Hz)

ESI/MS: 475 [M+Na]⁺

Example 138

- 5 5-Phenylethynyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 136.

mp: 185-186°C (AcOEt)

IR (KBr): 2974, 2214, 1653, 1628, 1583, 1527 cm⁻¹

- 10 ¹H NMR (CDCl₃, δ): 1.50 (6H, d, J=6.6Hz), 5.44 (1H, h, J=6.6Hz), 6.78 (1H, d, J=9.6Hz), 6.95-7.00 (1H, m), 7.03 (1H, d, J=9.6Hz), 7.35-7.50 (6H, m), 7.50-7.65 (4H, m), 8.15 (1H, dd, J=1.8, 0.9Hz), 8.47 (1H, dd, J=7.1, 0.9Hz)

ESI/MS: 453 [M+Na]⁺

- 15 Example 139

- To a mixture of 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid (50 mg) and cyclopropylamine (0.012 ml) in DMF (2 ml) was added 1-hydroxybenzotriazole (27 mg) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (51 mg). After stirring at ambient temperature for 24 hours, the reaction mixture was diluted with AcOEt, washed with 0.1N HCl, water, saturated sodium hydrogen carbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo.
- 25 The residue was purified by silica gel column chromatography (CH₂Cl₂-MeOH, 20:1 elution) to give N-cyclopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide (53.6 mg) as a yellow solid.

- 30 mp: 184-185°C (AcOEt)

IR (KBr): 3292, 3026, 2976, 1668, 1641, 1593, 1529 cm⁻¹

¹H NMR (CDCl₃, δ): 1.60-1.67 (2H, m), 1.87-1.95 (2H, m), 1.50 (6H, d, J=6.6Hz), 2.90-3.00 (1H, m), 5.45 (1H, h, J=6.6Hz), 6.43 (1H, s),

6.74 (1H, d, J=9.6Hz), 7.00 (1H, d, J=9.6 Hz), 7.26 (1H, dd, J=7.2, 2.0Hz), 7.42-7.65 (5H, m), 8.45 (1H, dd, J=2.0, 0.8Hz), 8.53 (1H, dd, J=7.2, 0.8Hz)

Negative ESI/MS: 412 [M-H]⁻

5 Example 140

N-Cycloheptyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 139.

10 mp: 239-240°C (AcOEt)

IR (KBr): 3309, 2925, 2858, 1666, 1630, 1593, 1527 cm⁻¹

¹H NMR (CDCl₃, δ): 1.45-1.74 (10H, m), 1.52 (6H, d, J=6.6Hz), 2.01-2.23 (2H, m), 4.12-4.24 (1H, m), 5.47 (1H, h, J=6.6Hz), 6.14 (1H, d, J=8.0Hz), 6.76 (1H, d, J=9.6Hz), 7.01 (1H, d, J=9.6Hz),
15 7.31 (1H, dd, J=7.2, 2.0Hz), 7.43-7.65 (5H, m), 8.43 (1H, dd, J=2.0, 0.8Hz), 8.54 (1H, dd, J=7.2, 0.8Hz)

Negative ESI/MS: 468 [M-H]⁻

Example 141

5-[(Hexahydro-1H-azepin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 139.

IR (KBr): 2927, 1664, 1630, 1591, 1533, 1479 cm⁻¹

¹H NMR (CDCl₃, δ): 1.45 (6H, d, J=6.6Hz), 1.55-1.78 (6H, m), 1.78-
25 1.92 (2H, m), 3.43-3.53 (2H, m), 3.65-3.75 (2H, m), 5.42 (1H, h, J=6.6Hz), 6.77 (1H, d, J=9.6Hz), 6.93 (1H, dd, J=7.1, 1.8Hz), 7.01 (1H, d, J=9.6Hz), 7.41-7.65 (5H, m), 7.99 (1H, dd, J=1.8, 0.9Hz), 8.54 (1H, dd, J=7.1, 0.9Hz)

ESI/MS: 478 [M+Na]⁺

30 Example 142

5-{[4-(2-Pyridinyl)-1-piperazinyl]carbonyl}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example

139.

IR (KBr): 2978, 1662, 1635, 1591, 1533, 1477, 1433 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.44 (6H, d, $J=6.6\text{Hz}$), 3.50–4.00 (8H, m), 5.41 (1H, h, $J=6.6\text{Hz}$), 6.65–6.73 (2H, m), 6.77 (1H, d, $J=9.6\text{Hz}$), 6.96–7.00 (1H, m), 7.01 (1H, d, $J=9.6\text{Hz}$), 7.42–7.65 (6H, m), 8.09 (1H, dd, $J=1.8$, 0.9Hz), 8.17–8.23 (1H, m), 8.58 (1H, dd, $J=7.1$, 0.9Hz)

ESI/MS: 542 $[\text{M}+\text{Na}]^+$

Example 143

N-(n-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 139.

mp: 185–186°C (AcOEt)

IR (KBr): 3303, 2958, 2931, 2871, 1668, 1641, 1593, 1533 cm^{-1}

^1H NMR (CDCl_3 , δ): 0.98 (3H, t, $J=7.3\text{Hz}$), 1.38–1.50 (2H, m), 1.51 (6H, d, $J=6.6\text{Hz}$), 1.55–1.67 (2H, m), 3.45–3.55 (2H, m), 5.45 (1H, h), 6.15–6.25 (1H, m), 6.75 (1H, d, $J=9.6\text{Hz}$), 7.01 (1H, d, $J=9.6\text{Hz}$), 7.29 (1H, dd, $J=7.2$, 2.0Hz), 7.42–7.65 (5H, m), 8.40–8.46 (1H, m), 8.55 (1H, dd, $J=7.2$, 0.8Hz)

Negative ESI/MS: 428 $[\text{M}-\text{H}]^-$

Example 144

N-(2-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide was prepared by similar procedure as that of Example 139.

mp: 193–194°C (AcOEt)

IR (KBr): 3273, 3051, 2979, 2933, 1666, 1637, 1595, 1533 cm^{-1}

^1H NMR (CDCl_3 , δ): 1.50 (6H, d, $J=6.6\text{Hz}$), 4.80 (2H, d, $J=4.4\text{Hz}$), 5.44 (1H, h, $J=6.6\text{Hz}$), 6.77 (1H, d, $J=9.6\text{Hz}$), 7.03 (1H, d, $J=9.6\text{Hz}$), 7.22–7.28 (1H, m), 7.28–7.35 (1H, m), 7.38–7.45 (1H, m), 7.45–7.66 (5H, m), 7.68–7.77 (1H, m), 7.87–7.95 (1H, m), 8.55–8.62 (3H, m)

Negative ESI/MS: 463[M-H]⁻

Example 145

A mixture of 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid (8.38 g), Et₃N (4.06 ml), and diphenylphosphoryl azide (6.28 ml) in t-BuOH-toluene (2:1, 210 ml) was stirred at 80°C for 22 hours. After cooling to ambient temperature, the mixture was evaporated, diluted with AcOEt, washed with saturated sodium hydrogen carbonate solution, water and brine, dried over sodium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl₃-EtOAc (2:1) to CH₂Cl₂-MeOH (10:1)) to give tert-butyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-ylcarbamate (10.76 g) as a pale yellow solid and N,N'-bis[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]urea (902 mg) as a yellow solid.

tert-Butyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-ylcarbamate

mp: 208-210°C (AcOEt)

IR (KBr): 1728, 1645, 1579, 1514 cm⁻¹

¹H NMR (CDCl₃, δ): 1.50(6H,d,J=6.7Hz), 1.54(9H,s), 5.42(1H,h,J=6.7Hz), 6.73(1H,d,J=9.6Hz), 6.79 (1H,dd,J=7.5, 2.4Hz), 7.48 (1H,d,J=9.6Hz), 7.37-7.50(3H,m), 7.52-7.65(2H,m), 8.25-8.30(1H, m), 8.38(1H,dd,J=7.5, 0.6Hz)

ESI/MS: 468 [M+Na]⁺

N,N'-Bis[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]urea

ESI/MS: 739 [M+Na]⁺

Example 146

A solution of tert-butyl 3-(2-isopropyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-

ylcarbamate (9.58 g) in TFA (60 ml) was stirred at ambient temperature for 2 hours. After evaporation, the residue was dissolved in AcOEt, and 3N NaOH solution was added thereto under ice-cooling. The mixture was extracted with AcOEt, washed with water and brine, dried over sodium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl₃-MeOH, 10:1) to give 5-amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (4.90 g) as a yellow solid.

mp: 196-197°C (AcOEt)

IR (KBr): 3425, 3325, 3222, 1651, 1583, 1537, 1469 cm⁻¹

¹H NMR (CDCl₃, δ): 1.47(6H, d, J=6.6Hz), 4.08(2H, s), 5.42(1H, h, J=6.6Hz), 6.37(1H, dd, J=7.4, 2.6Hz), 6.70(1H, d, J=9.6Hz), 6.95(1H, d, J=9.6Hz), 7.10(1H, d, J=2.6Hz), 7.38-7.63(5H, m), 8.28(1H, d, J=7.4 Hz)

ESI/MS: 368 [M+Na]⁺

Example 147

To a solution of 5-amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (60 mg) and pyridine (0.042 ml) in CH₂Cl₂ (1.5 ml) was added AcCl (0.015 ml) at 5°C and the mixture was stirred at the same temperature for 10 minutes. The reaction mixture was diluted with AcOEt, washed with 1N HCl, water, saturated sodium hydrogen carbonate solution, water and brine, dried over sodium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (CHCl₃-MeOH, 10:1) to give 5-acetylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (68.6 mg) as a solid.

mp: 221-222°C (AcOEt - n-Hexane)

IR (KBr): 3294, 3249, 3128, 3043, 2981, 1702, 1649, 1576, 1450 cm⁻¹

¹H NMR (CDCl₃, δ): 1.50(6H, d, J=6.6Hz), 2.25(3H, s), 5.42(1H, h, J=6.6Hz), 6.73(1H, d, J=9.6Hz), 6.89(1H, dd, J=7.4, 2.4Hz),

6.98 (1H, d, J=9.6Hz), 7.40-7.63 (5H, m), 7.83 (1H, s),
8.41 (1H, d, J=7.4Hz), 8.49 (1H, s)

Negative ESI/MS: 386 [M-H]⁻

Example 148

5 5-Benzoylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 147.

mp: 266-267°C (AcOEt)

IR (KBr): 3318, 2978, 1678, 1647, 1572, 1508, 1491 cm⁻¹

10 ¹H NMR (CDCl₃, δ): 1.38 (6H, d, J=6.6Hz), 5.24 (1H, h, J=6.6Hz),
6.86 (1H, d, J=9.6Hz), 7.08 (1H, d, J=9.6Hz), 7.29 (1H, dd, J=7.5,
2.3Hz), 7.43-7.67 (8H, m), 7.93-8.00 (2H, m), 8.75-8.83 (2H, m),
10.63 (1H, s)

Negative ESI/MS: 448 [M-H]⁻

15 Example 149

5-(2-Methylpropanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 147.

mp: 199-200°C (AcOEt)

20 IR (KBr): 3315, 2966, 1701, 1645, 1574, 1510, 1489 cm⁻¹

¹H NMR (CDCl₃, δ): 1.29 (6H, d, J=6.9Hz), 1.47 (6H, d, J=6.6Hz),
2.58 (1H, h, J=6.9Hz), 5.40 (1H, h, J=6.6Hz), 6.75 (1H, d, J=9.6Hz),
6.95 (1H, dd, J=7.4, 2.5Hz), 7.01 (1H, d, J=9.6Hz), 7.39-7.47 (3H, m),
7.52 (1H, s), 7.55-7.64 (2H, m), 8.37-8.44 (2H, m)

25 Negative ESI/MS: 414 [M-H]⁻

Example 150

5-Methylsulfonylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 147.

30 mp: 193-194°C (AcOEt)

IR (KBr): 3078, 2873, 1643, 1576, 1485, 1419, 1338 cm⁻¹

¹H NMR (CDCl₃, δ): 1.50 (6H, d, J=6.6Hz), 3.15 (3H, s), 5.43 (1H, h,

J=6.6Hz), 6.70-6.79 (2H,m), 6.97 (1H,d,J=9.6Hz), 7.40-7.67 (6H,m), 7.94 (1H,dd,J=2.5, 0.7Hz), 8.46 (1H,dd,J=7.4, 0.7Hz)
Negative ESI/MS: 422 [M-H]⁻

Example 151

- 5 Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-ylcarbamate was prepared by similar procedure as that of Example 147.

mp: 213-214°C (AcOEt)

IR (KBr): 3275, 1736, 1649, 1583, 1520 cm⁻¹

- 10 ¹H NMR (CDCl₃, δ): 1.49 (6H,d,J=6.6Hz), 3.83 (3H,s), 5.43 (1H,h,J=6.6Hz), 6.74 (1H,d,J=9.6Hz), 6.88 (1H,dd,J=7.5, 2.4Hz), 6.98 (1H, d, J=9.6Hz), 7.014 (1H,s), 7.38-7.65 (5H,m), 8.15-8.23 (1H,m), 8.41 (1H,d,J=7.5Hz)

Negative ESI/MS: 402 [M-H]⁻

- 15 Example 152

5-(4-Bromobutanoylamino)-3-(3-oxo-2,3-isopropyl-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 147.

IR (KBr): 3292, 3249, 1701, 1647, 1579, 1506 cm⁻¹

- 20 ¹H NMR (CDCl₃, δ): 1.48 (6H,d,J=6.6Hz), 2.25-2.35 (2H,m), 2.64 (2H,t,J=7.0Hz), 3.55 (2H,t,J=6.2Hz), 5.41 (1H,h,J=6.6Hz), 6.75 (1H,d,J=9.6Hz), 6.95 (1H,dd,J=7.6, 2.2Hz), 6.99 (1H,d,J=9.6Hz), 7.38-7.63 (5H,m), 7.82 (1H,s), 8.37-8.45 (2H,m)

Example 153

- 25 To a solution of 5-(4-bromobutanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (90 mg) in DMF (3 ml) was added NaH (60% oil suspension, 8.0 mg) at 5°C and the mixture was stirred at ambient temperature for 3 hours. The reaction mixture was poured into water, and
30 the resulting precipitate was collected by filtration, washed with ether to give 5-(2-oxo-1-pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (64.0 mg).

mp: 266–267°C (AcOEt)

IR (KBr): 2978, 1697, 1657, 1641, 1587, 1531 cm⁻¹

¹H NMR (CDCl₃, δ): 1.51 (6H, d, J=6.6Hz), 2.18–2.30 (2H, m), 2.65–2.73 (2H, m), 3.87–3.95 (2H, m), 5.46 (1H, h, J=6.6Hz), 6.73 (1H, d, J=9.6Hz), 6.98 (1H, d, J=9.6Hz), 7.41–7.63 (5H, m), 7.86 (1H, dd, J=7.6, 2.5Hz), 7.87–7.92 (1H, m), 7.46 (1H, dd, J=7.6, 0.5Hz)

ESI/MS: 436 [M+Na]⁺

Example 154

To a solution of 5-amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (60 mg), 35% formaldehyde solution (0.6 ml) and AcOH (0.020 ml) in CH₂Cl₂-MeOH (4:1, 7.5 ml) was added sodium triacetoxymethylborohydride (184 mg). After stirring at ambient temperature for 15 hours, the reaction mixture was diluted with AcOEt, washed with saturated sodium hydrogen carbonate solution, water, and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (n-hexane-AcOEt, 2:5) to give 5-[bis(methoxymethyl)amino]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (29.7 mg) as a green solid.

mp: 148–150°C (AcOEt)

IR (KBr): 2929, 1651, 1585, 1522 cm⁻¹

¹H NMR (CDCl₃, δ): 1.50 (6H, d, J=6.6Hz), 3.35 (6H, s), 4.88 (4H, s), 5.43 (1H, h, J=6.6Hz), 6.70 (1H, d, J=9.6Hz), 6.82 (1H, dd, J=7.7, 2.6Hz), 6.94 (1H, d, J=9.6Hz), 7.38–7.64 (6H, m), 8.36 (1H, d, J=7.7Hz)

ESI/MS: 456 [M+Na]⁺

Example 155

To a mixture of 5-(4-piperidinyloxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride (150 mg), 35% aq. HCHO (0.56 ml), and AcOH (0.018 ml) in CH₂Cl₂ (3.6 ml)–MeOH (0.9 ml) was added NaBH(OAc)₃ (136 mg), and the mixture was stirred at ambient

temperature for 1 hour. To the reaction mixture was added saturated sodium hydrogen carbonate solution (20 ml) and water (20 ml), and the mixture was extracted with AcOEt (40 ml x 2).

The organic layer was washed with water (30 ml) and brine, dried
5 over magnesium sulfate, filtered, and evaporated in vacuo. The residue was purified by silica-gel (6 g) column chromatography (CHCl₃ : MeOH = 9:1). The solid (40 mg) was dissolved in 1,4-dioxane (1 ml), and to the solution was added 4N-HCl in dioxane, then the resultant precipitate was collected by
10 filtration and washed with Et₂O and IPE, and dried to give 5-[(1-methyl-4-piperidinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride (31.0 mg).

mp: > 250°C (AcOEt)

15 NMR (DMSO-d₆, δ): 1.32 (6H, d, J=6.6Hz), 1.80-2.40 (4H, m), 2.78 (3H, s), 2.90-3.70 (4H, m), 4.55-4.95 (1H, m), 5.05-5.35 (1H, m), 6.70-6.95 (2H, m), 7.10 (1H, d, J=9.6Hz), 7.26 (1H, d, J=2.4Hz), 7.40-7.65 (5H, m), 8.73 (1H, d, J=6.9Hz), 10.31 (1H, br, s)

20 ESI/MS: 444 [M-HCl+H]⁺

Example 156

1,1-Dibenzyl-4-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine]oxy}piperidinium bromide was prepared by similar
25 procedure as that of Example 55.

mp: 211-213.5°C (AcOEt)

NMR (DMSO-d₆, δ): 1.23 (6H, d, J=6.6Hz), 2.25-2.65 (4H, m), 3.15-3.60 (4H, m), 4.60-4.90 (4H, m), 5.05-5.35 (1H, m), 6.43 (1H, dd, J=2.2, 7.5Hz), 6.84 (1H, d, J=9.6Hz), 7.04 (1H, d, J=9.6Hz),
30 7.14 (1H, d, J=2.4Hz), 7.35-7.75 (15H, m), 8.68 (1H, d, J=7.5Hz)

ESI/MS: 610 [M+Na]⁺

Example 157

5-[(4-Methoxybenzyl)oxy]-3-(3-oxo-2-isopropyl-2,3-

dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

NMR (DMSO-d₆, δ): 1.30 (6H, d, J=6.6Hz), 3.77 (3H, s), 5.13 (2H, s), 5.15-5.30 (1H, m), 6.80 (1H, dd, J=2.7, 7.5Hz), 6.85 (1H, d, J=9.6Hz), 6.98 (2H, td, J=2.4, 9.1Hz), 7.08 (1H, d, J=9.6Hz), 7.34 (1H, d, J=2.6Hz), 7.41 (2H, td, J=2.4, 9.2Hz), 7.44-7.60 (5H, m), 8.70 (1H, d, J=7.5Hz)

ESI/MS: 489 [M+Na]⁺

Example 158

10 5-{[(4-Trifluoromethyl)-2-pyridinyl]oxy}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

NMR (DMSO-d₆, δ): 1.16 (6H, d, J=6.6Hz), 5.10-5.25 (1H, m), 6.82 (1H, d, J=9.7Hz), 7.05-7.10 (2H, m), 7.45-7.55 (4H, m), 7.55-7.63 (2H, m), 7.65 (1H, d, J=2.1Hz), 8.35 (1H, dd, J=2.5, 8.7Hz), 8.68 (1H, s), 8.91 (1H, d, J=7.5Hz)

ESI/MS: 514 [M+Na]⁺

Example 159

20 5-(Nicotinamid-6-oxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 31.

NMR (DMSO-d₆, δ): 1.15 (6H, d, J=6.6Hz), 5.05-5.20 (1H, m), 6.81 (1H, d, J=9.6Hz), 7.00-7.10 (2H, m), 7.33 (1H, d, J=8.6Hz), 7.45-7.55 (3H, m), 7.55-7.65 (4H, m), 8.13 (1H, s), 8.38 (1H, dd, J=2.5, 8.5Hz), 8.74 (1H, d, J=2.3Hz), 8.89 (1H, d, J=7.5Hz)

ESI/MS: 489 [M+Na]⁺

Example 160

30 5-[2-Oxo-2-(1-piperidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 50.

NMR (DMSO-d₆, δ): 1.33 (6H, d, J=6.6Hz), 1.40-1.50 (2H, m),

1.50-1.65 (4H, m), 3.30-3.40 (2H, m), 3.40-3.50 (2H, m), 4.98 (2H, s), 5.10-5.30 (1H, m), 6.75-6.90 (2H, m), 7.02 (1H, d, J=9.6Hz), 7.16 (1H, d, J=2.7Hz), 7.40-7.50 (3H, m), 7.50-7.60 (2H, m), 8.68 (1H, d, J=7.5Hz)

5 ESI/MS: 494 [M+Na]⁺

Example 161

N-(tert-Butyl)-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of
10 Example 50.

NMR (DMSO-d₆, δ): 1.20-1.45 (15H, m), 4.54 (2H, s), 5.15-5.30 (1H, m), 6.80-6.90 (2H, m), 7.10 (1H, d, J=9.6Hz), 7.14 (1H, d, J=2.7Hz), 7.40-7.55 (3H, m), 7.55-7.60 (2H, m), 7.62 (1H, s), 8.71 (1H, d, J=7.5Hz)

15 Negative ESI/MS: 458 [M-H]⁻

Example 162

N-Cycloheptyl-2-{[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy}acetamide was prepared by similar procedure as that of
20 Example 50.

NMR (DMSO-d₆, δ): 1.29 (6H, d, J=6.6Hz), 1.20-1.65 (10H, m), 1.65-1.85 (2H, m), 3.70-3.90 (1H, m), 4.58 (2H, s), 5.10-5.28 (1H, m), 6.78-6.90 (2H, m), 7.10 (1H, d, J=9.6Hz), 7.14 (1H, d, J=2.6Hz), 7.40-7.52 (3H, m), 7.52-7.60 (2H, m), 8.02 (1H, d, J=8.0Hz), 8.72 (1H, d, J=7.6Hz)

Negative ESI/MS: 498 [M-H]⁻

Example 163

3-[2,3-Dihydropyridazin-6-yl]-6-methoxy-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar
30 procedure as that of Example 5.

NMR (DMSO-d₆, δ): 3.82 (3H, s), 6.75 (1H, d, J=3.9Hz), 6.90-7.00 (2H, m), 7.25-7.60 (6H, m), 8.41 (1H, d, J=3.4Hz),

12.97 (1H, s)

Negative ESI/MS: 317 [M-H]⁻

Example 164

6-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

ESI/MS: 383 [M+Na]⁺

Example 165

6-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 3.

ESI/MS: 369 [M+Na]⁺

Example 166

6-[2-(N, N-Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

Example 167

6-{2-[(2R, 6S)-2,6-Dimethyl-4-morpholinyl]ethoxy}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

ESI/MS: 488 [M+H]⁺

Example 168

6-(2-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 8.

ESI/MS: 460 [M+Na]⁺

Example 169

2-{[3-(3-Oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy}acetic acid was prepared by similar procedure as that of Example 8.

ESI/MS: 441 [M+Na]⁺

Example 170

Ethyl 2-{[3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy}acetic acid was prepared by similar procedure as that of Example 39.

Negative ESI/MS: 403[M-H]⁻

5 Example 171

N, N-Dimethyl-2-{[3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy}acetamide was prepared by similar procedure as that of Example 50.

10 ESI/MS: 454[M+Na]⁺

Example 172

6-[2-(1-Pyrrolidinyl)-2-oxo-ethoxy]-3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 15 50.

ESI/MS: 480[M+Na]⁺

Example 173

6-[2-(4-Methyl-1-piperazinyl)-2-oxo-ethoxy]-3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 20 50.

ESI/MS: 487[M+H]⁺

Example 174

6-{2-[(2R, 6S)-2,6-Dimethyl-4-morpholinyl]-2-oxo-ethoxy}-3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 25 50.

ESI/MS: 524[M+Na]⁺

Example 175

30 N-Cyclopentyl-2-{[3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy}acetamide was prepared by similar procedure as that of Example 50.

ESI/MS: 494 [M+Na]⁺

Example 176

N-Isopropyl-2-([3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy)acetamide was prepared by similar procedure as that of Example 50.

ESI/MS: 468 [M+Na]⁺

Example 177

N-Isobutyl-2-([3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy)acetamide was prepared by similar procedure as that of Example 50.

ESI/MS: 482 [M+Na]⁺

Example 178

6-Trifluoromethanesulfonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 68.

ESI/MS: 501 [M+Na]⁺

Example 179

6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

ESI/MS: 466 [M+Na]⁺

Example 180

6-(4-Methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 96.

ESI/MS: 451 [M+Na]⁺

Example 181

Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxylate was prepared by similar procedure as that of Example 69.

ESI/MS: 411[M+Na]⁺

Example 182

3-(3-Oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxylic acid was prepared
5 by similar procedure as that of Example 70.

ESI/MS: 397[M+Na]⁺

Example 183

N,N-Dimethyl-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine]-6-
10 carboxamide was prepared by similar procedure as that of Example 50.

ESI/MS: 424[M+Na]⁺

Example 184

6-[(4-Methyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example
15 50.

ESI/MS: 479[M+Na]⁺

Example 185

20 6-{[(2R,6S)-2,6-Dimethyl-4-morpholinyl]carbonyl}-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 50.

ESI/MS: 494[M+Na]⁺

25 Example 186

N-Isobutyl-[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine]-6-carboxamide was prepared by similar procedure as that of Example 50.

ESI/MS: 452[M+Na]⁺

30 Example 187

7-Acetylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 147.

mp: 92-96°C

NMR (DMSO-d₆, δ): 1.30 (6H, d, J=6.6Hz), 2.33 (3H, s), 5.14-5.28 (1H, m), 6.86 (1H, d, J=9.7Hz), 7.14 (1H, d, J=9.7Hz), 7.38-7.69 (8H, m), 10.50 (1H, s)

5 ESI/MS: 388 [M+H]⁺

Example 188

7-Methoxy-3-(3-oxo-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 1.

10 NMR (CDCl₃, δ): 4.17 (3H, s), 6.22 (1H, d, J=7.3Hz), 6.82 (1H, d, J=9.8Hz), 7.07 (1H, d, J=9.8Hz), 7.24 (1H, t, J=8.3Hz), 7.35-7.55 (3H, m), 7.55-7.70 (2H, m), 7.71 (1H, d, J=8.7Hz), 13.08 (1H, s)
APCI/MS: 319 [M+H]⁺

Example 189

15 7-Methoxy-3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

NMR (DMSO-d₆, δ): 1.30 (6H, d, J=6.6Hz), 4.16 (3H, s), 5.10-5.35 (1H, m), 6.57 (1H, dd, J=7.1, 1.5Hz), 6.85 (1H, d, J=9.6Hz), 7.12 (1H, d, J=9.6Hz), 7.35-7.65 (7H, m)
20 APCI/MS: 361 [M+H]⁺

Example 190

7-Methoxy-3-(3-oxo-2-methyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar
25 procedure as that of Example 2.

NMR (DMSO-d₆, δ): 3.75 (3H, s), 4.15 (3H, s), 6.57 (1H, d, J=6.7Hz), 6.85 (1H, d, J=9.6Hz), 7.04 (1H, d, J=9.6Hz), 7.35-7.55 (4H, m), 7.55-7.70 (3H, m)
APCI/MS: 333 [M+H]⁺

30 Example 191

7-Methoxy-3-(3-oxo-2-ethyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar

procedure as that of Example 2.

NMR (DMSO-d₆, δ): 1.36 (3H, t, J=7.2Hz), 4.00-4.30 (5H, m), 6.58 (1H, dd, J=7.4, 1.0Hz), 6.86 (1H, d, J=9.6Hz), 7.09 (1H, d, J=9.6Hz), 7.30-7.75 (7H, m)

5 APCI/MS: 347 [M+H]⁺

Example 192

7-Methoxy-3-(3-oxo-2-n-propyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

10 NMR (DMSO-d₆, δ): 0.92 (3H, t, J=7.4Hz), 1.78 (2H, 6-plet, J=7.3Hz), 4.00-4.20 (5H, m), 6.57 (1H, dd, J=7.3, 1.3Hz), 6.86 (1H, d, J=9.6Hz), 7.09 (1H, d, J=9.6Hz), 7.30-7.75 (7H, m)

APCI/MS: 361 [M+H]⁺

Example 193

15 4-Methoxy-3-(3-oxo-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 1.

NMR (DMSO-d₆, δ): 3.87 (3H, s), 6.75 (1H, d, J=7.6Hz), 6.80-7.00 (2H, m), 7.23-7.65 (6H, m), 8.41 (1H, d, J=6.7Hz), 12.97 (1H, s)

20 APCI/MS: 319 [M+H]⁺

Example 194

4-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 2.

25 mp: 185-186°C (AcOEt)

NMR (DMSO-d₆, δ): 1.01 (6H, d, J=6.6Hz), 3.84 (3H, s), 4.95-5.20 (1H, m), 6.77 (1H, d, J=7.7Hz), 6.90 (1H, d, J=9.6Hz), 6.95 (1H, t, J=7.3Hz), 7.30-7.50 (5H, m), 7.53 (1H, d, J=9.6Hz) 8.42 (1H, d, J=6.8Hz)

30 APCI/MS: 361 [M+H]⁺

Anal. Calcd for C₂₁H₂₀N₄O₂: C, 69.98; H, 5.59; N, 15.55

Found: C, 70.19; H, 5.68; N, 15.54

Example 195

4-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 3.

5 mp: 229-230°C (EtOH)

NMR (DMSO-d₆, δ): 1.01 (6H, d, J=6.6Hz), 4.93-5.20 (1H, m), 6.59 (1H, d, J=7.5Hz), 6.82 (1H, d, J=7.0Hz), 6.90 (1H, d, J=9.4Hz), 7.26-7.65 (6H, m), 8.31 (1H, d, J=6.8Hz), 10.73 (1H, s)

APCI/MS: 347 [M+H]⁺

10 Anal. Calcd for C₂₀H₁₈N₄O₂: C, 69.35; H, 5.24; N, 16.17

Found: C, 69.73; H, 5.23; N, 16.23

Example 196

To a mixture of 4-hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (80.0
15 mg) and potassium carbonate (96.0 mg) in DMF (3 ml) was added ethyl iodide (0.022 ml) and stirred at 60°C for 1 hour. The reaction mixture was diluted with AcOEt, washed with water and brine, dried over sodium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (AcOEt :
20 n-hexane = 5:2) to give 4-ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (76.0 mg) as a solid.

mp: 157-158°C (AcOEt - n-Hexane)

IR (KBr): 3097, 3055, 2979, 1657, 1589, 1545, 1284 cm⁻¹

25 ¹H NMR (CDCl₃, δ): 1.12 (6H, d, J=6.6Hz), 1.30 (3H, t, J=7.0Hz), 4.08 (2H, q, J=7.0Hz), 5.26 (1H, hept, J=6.6Hz), 6.44 (1H, d, J=7.6 Hz), 6.72 (1H, dd, J=7.6, 6.9Hz), 6.87 (1H, d, J=9.5Hz), 7.23-7.39 (3H, m), 7.43 (1H, d, J=9.5Hz), 7.47-7.69 (2H, m), 8.17 (1H, d, J=6.9Hz)

30 APCI/MS: 375 [M+H]⁺

Example 197

4-n-Propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar

procedure as that of Example 196.

mp: 176-177°C (AcOEt - n-Hexane)

IR (KBr): 3097, 2979, 2935, 1655, 1591, 1545, 1284 cm⁻¹

¹H NMR (CDCl₃, δ): 0.85 (3H, t, J=7.4Hz), 1.13 (6H, d, J=6.6Hz),

5 1.55-1.78 (2H, m), 3.97 (2H, t, J=6.3Hz), 5.27 (1H, hept, J=6.6Hz),
6.44 (1H, d, J=7.6Hz), 6.73 (1H, dd, J=7.6, 6.9Hz), 6.88 (1H, d,
J=9.5Hz), 7.25-7.39 (3H, m), 7.42 (1H, d, J=9.5Hz), 7.48-
7.60 (2H, m), 8.17 (1H, dd, J=6.9, 0.8Hz)

APCI/MS: 389 [M+H]⁺

10 Example 198

4-(2-(Dimethylamino)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was prepared by similar procedure as that of Example 196.

mp: 137-138°C (AcOEt - n-Hexane)

15 IR (KBr): 2979, 2763, 1658, 1585, 1282, 1097 cm⁻¹

¹H NMR (CDCl₃, δ): 1.10 (6H, d, J=6.6Hz), 2.20 (6H, s), 2.59 (2H, t,
J=5.7Hz), 4.13 (2H, t, J=5.7Hz), 5.25 (1H, hept, J=6.6Hz),
6.48 (1H, d, J=7.6Hz), 6.74 (1H, dd, J=7.6, 7.0Hz),
6.90 (1H, d, J=9.5Hz), 7.26-7.40 (3H, m), 7.45-7.58 (3H, m),

20 8.19 (1H, d, J=7.0Hz)

APCI/MS: 418 [M+H]⁺

Example 199

4-(2-(4-Morpholinyl)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was
25 prepared by similar procedure as that of Example 196.

IR (neat): 2962, 2931, 2856, 1658, 1589, 1547, 1286 cm⁻¹

¹H NMR (CDCl₃, δ): 1.09 (6H, d, J=6.6Hz), 2.35-2.48 (4H, m), 2.66 (2H,
t, J=5.6Hz), 3.55-3.73 (4H, m), 4.16 (2H, t, J=5.6Hz), 5.25 (1H, hept,
J=6.6Hz), 6.48 (1H, d, J=7.6Hz), 6.74 (1H, t-like, J=7.2Hz),

30 6.88 (1H, d, J=9.5Hz), 7.25-7.42 (3H, m), 7.42-7.57 (3H, m),
8.19 (1H, d, J=6.8Hz)


APCI/MS: 460 [M+H]⁺

Examples 200 to 331

Desired Amide Derivatives of Examples 200 to 331, which are represented by the following formula (Ik) was obtained according to the following standard procedure.

5

10




Wherein R and R' are as defined as the following Table 3.

Standard procedure for the synthesis of Amide Derivatives (Ik)

15

20



25

30












To a mixture of 3-(3-oxo-2-isopropyl-2, 3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid (Il) (7.48 mg, 0.020 mmol), 1.0 M *N,N*-diisopropylethylamine in *N*-methyl-2-pyrrolidinone (NMP) (20 μ l), 1.0 M solution of 1-hydroxybenzotriazole (HOBt) in NMP (22 μ l) was added 1.0 M solution of 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDAC) in NMP (24 μ l) at ambient temperature. After stirring for 1 hour, the mixture was treated with 0.5 M solution of an amine(XIV) (defined as the following Table 3) in NMP (40 μ l) at ambient temperature for 30 minutes, and then 60°C for 90 minutes. The reaction mixture was purified by solid-phase extraction (SPE) on SPE column (Varian















Nexus, 300 mg of sorbent) eluting with acetonitrile (400 μ l) and then dichloroethane (400 μ l). The fractions containing desired compound were concentrated and dried under reduced pressure to give desired compound (Ik). Purity was estimated by HPLC
5 analysis (reverse phase C₁₈, 5 μ , 4.6 mm x 35 mm column, 254 nm, 0-80% CH₃CN (containing 0.05% HCO₂H) / H₂O (containing 0.05% HCO₂H), over 4 minutes, 2 ml/min).















Concerning each Example compound, the formula of amine
10 $\begin{array}{c} \text{R} \\ \diagdown \\ \text{NH} \\ | \\ \text{R}' \end{array}$) and MS spectrum of the desired compound (Ik) of the compound was shown in Table 3.















15















Table 3.















	Amines	MW	purity	Mass
Example No.	$\begin{array}{c} \text{R} \\ \\ \text{NH} \\ \\ \text{R}' \end{array}$		[%]	$[\text{M}+\text{H}]^+$
200		482.57	95	484
201		443.49	94	444
202		413.47	94	414
203		477.55	100	479
204		507.58	96	509
205		479.53	78	481
206		455.55	97	457
207		413.47	90	414
208		445.51	90	447
209		477.55	96	479
210		479.53	86	481














211		457.52	88	459
212		445.51	80	447
213		445.51	84	447
214		478.54	90	480
215		512.00	95	513
216		454.48	82	455
217		480.51	87	482
218		497.97	100	499
219		515.51	85	517
220		457.52	92	459
221		541.60	100	543
222		483.60	96	485
223		513.59	100	515
224		515.56	100	517














225		534.62	87	536
226		457.52	85	459
227		484.55	89	486
228		515.56	70	517
229		471.55	81	473
230		447.48	87	448
231		499.94	72	501
232		471.55	80	473
233		453.49	76	454
234		486.56	87	488
235		523.58	84	525
236		463.53	93	465
237		429.51	79	431
238		455.55	90	457














239		489.56	80	491
240		546.62	88	548
241		475.54	95	477
242		457.56	91	459
243		491.58	97	493
244		523.58	94	525
245		555.58	85	557
246		431.48	86	432
247		493.55	90	495
248		527.61	91	529
249		506.55	91	508
250		485.57	82	487
251		431.48	80	432
252		458.55	95	460

253		493.55	92	495
254		488.54	88	490
255		491.58	96	493
256		459.54	87	461
257		493.55	95	495
258		527.61	86	529
259		578.63	89	580
260		459.54	90	461
261		493.55	96	495
262		465.50	85	466
263		489.52	94	491
264		520.62	83	522
265		590.67	96	592
266		514.57	90	516

267		441.52	90	443
268		461.51	90	463
269		493.55	84	495
270		491.54	81	493
271		518.61	94	520
272		492.57	91	494
273		461.57	91	463
274		493.55	76	495
275		532.42	79	533
276		467.49	95	468
277		519.59	91	521
278		443.54	96	445
279		463.53	85	465
280		497.97	89	499

281		537.61	86	539
282		470.54	73	472
283		520.54	90	522
284		443.54	100	445
285		497.97	100	499
286		491.58	100	493
287		623.74	84	625
288		524.65	100	526
289		497.97	100	499
290		539.63	88	541
291		474.51	100	476
292		528.60	95	530
293		546.66	100	548


294		477.55	100	479
295		493.55	80	495
296		548.63	100	550
297		469.57	100	471
298		477.55	100	479
299		493.55	100	495
300		510.50	100	511
301		528.94	100	530
302		558.63	88	560
303		471.55	100	473
304		500.63	100	502
305		553.65	100	555
306		510.50	100	511

307		645.75	100	647
308		573.64	100	575
309		445.51	93	447
310		472.58	100	474
311		503.59	100	505
312		646.74	100	648
313		608.73	100	610
314		477.55	100	479
315		535.49	100	536
316		623.74	100	625
317		477.55	100	479
318		507.54	92	509
319		540.61	100	542

320		541.60	95	543
321		542.42	100	543
322		542.42	100	543
323		550.01	97	551
324		552.93	77	554
325		553.61	91	555
326		555.62	100	557
327		575.40	86	576
328		515.58	91	517
329		537.61	91	539
330		559.59	56	561
331		590.50	74	591

CLAIMS

1. A pyrazolopyridine compound of the following formula (I).



10 wherein

R^1 is hydrogen, lower alkyl optionally substituted by substituent(s), or cyclo(lower)alkyl which may be interrupted by an oxygen or nitrogen atom and optionally substituted by substituent(s);

15 R^2 is hydrogen, halogen or lower alkoxy;

R^3 is a substituent; and

n is an integer from 1 to 4,

provided R^3 may be different from each other when n is 2, 3 or 4,

20 or a salt thereof.

2. A compound of claim 1,

wherein

R^1 is hydrogen, lower alkyl optionally substituted by lower alkoxy, or cyclo(lower)alkyl which may be interrupted by an oxygen or nitrogen atom and optionally substituted by lower alkyl;

R^3 is

(1) a group of the formula:

30 R^4-A-O-

in which


A is lower alkylene, and

R^4 is hydrogen;

- cyclo(lower)alkyl;
aryl optionally substituted by lower alkoxy;
a group of the formula:
R⁵-(R⁶-)N-
5 wherein R⁵ and R⁶ are each independently
hydrogen, or
lower alkyl;
heterocyclic group optionally substituted by
oxo, lower alkyl or
10 lower alkoxy(lower)alkyl;
carboxy;
lower alkoxycarbonyl;
aryl(lower)alkoxycarbonyl;
lower alkanoyl;
15 a group of the formula:
R⁷-(R⁸-)N-CO-
wherein R⁷ and R⁸ are each independently
hydrogen;
lower alkyl optionally substituted by
20 lower alkoxy, N,N-di(lower)alkylamino or
heterocyclic group;
cyclo(lower)alkyl optionally substituted by hydroxy;
aryl optionally substituted by lower alkoxy; or
a group of the formula:
25 Het-CO-
wherein Het is N-containing heterocyclic group
optionally substituted by
lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
N,N-di(lower)alkylcarbonyl or aryl(lower)alkyl,
30 (2) a group of the formula:
R⁹-O-
in which
R⁹ is hydrogen;

aryl optionally substituted by lower alkanoylamino;
heterocyclic group optionally substituted by
lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
carbamoyl, N,N-di(lower)alkylcarbamoyl,
5 aryl(lower)alkyl, lower alkoxy, halo(lower)alkyl or
nitro; or
arylsulfonyl optionally substituted by
lower alkyl or lower alkoxy,

10 (3) a group of the formula:



in which

R^{10} and R^{11} are each independently
hydrogen;

15 cyclo(lower)alkyl;

heterocyclic group optionally substituted by lower alkyl;
lower alkyl optionally substituted by


hydroxy, lower alkoxy, aryl, aryloxy,

N,N-di(lower)alkylamino or heterocyclic group; or

20 R^{10} and R^{11} may be combined together with N atom to which
they are attached to form N-containing heterocyclic group
optionally substituted by

lower alkyl, aryl, lower alkanoyl or heterocyclic group,

25 (4) a group of the formula:



in which

R^{12} and R^{13} are each independently
hydrogen;

30 lower alkyl optionally substituted by lower alkoxy;

lower alkanoyl optionally substituted by aryl or halogen;

lower alkoxycarbonyl;

lower alkylsulfonyl; or

R¹² and R¹³ may be combined together with N atom to which they are attached to form N-containing heterocyclic group optionally substituted by

hydroxy, oxo, lower alkyl, lower alkoxy,
5 lower alkanoyl optionally substituted by
N,N-di(lower)alkylamino or aryl,
lower alkoxycarbonyl,
N,N-di(lower)alkylcarbamoyl,
lower alkylsulfonyl, arylsulfonyl, aryl,
10 aryl(lower)alkyl or heterocyclic group,

(5) a group of the formula:

R¹⁴-A'-

in which

15 A' is lower alkynyl,
R¹⁴ is hydroxy; cyclo(lower)alkyl; or aryl,
or

(6) carboxy, lower alkoxycarbonyl or cyano.

20 3. A compound of claim 2,
wherein

R¹ is hydrogen, lower alkyl optionally substituted by lower alkoxy, tetrahydrofuryl, tetrahydropyranyl or piperidinyl;
R³ is

25 (1) a group of the formula:

R⁴-A-O-

in which

A is lower alkylene, and

R⁴ is hydrogen;

30 cyclo(lower)alkyl;

phenyl optionally substituted by lower alkoxy;

a group of the formula:


R⁵-(R⁶-)N-

- wherein R⁵ and R⁶ are each independently
hydrogen or lower alkyl;
aziridinyl, pyrrolidinyl, piperidinyl, morpholinyl,
pyridyl or isoindolyl, each of which is optionally
5 substituted by
oxo, lower alkyl or lower alkoxy(lower)alkyl;
carboxy;
lower alkoxycarbonyl;
phenyl(lower)alkoxycarbonyl;
10 lower alkanoyl;
a group of the formula:
R⁷-(R⁸-)N-CO-
wherein R⁷ and R⁸ are each independently
hydrogen;
15 lower alkyl optionally substituted by
lower alkoxy, N,N-di(lower)alkylamino or pyridyl;
cyclo(lower)alkyl optionally substituted by hydroxy;
phenyl optionally substituted by lower alkoxy; or
a group of the formula:
20 Het-CO-
wherein Het is pyrrolidinyl, piperidinyl, piperazinyl
or morpholinyl, each of which is optionally substituted
by
lower alkyl, lower alkanoyl, lower alkoxycarbonyl,
25 N,N-di(lower)alkylcarbamoyl, phenyl(lower)alkyl,
(2) a group of the formula:
R⁹-O-
in which
30 R⁹ is hydrogen;
phenyl optionally substituted by lower alkanoylamino;
piperidinyl, tetrahydropyranyl or pyridinyl, each of which
is optionally substituted by

lower alkyl, lower alkanoyl, lower alkoxy carbonyl, carbamoyl, N,N-di(lower)alkylcarbamoyl, phenyl(lower)alkyl, lower alkoxy, halo(lower)alkyl or nitro;

5 phenylsulfonyl optionally substituted by lower alkyl or lower alkoxy,

(3) a group of the formula:



10 in which

R^{10} and R^{11} are each independently hydrogen;

cyclo(lower)alkyl;

thiazolyl optionally substituted by lower alkyl;

15 lower alkyl optionally substituted by

hydroxy, lower alkoxy, phenyl, phenoxy,

N,N-di(lower)alkylamino, pyrrolidinyl or pyridinyl; or R^{10} and R^{11} may be combined together with N atom to which they are attached to form pyrrolidinyl, piperidinyl, 20 hexahydroazepinyl, piperazinyl or morpholinyl, each of which is optionally substituted by

lower alkyl, phenyl, lower alkanoyl or pyridinyl,

(4) a group of the formula:



in which

R^{12} and R^{13} are each independently hydrogen;

lower alkyl optionally substituted by lower alkoxy;

30 lower alkanoyl optionally substituted by phenyl or halogen;

lower alkoxy carbonyl;

lower alkylsulfonyl; or

R^{12} and R^{13} may be combined together with N atom to which

they are attached to form pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, each of which is optionally substituted by

hydroxy, oxo, lower alkyl, lower alkoxy,
 5 lower alkanoyl optionally substituted by
 N,N-di(lower)alkylamino or phenyl,
 lower alkoxycarbonyl,
 N,N-di(lower)alkylcarbamoyl
 lower alkylsulfonyl, phenylsulfonyl, phenyl,
 10 phenyl(lower)alkyl, pyridinyl or pyrimidinyl,

(5) a group of the formula:

$R^{14}-A'-$

in which

15 A' is lower alkynyl,
 R^{14} is hydroxy; cyclo(lower)alkyl; or phenyl,
 or

(6) carboxy, lower alkoxycarbonyl or cyano.

20 4. A compound of claim 3,

wherein


R^1 is (C1-C4)alkyl,

R^2 is hydrogen,

R^3 is (C1-C4)alkoxy, and

25 n is 1.

5. A process for preparing the pyrazolopyridine compound of the following formula (I).




wherein R^1 , R^2 , R^3 and n are each as defined in claim 1,
or a salt thereof, which comprises

5

(1) hydrolyzing a compound of the formula (II):

10




wherein

R^2 , R^3 and n are each as defined above, and

15 R^{15} is arylsulfonyl optionally substituted by substituent(s),
di(lower)alkylamino, lower alkoxy, lower alkylthio, or acyloxy;
or a salt thereof,

to give a compound of the formula (Ia):

20



25 wherein R^2 , R^3 and n are each as defined above
or a salt thereof,


(2) reacting a compound of the formula (Ia) or a salt thereof,
with a compound of the formula (III):

30




wherein R^{1a} is lower alkyl or cyclo(lower)alkyl which may be
interrupted by an oxygen atom, and

Y is a leaving group;
 or a salt thereof,
 to give a compound of the formula (Ib):




10 wherein R^{1a}, R², R³ and n are as defined above
 or a salt thereof,

(3) eliminating of alkyl group of a compound of the formula (Ic):




wherein

R¹ and R² are as defined above; and
 R¹⁶ is lower alkyl, or a salt thereof,
 to give a compound of a formula (Id):




30 wherein R¹ and R² are as defined above,
 or a salt thereof, or

(4) reacting a compound of the formula (Id):



wherein R^1 and R^2 are as defined above or a salt thereof,
with a compound of the formula (IV):




wherein R^{17} is a substituent selected from the group consisting
of a group of the formula: $-A-R^4$ and a group of the formula:
 $-R^9$

[wherein A is as defined above, and R^4 and R^9 are each as defined
15 in claim 2], and

Y is a leaving group,


or a salt thereof,

to give a compound of the formula (Ie):




25 wherein R^1 , R^2 and R^{17} are as defined above
or a salt thereof.


(5) subjecting a compound of the formula (If):



wherein R^1 and R^2 are as defined above, or a salt thereof,
to acylation reaction with an amine of the formula (V):




5 to give a compound of the formula (Ig):




wherein R^1 and R^2 are as defined above, and
 R^{10} and R^{11} are each as defined in claim 2,
15 or a salt thereof,

(6) subjecting a compound of the formula (Ih):




25 wherein R^1 and R^2 are as defined above, and A is lower alkylene,
or a salt thereof,

to acylation reaction with an amine of the formula (VI):




to give a compound of the formula (Ii):



wherein R^1 , R^2 and A are as defined above, and
 R^7 and R^8 are each as defined in claim 2,
 or a salt thereof,

5

(7) reacting a compound of the formula (VII):




wherein

R^2 , R^3 and n are as defined above,

15 or a salt thereof,

with hydrazine and glyoxylic acid,

to give a compound of the formula (Ia):



25 wherein

R^2 , R^3 and n are as defined above

or a salt thereof.

6. A pharmaceutical composition comprising the compound of claim
 30 1 or a pharmaceutically acceptable salt thereof in admixture
 with a pharmaceutically acceptable carrier.

7. A process for preparing a pharmaceutical composition which comprises admixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.

5

8. A method for preventing or treating a disease resulting from a stimulation of adenosine A₁ and/or A₂ receptor in a human being or an animal, which comprises administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being
10 or an animal.

9. A method for preventing or treating a disease on which an adenosine antagonist is therapeutically effective, which comprises administering the compound of claim 1 or a
15 pharmaceutically acceptable salt thereof to a human being or an animal.

10. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's
20 disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal
25 insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus,
30 myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack and angina pectoris, which comprises administering the compound of claim 1 or a

pharmaceutically acceptable salt thereof to a human being or an animal.

11. A method for preventing or treating a disease selected from
5 the group consisting of Parkinson's disease and symptoms associating therewith, which comprises administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.
- 10 12. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.
13. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as an adenosine antagonist.
- 15 14. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as an adenosine A₁ receptor and A₂ receptor dual antagonist.
- 20 15. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition for the therapy and/or prevention of a disease resulting from a stimulation of adenosine A₁ and/or A₂ receptor.
- 25 16. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition for the therapy of a disease on which an adenosine antagonist is therapeutically effective.
- 30 17. A method for evaluation of adenosine antagonism, which comprises use of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/JP 01/07322

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/04 A61K31/437 A61P25/00 //(C07D471/04, 231:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 24742 A (FUJISAWA) 4 May 2000 (2000-05-04) claims 1,6; examples 35,36 -----	1,6



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

21 November 2001

Date of mailing of the international search report

30/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT
information on patent family members

Intern Application No
PCT/JP 01/07322

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0024742 A	04-05-2000	WO 0024742 A1	04-05-2000